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ABSTRACT

Barnard, Alle N. M.S., Purdue University, August 2014. 1,25-dihydroxyvitamin D
alters lipid metabolism and epithelial-to-mesenchymal transition in metastatic
epithelial breast cancer cells. Major Professor: Dorothy Teegarden.
Evidence suggests that high vitamin D status (marked by serum 25hydroxyvitamin D, 25(OH) 2 D) is associated with a decreased risk of breast
cancer. It has been established that 1,25-dihydroxyvitamin D (1,25(OH) 2 D) can
alter glycolysis and the Krebs cycle of breast cancer cells (Jiang et al., 2010;
Zheng et al., 2013) but little information is available on 1,25(OH) 2 D's alterations
of lipid metabolism in breast cancer cells. Thus, the current research
investigates if there was an effect of 1,25(OH) 2 D on proteins that regulate lipid
metabolism in MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a epithelial
breast cancer cells. While no significant effects were seen at 24 hours of
treatment with 10 nM of 1,25(OH) 2 D, several changes were see at 48 hours with
the most significant effects in the MCF10CA1a line. With 48 hour treatment of
1,25(OH) 2 D there was a significant increase of fatty acid synthase (FAS), acylCoA cholesterol acyltransferase 1 (ACAT1), insulin-inducing gene 2 (Insig2),
perilipin 2 (PLIN2), and a non-significant trend towards an increase in stearoylCoA desaturase 1 (SCD1) in the MCF10CA1a line. Additionally, there was a
non-significant trend towards a decrease in carnitine palmitoyl transferase 1a

xvii
(CPT1a), adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL).
Lipid accumulation was greater in the MCF10CA1a compared to the other
MCF10A cell lines as shown by oil red O staining. 1,25(OH) 2 D treatment caused
a non-significant trend towards a decrease in total triglyceride concentration in
the MCF10CA1a cells. Additionally, a multitude of alterations upon 1,25(OH) 2 D
treatment were noted in specific phosphotidylcholines (PCs), sphingomyelins,
and ceramides using MS-MS. Together, these results suggest that 1,25(OH) 2 D
may alter lipid metabolism by increasing lipid storage and decreasing lipid
degradation in epithelial breast cancer cells.
Additionally, while it is known that 1,25(OH) 2 D exerts anti-cancer effect on
primary breast tumors (Welsh, 2004),the role of 1,25(OH) 2 D in metastasis has
yet to be determined. Thus, the current research also investigates if there was
an effect of 1,25(OH) 2 D on epithelial-to-mesenchymal transition (EMT) protein
markers and cell viability in MCF10CA1a metastatic epithelial breast cancer cells.
To identify the impact of 1,25(OH) 2 D regulation of EMT and metastasis of breast
epithelial cells to bone we employed a reconstructed metastasis (rMET) model.
Upon 1,25(OH) 2 D treatment in the 3D matrix which recapitulates the mammary
environment, mammospheres were visually smaller compared to vehicle treated
cells though 3-(4,5-dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT)
assays did not show a significant difference in the amount of live cells between
treatments in 3D. Additionally, the total number of cells to metastasize and
survive in the reconstructed bone matrix (rBM) was significantly reduced in the
1,25(OH) 2 D group versus vehicle. To determine the impact of 1,25(OH) 2 D

xviii
regulation of EMT, the mRNA abundance of markers of EMT in the upper well
was determined. Treatment with 1,25(OH) 2 D induced a significant increase in
vimentin and fibronectin mRNA abundance, both markers of EMT, following 48
hours of 10 nM of 1,25(OH) 2 D treatment compared to vehicle in 2D cell culture.
Additionally, mRNA abundance of epithelial-cadherin (E-cadherin), which is
decreased during EMT, had a trend towards an increase while neuronal-cadherin
(N-cadherin) was unchanged. Immunofluorescent staining of the upper well
mammospheres for E-cadherin, vimentin, perilipin 2 (PLIN2), co-stained with
neutral lipid stain, Bodipy, and the nuclear stain, DAPI, were completed.
Although a visual difference employing Zeiss microscope, showed little difference
between treatments, confocal images are being obtained and analyzed by our
laboratory to more carefully assess the differences in protein expression.
Together, these results suggest that 1,25(OH) 2 D decreases breast to bone
metastasis by altering viability in the rBM and alterations in characteristic EMT
protein expression in metastatic epithelial breast cancer cells, therefore
decreasing cancer aggressiveness. Overall, our findings contribute to the
knowledge of vitamin D biology and its function in mammary cancer and
advocates that vitamin D is a potentially safe chemopreventative agent.
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CHAPTER 1 INTRODUCTION

1.1. Vitamin D
The two major physiological forms of vitamin D are ergocalciferol (vitamin
D 2 ) from plants and cholecalciferol (vitamin D 3 ) from animal sources. While both
forms can be obtained from the diet, there are only a few foods with naturally
occurring vitamin D. These include fatty saltwater fish, beef, liver, egg yolks,
yeast, and mushrooms (Hill et al., 2012). More often, vitamin D is fortified in
foods such as dairy products, juices, and ready-to-eat breakfast cereals (Hill et
al., 2012; National Institutes of Health). The major source of cholecalciferol is
through generation in the skin from 7-dehydrocholesterol upon exposure to
ultraviolet B (UVB) radiation. The current recommended dietary allowances
(RDAs) for vitamin D are 600 International Units (IU)/day (15 micrograms (mcg))
(1 mcg = 40 IU) for both males and females ages one to 70 years old, as well as
for women during pregnancy and lactation (Office of Dietary Supplements). The
RDA increases to 800 IU/day (20 mcg) for both men and women for those over
70 years old (Office of Dietary Supplements). Research suggests that vitamin D
has a plethora of roles involving bone homeostasis, cancer prevention, immune
function, insulin resistance in muscle, cardiovascular disease, and more(Rosen
et al., 2012).

2
1.1.1. Vitamin D Action
Due to the multiple functions proposed for vitamin D, a wide range of
research has been completed and is still ongoing to study vitamin D biology and
its' effects in homeostatic and diseased states. In this section, vitamin D
metabolism, mechanism of action, and specific actions will be discussed.

1.1.1.1. Vitamin D Metabolism
When UV form sunlight is absorbed in the skin, it converts 7dehydrocholesterol, the vitamin D precursor, to previtamin D 3 , which is rapidly
isomerized into vitamin D 3 (cholecalciferol) in the dermis and epidermis.
Cholecalciferol, or vitamin D, from both sunlight and foodstuffs, is transported in
the bloodstream to the liver where it is metabolized to 25-hydroxyvitamin D
(25(OH)D) by 25-hydroxylase (DeLuca, 2004; Jiang et al., 2010). Because this
conversion is uncontrolled, serum 25(OH)D is a valid biomarker of vitamin D
status. However, this metabolite does not readily bind to the nuclear vitamin D
receptor (VDR) and so it is not biologically active. The 1α-hydroxylase, coded
from the CYP27B1 gene, in the kidney further hydroxylates 25(OH)D to its
bioactive form, 1,25-dihydroxyvitamin D (1,25(OH) 2 D) , which has a high affinity
for VDR. More recently, it has been found that extra-renal tissues also contain
the 1α-hydroxylase enzyme for localized conversion (see section 1.1.1.3.). The
expression of 1α-hydroxylase is stimulated by parathyroid hormone (PTH) in
response to a low serum calcium level. Additionally, this active metabolite
regulates serum concentrations of calcium and phosphorus, certain hormones,
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and reduces the risk of many diseases (DeLuca, 2004). Both the 25(OH)D
serum marker and the 1,25(OH) 2 D active form can be hydroxylated again by 24hydroxylase, coded from the CYP24A1 gene, to generate 24,25-dihydroxyvitamin
D and 1,24,25-trihydroxyvitamin D, respectively. This additional hydroxylation
marks both metabolites for degradation and then excretion (Inouye and Sakaki,
2001; Sakaki et al., 2005).

1.1.1.2. Vitamin D Signaling
The most well-researched and understood mechanism of vitamin D action
is binding of the 1,25(OH) 2 D form to the VDR to initiate the transcription of
several specific target genes. In order for this process to occur, 1,25(OH) 2 D
must bind to the VDR, which heterodimerizes with the retinoid X receptor (RXR)
creating a VDR-RXR dimer. Liganded VDR-RXR binds to vitamin D response
elements (VDREs) in the promoter regions of target genes (Sutton and
MacDonald, 2003). Co-activators, along with basal transcriptional machinery,
and histone modifiers complex together around the VDR-RXR on the VDRE to
stimulate expression of 1,25(OH) 2 D regulated genes such as those involved in
cell proliferation, differentiation, and apoptosis (Sutton and MacDonald, 2003).

1.1.1.2.1. Classic VDR and Target Genes
Traditionally, 1,25(OH) 2 D works through VDR to regulate the serum
calcium and phosphate levels (see section 1.1.2.) (Haussler et al., 1997). It is
now widely recognized that VDR participates in transcriptional regulation of
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proteins involved in cell proliferation, apoptosis, differentiation, immune functions,
and more, through liganded-1,25(OH) 2 D. For example, 1,25(OH) 2 D regulation
through VDR acts on cell cycle regulators p21 and p27 to inhibit cell proliferation
in multiple cancers (Welsh, 2007). The same mechanism dephosphorylates the
retinoblastoma-protein (Rb-protein) and increases thioredoxin reductase-1,
thereby preventing entrance into the S-phase of the cell cycle (Swami et al., 2003;
Welsh, 2007). Similarly, liganded VDR-RXR induces cancer cell apoptosis by
increased generation of reactive oxygen species (ROS), disruption of the
mitochondrial membrane, and release of cytochrome C (Welsh, 2007). Further,
VDR-regulated 1,25(OH) 2 D down regulation of matrix metalloproteinases (MMPs)
leads to increased invasive potential and eventual metastasis if left unchecked
(Swami et al., 2003). Thus, 1,25(OH) 2 D action through transcriptional regulation
of the VDR is broad and has the capability to regulate cellular invasion, and
proliferation.

1.1.1.2.2. Non-genomic Response of Vitamin D
In addition to the classic genomic signaling of 1,25(OH) 2 D, research
indicates that 1,25(OH) 2 D can rapidly stimulate ion fluxes and activate protein
kinases, independent of the genomic mechanisms (Fleet, 2004). There are three
proposed explanations for these events: 1) there is a membrane-bound receptor
which functions as a vitamin D receptor; 2) these are new roles by the classical
VDR that mediates membrane associated non-genomic effects; and 3),
1,25(OH) 2 D can directly activate signal transduction pathways into the cell
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(Fleet, 1999). The first explanation is supported by Nemere et al. (1998) who
identified a unique membrane-receptor for 1,25(OH) 2 D through its regulation of
protein kinase C in cartilage cells (Nemere et al., 1998). The second explanation
is supported by the discovery of a VDR-alternative pocket, so a new ligand
binding site within the VDR, suggesting new roles (Menegaz et al., 2011). The
third explanation has not yet been investigated at this time. While it is possible
both genomic and non-genomic 1,25(OH) 2 D signaling participates in cancer cell
regulation, their contributions have yet to be clearly elucidated.

1.1.1.3. Extra-renal 1α-hydroxylase
As mentioned in section 1.1.1.1., the main location for 1α-hydroxylase, the
enzyme which converts circulating form of vitamin D, 25(OH)D to the active form,
1,25(OH) 2 D, is in the kidney. However, multiple extra-renal tissues such as,
adipose (Li et al., 2008), bone (van Driel et al., 2006), breast (Friedrich et al.,
2006; Townsend et al., 2005), brain (Eyles et al., 2005), colon (Bises et al., 2004),
macrophages (Hewison et al., 2007), endothelial cells (Zehnder et al., 2002),
keratinocytes (Bikle et al., 2004), the pancreas (Bland et al., 2004), the
parathyroid (Segersten et al., 2002), the placenta (Evans et al., 2004), and the
prostate (Blomberg Jensen et al., 2010; Henry, 2011) have shown the presence
of 1α-hydroxylase. These discoveries have spurred the suggestion that local
conversion may affect diseases such as cancer as 1,25(OH) 2 D can affect the cell
cycle, viability, proliferation, and invasion as previously mentioned.
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1.1.2. Calcium Homeostasis
Vitamin D, along with parathyroid hormone (PTH), is traditionally known
for its role as a key regulator in maintaining calcium homeostasis, thus
preserving the skeletal system mineralization (Sutton and MacDonald, 2003).
Conversion of 25(OH)D to 1,25(OH) 2 D is stimulated by increased PTH when low
serum calcium levels are sensed. 1,25(OH) 2 D acts on the intestine to increase
calbindin D9k (CaBPD9k), transient receptor vanelloid family member 6 (TRPV6)
(Christakos et al., 2007), and basolateral calcium pump Ca2+-ATPase (PMCA1b)
(Khuituan et al., 2013) synthesis to increase calcium absorption. 1,25(OH) 2 D
additionally acts to increase alkaline phosphatase activity subsequently
increasing phosphate absorption (Khuituan et al., 2013). Within the kidney, PTH
simulates activation of 1α-hydroxylase (Sutton and MacDonald, 2003), increasing
synthesis of 1,25(OH) 2 D, and subsequently calbindin D28k (CaBPD28k)
(Hemmingsen et al., 2002) synthesis, thus increasing resorption or calcium from
the filtrate while simultaneously increasing phosphate excretion in the kidney.
Additionally, when serum calcium levels are low, 1,25(OH) 2 D causes resorption
of calcium and phosphate from the skeletal system through increased receptor
activator of nuclear factor kappa B ligand (RANK-L) (Kitazawa et al., 2003).
Conversely, if serum calcium levels exceed the normal range, calcitonin is
released from the thyroid, causing mineralization of calcium and phosphate in the
bone. Together these actions serve to restore the serum calcium levels to
normal range of 4.5-5.1 mg/dL in order to maintain normal cellular function
(DiPiro et al., 2011).
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1.1.3. Hypovitaminosis D and Toxicity
The current recommendation for vitamin D is 600 IU/day but, epidermal
synthesis of vitamin D varies greatly depending on sunscreen use, age, ethnicity,
gender, skin pigmentation, season, latitude, subcutaneous adipose deposition,
and more (Binkley et al., 2007). Therefore, these variations can lead to
insufficiencies or toxicities in some populations.

1.1.3.1. Vitamin D Insufficiency
Despite endogenous synthesis, fortified foods, and natural vitamin D
containing foods, vitamin D insufficiency, defined as <50 nmol/L (Office of Dietary
Supplements), is common in several populations. Most often these include the
elderly (Mateo-Pascual et al., 2014), institutionalized individuals (Nwosu et al.,
2014), and populations living in northern climates (Janssen et al., 2013). In
children, vitamin D insufficiency causes rickets, a disease characterized by soft
bones and skeletal malformation (Wharton and Bishop, 2003). In adolescents
and adults, vitamin D insufficiency can lead to osteomalacia (Sunyecz, 2008),
weakening of the bones, and eventually osteoporosis, which is structural
deterioration of the skeletal mass. As a result, there is an increase in fractures,
breaks, and kyphosis in vitamin D insufficient individuals (Basit, 2013; Heaney,
2003). In a study with healthy ambulatory women, median age 84 years old,
women consumed either a double placebo or a pill with 1.2 g of calcium and 800
IU of vitamin D 3 /day for 18-months showed the number of fractures significantly
decreased with supplementation (Chapuy et al., 1992). Additionally, serum
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25(OH)D increased 162% and proximal femur bone density increased 2.7% in
the supplemented group (Chapuy et al., 1992). Therefore, the results of this
study demonstrate the importance of adequate vitamin D and calcium in reducing
the risk of fractures. Another study showed that 200 IU/day of vitamin D was not
adequate to inhibit bone loss in post-menopausal women residing in northern
regions (latitude 42N) during a 2-year randomized, double-blind, trial (DawsonHughes et al., 1995). Together, these studies conclude that adequate vitamin D
(>200 IU) is necessary for preventing osteomalacia, osteoporosis, and
decreasing the risk of fractures.

1.1.3.2. Vitamin D Safety
All micronutrients have an established tolerable upper limit to prevent
toxicity. Upper limits for vitamin D range from 1000-3000 IU/day for children 0-8
years old and is set at 4000 IU/day for all people 9 years of age or older,
including those pregnant or lactating (Office of Dietary Supplements). It is
important to note that hypervitaminosis D is only possible through excessive
dietary intakes and not through endogenous production. Symptoms of
hypervitaminosis D include hypercalcemia, anorexia, weight loss, heart
arrhythmias, cardiovascular system damage, polyuria, kidney damage, and
calcification of soft tissues (Jones, 2008; Sunyecz, 2008). However, there is
evidence that a higher daily intake may have additional therapeutic effects (Grant
and Holick, 2005; Holick, 2013; Vieth, 2004; Vieth et al., 2001, 2004), such as
cancer prevention (Lokeshwar et al., 1999; Woo et al., 2005), thus challenging
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current recommendations and the upper limit. A risk assessment by Hathcock et
al. (2007) reported several human trials that used vitamin D doses greater than
or equal to 10,000 IU/day without indications of toxicity (Hathcock et al., 2007).
Therefore, recommendations and the upper limit may need to be increased in
order to receive the full spectrum of benefits from vitamin D.

1.2. Breast Cancer
In 2013, it is estimated that 232,340 people will be diagnosed and 39,620
will die of breast cancer in the United States alone (PDQ Screening and
Prevention Editorial Board, 2014). Breast cancer is also the most common
cancer of any race or ethnicity within the United States (Centers for Disease
Control and Prevention). Of those diagnosed with breast cancer, 32% of will
have spread to lymph nodes and another 5% to distant sites with 84.4% and 24.3%
survival rates, respectively. Compared to a 98.6% survival rate of patients with
breast tumors only at diagnosis, it is clear metastasis of the tumor is correlated
with increased mortality (Centers for Disease Control and Prevention). While
there are several non-modifiable breast cancer risk factors such as age, gender,
and genetics; it may be possible to prevent breast cancer progression and/or
metastasis by altering other modifiable factors. Thus, additional research is
needed to determine alternative strategies for breast cancer progression and/or
metastasis prevention.
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1.2.1. Mammary Gland Biology
Female mammary gland development occurs throughout the lifecycle with
its first changes beginning at puberty. During puberty, hormones such as
estrogen induce mammary gland growth via the epithelium branching into ducts.
Additional changes occur if a female becomes pregnant and the ducts prepare
for milk secretion by expanding. Upon weaning, the mammary gland regresses
back to its pre-pregnancy state (Hansen and Bissell, 2000).

1.2.1.1. Mammary Tissue Development
Human mammary gland development begins as early as the tenth day
after conception (Macias and Hinck, 2012). The gland remains unchanged from
birth until puberty when it responds to the ovarian steroid hormone, estrogen, as
well as growth hormone (Hansen and Bissell, 2000; Macias and Hinck, 2012).
Mammary gland estrogen response includes epithelial branching into ducts with
alveolar-likes structures on the terminal ends, called acini. While breast
development can vary between breasts and individuals, all contain adipocyte
filled fat pads that help maintain the acini structures (Harvey and Bovbjerg, 2004;
Macias and Hinck, 2012).
A second growth stage for mammary epithelial cells occurs during
pregnancy. Steroid hormones, progesterone and estrogen, significantly increase
causing acini to expand and differentiate into lobules, preparing the mammary
gland for milk synthesis and secretion (Hansen and Bissell, 2000). After weaning
and completion of lactation, the lobules regress, termed involution, via apoptosis
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and return to the pre-pregnancy gland state. Hence, the human female
mammary gland cycles through growth, differentiation, apoptosis, regression,
and remodeling over its lifetime (Bissell et al., 2003).

1.2.1.2. Mammary Tissue Structure
Regardless of the mammary gland developmental stage, there is a
polarized epithelium bilayer consisting of a luminal layer of the acini and ducts,
and a basal myoepithelial layer near the basement membrane (Sopel, 2010). At
least 80% of the breast volume consists of mammary stroma which includes
adipose tissues, loose and dense connective tissues, and blood vessels (Hansen
and Bissell, 2000; Rønnov-Jessen et al., 1996). Normal mammary epithelial
cells bud into three dimensional, hollow lumen, acini, post-puberty (O’Brien et al.,
2002).
The epithelial layers are most susceptible to tumors. Human studies by
Rudman et al. showed that benign breast tumors contained both epithelial and
myoepithelial cells, whereas malignant tumors contained only epithelial cells,
indicating a potential tumor suppressive role of the myoepithelial cells (Rudland,
1987, 1993; Rudland et al., 1995).

1.2.2. Breast Cancer Development
The most common type of breast cancer is ductal carcinoma (70% breast
cancer cases), followed by lobular carcinoma (10% breast cancer cases) which
begin in the milk ducts and lobules, respectively (PDQ Screening and Prevention
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Editorial Board, 2014). Other breast cancers are either a rare type or a mix of
the two (PDQ Screening and Prevention Editorial Board, 2014).

1.2.2.1. Breast Cancer Risk Factors
While many factors are non-modifiable, such as age, gender, and genetics,
some can be controlled, thus reducing breast cancer risk.
Increased risk is associated with
obesity (>180.84 lbs; RR=2.85); combination hormone therapy (estrogen
and progesterone; +26%) ; ionizing radiation exposure (6-fold); alcohol
intake(RR +7%/drink/day); genetic mutations (ex: BRCA1&2) (+80%;
mutation dependent), increasing age, female (100x vs. men), and family
history (20-30% with breast cancer have a family history of it)(PDQ
Screening and Prevention Editorial Board, 2014).
Decreased risk is associated with
early pregnancy (<20yo, -50%); breast-feeding (-4.3%/year; -7%/birth);
exercise (>4hrs/week, premenopausal, normal weight; -30-40%);estrogenreplacement post-hysterectomy (-23%) (PDQ Screening and Prevention
Editorial Board, 2014).

1.2.2.2. Multistage Carcinogenesis
Cancer incidence is not a single initiating event; rather it is a multistage
pathway that often takes decades, therefore explaining why incidence increases
with age. The majority of researchers now agree that tumor development occurs
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in three generally defined phases: initiation, promotion, and progression (Fearon
and Vogelstein, 1990; Lopez-Garcia et al., 2010; Weinstein, 1988). During
initiation, a normal cell experiences an initiating event such as radiation exposure,
infection, or a variety of other incidents, allowing for one or more mutations,
possibly leading to abnormal growth and differentiation (Weinstein, 1988). In the
promotion phase, the initiated cells continue to expand and grow, forming a
population of abnormal cells. When one or more of these initiated cells attains
additional genetic changes via a second event, the population continues to
evolve toward a cancerous cell. Continuous replication and growth of these
mutated cells can lead to a benign tumor. Progression occurs when the benign
tumor or cells become malignant (Weinstein, 1988).
Continuous survival of the tumor requires oxygen, nutrients, and disposal
of cellular wastes which is accomplished via angiogenesis (detailed explanation
later, section 1.3.1.2.1.1.). If the tumor is able to survive and grow unchecked, it
may spread to secondary sites through a process called metastasis, which will be
discussed in detail later (see section 1.4.). This general, simplified, three step
model helps explain the development of breast cancer though it is important to
note that the initiations and secondary mutations vary case to case, thus
individual cases often have distinct morphology and histology.

1.2.2.3. Tumor Receptor Status
Aggressiveness and treatment of breast cancer is often determined by the
tumors' hormone receptor status. Tumors have three hormone receptor
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subtypes: estrogen receptor (positive/negative) (ER+/-), progesterone receptor
(positive/negative) (PR+/-), and human epidermal growth factor receptor
(positive/negative) (+/-). There are four groups of receptor expression
combinations called luminal A, luminal B, basal-like, and HER2 enriched which
represent 40%, 10-20%, 10-20%, and about 10% of tumors, respectively
(American Cancer Society, 2014).
Luminal A breast cancers are HER2- and are ER+ and/or PR+ and are
classified by their slow growth and lower aggressiveness compared to the other
receptor combinations. Since this type of cancer has at least one, and often two,
receptors present, it is easier to therapeutically target and treat. Thus, luminal A
breast cancers have the best prognosis in the short-term, though long-term
survival is surprisingly the same or even lower compared to the other receptor
combinations (American Cancer Society, 2014). Luminal B breast cancers have
similar receptor expression, being ER+ and/or PR+ but may also be HER2+
and/or have a high growth rate (Cheang et al., 2009).
Basal-like breast tumors are more commonly referred to as triple-negative
as they are ER-, PR-, and HER2- (Perou and Børresen-Dale, 2011).
Subsequently, these tumors have the poorest patient prognosis as there are no
treatment targets. Women most likely to have a basal-like tumor include those
with the Breast Cancer 1 (BRCA1) gene mutation, premenopausal women, and
African American women (American Cancer Society, 2014).
Lastly, HER2 enriched breast cancers are ER- and PR- but have excess
HER2 expression. These tumors also have increased aggressiveness,
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consequently leading to a lower prognosis compared to ER+ tumors (Blows et al.,
2010). Fortunately, due to the high expression of HER2, treatments have an
easy target, allowing for easier treatment than the basal-like tumors.

1.2.2.4. ras Oncogene
Genetic alterations, or gene mutations, are usually involved in cancer
development, including that of the breast. Upon gene mutation, numerous
proteins are altered consequently being under- or over-expressed within the
tumor cell population. One common mutation in tumors is that of protooncogenes and once altered, cause changes in cell survival, growth, and
differentiation (ICRP(1998). There are nine main classes of oncogenes: growth
factors (i.e. GDGF-beta chain sis), receptor/non-receptor protein tyrosine kinases
(erbB), receptors lacking protein kinase activity (angiotensin receptor),
membrane associated G-proteins (Ras), cytoplasmic protein-serine kinases (raf1), cytoplasmic regulators (crk), nuclear transcription factors (myc, jun), cell
survival factors (bcl-2), and cell cycle genes (cyclin D1) (ICRP(1998).
The ras oncogene was first discovered in 1964 (Malumbres and Barbacid,
2003). Three types of ras oncogenes exist: Neuroblastoma-ras (N-ras), Harveyras (H-ras), and Kirsten-ras (K-ras) and all code for GTPases, allowing signal
transduction across the cell membrane (Malumbres and Barbacid, 2003). Ras
signaling occurs through multiple pathways, though the most studied pathway is
that of Ras to Raf to MEK to mitogen-activated protein kinase (MAPK)
(ICRP(1998). Upon Ras recruitment via GTP activation, serine/threonine kinase
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Raf is subsequently activated. Raf then activates MEK, a dual specificity
serine/threonine and tyrosine kinase, via phosphorylation (Stamatakos et al.,
2010). In turn, MEK activates the extracellular signal-regulated (Erk) family of
MAPK. Erk proteins effect and regulate growth survival and angiogenesis
pathways as well as invasiveness through phosphorylation (Stamatakos et al.,
2010). Alternatively, ras activation can also lead to phosphatidylinositol-3-OH
kinase (PI3K) activation, leading to stimulation of the serine/threonine kinase,
protein kinase B (Akt/PKB). Akt/PKB stimulation often leads to apoptosis
protection and cytoskeleton reorganization (Stamatakos et al., 2010). The third
most recognized downstream effector pathway is that of Ral guanine exchange
factors (RalGEFs). Upon ras activation, RalGEFs stimulates smaller downstream
GTPases (e.g. RalA, RalB) and have the ability to transform both rodent and
human cells (Mishra et al., 2010). Additionally, genetic knockdown of Ral
function in vivo resulted in a reduced malignant phenotype (Mishra et al., 2010).
Ras induces several other downstream effectors including Ras association family
member (RASSF), and phospholipase C, epsilon, which induce apoptosis, and
regulate cell growth, differentiation, and gene expression, respectively (Smith
and Ikura, 2014). Thus, GTP-bound Ras can effect numerous proteins that
control cell growth, survival, differentiation, movement, and adhesion (Marshall,
1996).
Despite the low frequency of ras mutations seen in breast cancers (<5%),
uncontrolled or activated Ras can still effect breast cancer promotion and
progression (Eckert et al., 2004). This may occur due to continuous upstream
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signaling from proteins and genes such as HER2, which is commonly overexpressed in breast cancers. In fact, cancer promotion by HER2 signaling is
partially activated via Ras protein (Eckert et al., 2004). Due to this intricate
overlap, the mechanisms by which HER2 and Ras act independent of each other
has not been clearly determined. Despite this, it is important to understand the
molecular development of human breast cancer in order to advance preventative
measures.

1.3. Chemoprevention of Breast Cancer by Vitamin D
Due to the prevalence of breast cancer in the world, it is important to
identify methods of prevention. There are three levels of breast cancer
prevention: primary, secondary, and tertiary. Primary prevention is defined as
inhibiting the development of abnormal breast tissue growth and mutations
(Teegarden et al., 2012). Secondary prevention is defined as inhibiting
progression of breast tumors, and tertiary prevention is defined as inhibiting
metastasis and metastatic growth of breast tumors to new sites. Many
compounds have been proposed to play a role in breast cancer prevention; one
of these is 1,25(OH) 2 D.
1,25(OH) 2 D is thought to exert many of its anti-cancer effects via the VDR,
which is consistent with levels of VDR found in different stage breast tumors
(Christakos et al., 2003). Results demonstrate that the VDR is abundant in
benign breast tumors; however, it is significantly less abundant in more malignant
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breast tumors (Lopes et al., 2010, 2012; Satish Rao et al., 2006). These results
suggest decreased 1,25(OH) 2 D signaling capability, with decreased VDR, as
cancer aggressiveness increases, and thus their ability to be affected by
1,25(OH) 2 D is reduced as breast cancer progression continues to advance
(Yagmurdur et al., 2009).

1.3.1. Evidence for Anti-cancer Effects of Vitamin D
Epidemiological studies link increased UV exposure, thus vitamin D levels,
to a decreased prevalence of breast cancer. In a retrospective study of NHANES
I, it was found that within a cohort of 5009 women, non-Caucasian ethnicity and a
low sun exposure index were associated with increased breast cancer risk (John
et al., 1999). Similarly, in the same study increased sun exposure index and
dietary vitamin D levels were associated with decreased breast cancer risk (John
et al., 1999). Confirming the results of this study, Anderson et al. (2011) linked
an increased solar vitamin D score (measurement including all cutaneous vitamin
D effectors such as sun screen use, outdoor exposure, latitude, etc) with
decreased breast cancer risk in a population-based case-control study of 6,572
women (Anderson et al., 2011). Enhancing the link between vitamin D and
breast cancer disease, a study by Kermani et al. (2011) suggests an association
between breast cancer prognosis and serum 25(OH) 2 D in 119 newly diagnosed
women with breast cancer disease (Kermani et al., 2011). Taken together, there
is strong epidemiological support for an association between vitamin D status
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and breast cancer risk; however, the mechanisms involved were not defined by
these studies.

1.3.1.2. Anti-cancer Effects of Vitamin D: Mechanisms of Action
Given the epidemiological evidence for the potential anti-cancer functions
of vitamin D, it was necessary to utilize in vitro and in vivo studies to define the
mechanisms of action and effects.

1.3.1.2.1. Molecular Targets of Vitamin D in Cancer
1,25(OH) 2 D is involved in secondary prevention by acting on the breast
tumor to reduce tumor growth and progression through decreasing angiogenesis
and proliferation, and increasing apoptosis (Hanahan and Weinberg, 2011). A
fundamental aspect of breast cancer disease is the formation of a solid tumor in
the mammary gland. A tumor requires oxygen and nutrients which are delivered
to the tumor via new blood vessels driven by increased angiogenesis. In addition,
a tumor has unregulated cell proliferation contributing to the increase in size of
tumor. Finally, cells within tumors also have the ability to evade apoptosis. All of
these characteristics are targets of 1,25(OH) 2 D to prevent tumor survival, growth,
and progression.

1.3.1.2.1.1. Cancer Characteristics: Tumor Angiogenesis
Angiogenesis is the growth and differentiation of blood vessels to provide
oxygen, nutrients, and other factors to an organ or tumor. Unlike in normal tissue,
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where angiogenesis is quiescent and only transiently activated, tumor
angiogenesis is almost always activated (Hanahan and Weinberg, 2011).
Identification of factors that regulate angiogenesis are thus important for the
prevention of tumor growth and progression. The most well known angiogenic
inducer is vascular endothelial growth factor (VEGF) (Hanahan and Weinberg,
2011). VEGF is a glycosylated protein that stimulates endothelial cell growth,
causing new blood vessel formation and mediating vascular permeability.
Endothelial cells line the interior of arteries and lymph vessels and act as a semiselective barrier between blood and interstitial space. In breast tumor cells,
expression of VEGF is increased in cell culture, animal models, and human
tumor samples (Syed Khaja et al., 2013). The same study showed increased
VEGF tumor cell expression caused increased angiogenesis to the tumor site,
allowing blood to bring the necessary nutrients for the tumors growth in the
xenograft mouse model (Syed Khaja et al., 2013). A preliminary study induced
over-expression of VEGF in endothelial cells via recombinant human VEGF and
in breast carcinoma-xenografted mice via VEGF transfected MCF-7 cells and
showed that both cellular and mouse models had increased endothelial cell
proliferation and angiogenesis upon VEGF over-expression (Mantell et al., 2000).
The most recognized angiogenic inhibitor is thrombospondin-1 (TSP-1)
(Hanahan and Weinberg, 2011). TSP-1 is an adhesive glycoprotein that is
involved in cell to cell interactions and inhibits angiogenesis. TSP-1 up regulation
inhibited in vitro cell migration of MCF-7 breast cancer and PC3 prostate cancer
cells and was further confirmed when a cellular TSP-1 knockdown model showed
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significant increases in cellular migration (Kim et al., 2013). Additionally, high
TSP-1 levels in breast tissue from breast cancer patients was associated with
reduced breast cancer reoccurrence as analyzed in 124 patients (Ioachim et al.,
2012). Other factors that regulate angiogenesis have been reviewed in a paper
by Rice and Quinn (Rice and Quinn, 2002). The therapeutic potential for these
factors was first recognized in 1971 and have remained of interest as
preventative and therapeutic targets (Folkman, 1971).

1.3.1.2.1.1. Vitamin D Induced-Decrease of Angiogenesis in Breast Cancer
VEGF has a well established role in breast cancer angiogenesis and has
been shown to be inhibited by 1,25(OH) 2 D. Treatment of 1,25(OH) 2 D inhibited
the VEGF-induced endothelial cell proliferation and angiogenesis in vitro and
decreased tumor vascularization in vivo (Mantell et al., 2000). 1,25(OH) 2 D's
ability to reduce VEGF is a mechanism of action for prevention of angiogenesis
and thus secondary prevention of breast cancer. Unfortunately, there is no
current literature on breast tumor TSP-1 levels after treatment with 1,25(OH) 2 D in
breast cancer, but future studies may be able to link 1,25(OH) 2 D's effects to
increased TSP-1 as part of secondary prevention.

1.3.1.2.1.3. Cancer Characteristics: Increased Proliferation
Cell proliferation is the carefully controlled replication of cells which is
necessary for normal tissue growth and remodeling. In cancer, cell proliferation
is often uncontrolled due to dysregulated cell cycle signals that allow for
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uninhibited cycle progression, thus allowing a tumor to grow unchecked. Tumor
suppressor genes also have a role in cell proliferation by controlling the cell
replication cycle, but these genes are frequently inactivated in many cancers
(Sherr, 2004). Continuous cell proliferation that promotes the development of a
tumor also has multiple pathways including autocrine signaling with growth
factors (da Costa et al., 2014), stimulation of neighboring normal stroma cells to
enhance growth factor release (Cheng et al., 2008), hyper-responsive growth
receptors (Hanahan and Weinberg, 2011) and/or constant activation of
downstream proliferation pathways (i.e. growth factor independent) (Davies and
Samuels, 2010). Three well established factors that promote cell proliferation in
breast cancer are PI3K, the mammalian target of rapamycin (mTOR), and
phosphatase and tensin homolog (PTEN) (Hanahan and Weinberg, 2011).
PI3K has both regulatory and catalytic functions in a wide range of cellular
processes, such as cell growth and proliferation, and is known for its role in
development of several different cancers, including breast (Fernandis and Wenk,
2009). In breast cancer, PI3K is both a marker of progression as well as a
marker of metastatic transition. Breast cancer patients with circulating tumor
cells (CTCs) have increased PI3K expression compared to breast cancer
patients without CTCs, indicating increased PI3K is associated with progression
of breast cancer (Kasimir-Bauer et al., 2012). Inhibition of these signaling
pathways within the breast tumor cells may be a prevention or treatment target.
mTOR is both an up- and down-stream factor of the PI3K pathway. In normal
tissue, mTOR mediates cell growth changes due to biological stressors.
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However, in breast cancer tumor biopsies, up-regulation of the mTOR pathway
was shown to be associated with poor prognosis in breast cancer patients
(Creighton, 2007).
The PTEN gene in normal tissue is a tumor suppressor gene and codes
for lipid metabolism enzymes. PTEN is often mutated in breast cancer, leading
to high levels of phosphorylated lipids which then act as growth-stimulating
factors and, thus causing cancer cell proliferation. Specific to its tumor
suppressor function, mutated PTEN also increases tumor cell viability by
inhibiting PI3K-dependent activation of the Akt pathway, leading to dysregulated
cell cycle control (Cantley and Neel, 1999; Fernandis and Wenk, 2009).

1.3.1.2.1.4. Vitamin D Induced-Decrease in Proliferation in Breast Cancer
Animal studies have shown that 1,25(OH) 2 D can prevent tumor growth
and stunt tumor size by inhibiting breast cancer cell proliferation. 1,25(OH) 2 D
significantly decreased tumor growth in athymic female mice xenografted with
human breast cancer cells, T-47D, compared to the control group (García-Quiroz
et al., 2013). Furthermore, malignant mastectomy patient tissue samples treated
with 1,25(OH) 2 D for 24 hours dose dependently (0, 10, and 100 nM) decreased
the number of proliferating cells as determined by ki-67 staining (Suetani et al.,
2012). 1,25(OH) 2 D has been hypothesized to effect several specific pathways
related to cell proliferation including PI3K (Vivanco and Sawyers, 2002), mTOR
(O’Kelly et al., 2006), and PTEN (Stefanska et al., 2012), which will be briefly
reviewed in this section.
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The PI3K pathway may be altered by 1,25(OH) 2 D (Vivanco and Sawyers,
2002). 1,25(OH) 2 D treatment caused PI3K activation and allowed for cancer cell
survival in squamous cell carcinoma cells (Ma et al., 2006). However, there is
also evidence that vitamin D analogs, such as BXL628, may inhibit the PI3K
pathway, as seen with inhibition of cancer cell survival in prostate cancer cell
lines (Bonaccorsi et al., 2006). Therefore, the role of 1,25(OH) 2 D in regulating
PI3K in breast cancer remains elusive but needs urgent review as PI3K is an
established marker in many cancers and is known to be mutated in breast cancer.
mTOR has been shown to be regulated by the vitamin D analog, Gemini.
Treatment with the Gemini analog caused a decrease in mRNA
translation/protein synthesis, an action of mTOR, in MCF-7 breast cancer cells,
thus decreasing proliferation (O’Kelly et al., 2006). The same study also noted
downstream mTOR effectors were inhibited by the Gemini analog (O’Kelly et al.,
2006). More studies on 1,25(OH) 2 D 's inhibitory role of mTOR effectors, thus
decreased cancer cell proliferation, are needed.
Additionally, PTEN is up regulated by cholecalciferol. Cholecalciferol
treatment led to decreased methylation of PTEN and therefore increased PTEN
activity and suppression of oncogene signaling transduction pathways in MDAMB-231 breast cancer cells (Stefanska et al., 2012). Additional studies repeating
this outcome would further solidify vitamin D's role as an inhibitor of breast
cancer proliferation by increasing PTEN activity.
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1.3.1.2.1.5. Cancer Characteristics: Evasion of Apoptosis
Apoptosis is the process of programmed cell death. The B-cell lymphoma
2 (Bcl-2) regulatory protein family controls the balance of pro- and anti-apoptotic
effectors, largely by either suppressing or allowing expression of pro-apoptotic
proteins, Bax and Bak, among other mechanisms (Hanahan and Weinberg,
2011). The mechanism of action for Bax and Bak involves altering the potential
of the mitochondrial membrane and allowing cytochrome c release, which causes
a caspase activation cascade resulting in cell death. Bcl-2 expression shifts the
balance towards inhibition of apoptosis. An increase in Bcl-2 expression is
correlated with tumor size and grade, lymph node invasion and status, estrogen
receptor levels, progesterone receptor levels, and epidermal growth factor
receptor levels, histological tumor type, HER2, p53, and overall patient survival in
582 breast cancer biopsies (Tawfik et al., 2012). Therefore, evaluation of Bcl-2
expression in cancer tissue may be beneficial to predict patient outcomes.
Evasion of apoptosis allows for cancer cells to survive longer by
increasing cell number and thus tumor growth, which adds to the progression of
a tumor as a whole. Cancer cells elude apoptosis through several pathways,
most commonly via loss of p53 tumor suppressor function (Muller et al., 2011).
Additional pathways include increases in survival signals (Liu et al., 2013),
decreased or down-regulated pro-apoptotic proteins (Gogada et al., 2013)
increased anti-apoptotic regulators (Yadav and Chandra, 2014), and/or
circumventing the ligand-induced death pathway (Hanahan and Weinberg, 2011).
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A thorough understanding of the pathways can be utilized to target breast tumor
gene expression for prevention or treatment.

1.3.1.2.1.6. Vitamin D Induced Apoptosis in Breast Cancer
Several studies have examined the role of 1,25(OH) 2 D in inducing
apoptosis of breast cancer cells. A dose dependent decrease in MCF-7 cell
numbers were seen upon 1,25(OH) 2 D treatment. Treatments of 10, 100, and
1000 nM significantly lowered cell number compared to vehicle, 0.1, and 1 nM
treatments of 1,25(OH) 2 D (Simboli-Campbell et al., 1996). Furthermore, human
mammary epithelial cells and MCF-7 cells treated with 100 nM of 1,25(OH) 2 D for
one, three, or six days, significantly increased the number of apoptotic cells as
measured by DNA fragmentation and caspase activity (Sergeev, 2004).
One mechanism by which, 1,25(OH) 2 D has been shown to regulate
apoptosis is through tumor necrosis factor-α (TNF-α) and Bcl-2. TNF-α, a gene
that codes for a multifaceted cytokine involved in cell survival, progression, and
death, is regulated by 1,25(OH) 2 D. Specific to apoptosis, Pileczki et al. (2012)
created a TNF-α knockdown triple negative breast cancer cell (Hs578T) resulting
in a significant increase of apoptosis via increased mRNA abundance of 12 proapoptotic genes (Pileczki et al., 2012). Studies show 1,25(OH) 2 D treatment
increases apoptosis in vitro in breast cancer cells by altering TNF-α.
1,25(OH) 2 D and TNF-α synergistically increased cytotoxicity in breast cancer
MCF-7 cells when treated between one to 24 hours. The authors suggest
1,25(OH) 2 D's pro-apoptotic effects are partially due to inhibiting the p38/MAPK
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pathway, whose predominant action is to inhibit apoptosis in cancer (Weitsman
et al., 2004). Similarly, 1,25(OH) 2 D treatment increased apoptosis via an
upstream regulator of TNF-α, Nuclear factor kappa B (NFκB), in breast cancer
lines MCF-7 and MDA-MB-231 (Tse et al., 2010). In breast cancer, NFκB
promotes cell survival but 1,25(OH) 2 D treatment reversed this effect by
repressing transcription of the NFkB activator component, p65 (Tse et al., 2010).
Much remains to be investigated regarding the role of TNF-α in 1,25(OH) 2 D
regulation of breast cancer, as both knockdown and up-regulation of TNF-α
caused apoptotic effects in breast cancer. It is possible that 1,25(OH) 2 D
treatment acts on multiple upstream and downstream regulators of TNF-α, such
as NFκB and p38/MAPK to enhance pro-apoptotic effects. Given TNF-α's control
of cancer cell apoptosis, further investigation of 1,25(OH) 2 D's mechanism of
action on TNF-α's pro-apoptotic pathways is necessary.
As mentioned prior, the Bcl-2 regulatory protein family controls the
balance of pro- and anti-apoptotic effectors, largely by either suppressing or
allowing expression of pro-apoptotic proteins, Bax and Bak, among other
mechanisms (Hanahan and Weinberg, 2011). Some studies show 1,25(OH) 2 D
treatment in vitro is pro-apoptotic via Bcl-2 down regulation (Hanahan and
Weinberg, 2011). Similarly, vitamin D analog treatments induced apoptosis in
both MCF-7 and T47D breast cancer lines (Mathiasen et al., 1999). This effect
was eliminated with over expression of Bcl-2, suggesting that anti-apoptotic
1,25(OH) 2 D action must occur prior to Bcl-2 over-expression (Mathiasen et al.,
1999). Co-treatment of 1,25(OH) 2 D and immunomodulary drug, Lenalidomide,
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caused a decrease in Bcl-2 expression which led to increased pro-apoptotic
proteins (i.e. p53, p21, claspin, etc) in the MDA-MB-231 breast cancer cell line
(Brosseau et al., 2012). It is possible that 1,25(OH) 2 D causes decreased Bcl-2
expression which leads to increased apoptosis in breast cancer, though more
studies are needed to confirm this relationship.

1.4. Cancer Metastasis
In order to advance, a tumor must activate changes leading to invasion
and metastasis into new sites. Metastasis has no strict definition, but includes
successful colonization of a new site as a result of specific interactions between
cancer cells and their microenvironment, allowing these cells to override their
innate behavior and eventually become a clinically detectable tumor (Chiang and
Massagué, 2008; Hanahan and Weinberg, 2011; Hunter et al., 2008; Ooi et al.,
2011). Metastasis can be grouped into three general steps: initiation,
progression, and perturbation/virulence but theories of mechanism differ.

1.4.1. Theories of Cancer Metastasis
Throughout the years of cancer research, several hypotheses have
developed to explain the exact mechanism of metastasis. While no one theory
encapsulates all that is observed during cancer metastasis, six models have
emerged that attempt to explain primary tumor cell disassociation, secondary site
invasion, colonization, and metastatic progression (Hunter et al., 2008), these
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include the progression, transient compartment, fusion, gene transfer, early
oncogenesis, and genetic predisposition, models.

1.4.1.1. Progression Model
For over 30 years, the progression model of metastasis has been the most
well accepted. The model was first proposed in 1976 by Nowell and promotes
the idea of primary tumor cell subpopulations, some of which acquire the ability
to metastasize (Nowell, 1976). Since not all cells in the primary tumor
disseminate and migrate to a secondary site, the higher aggression
subpopulations explain why the primary tumor stays intact and grows while
additional tumors arise elsewhere. While a long history of experiments back this
theory (Fidler and Kripke, 1977; Kang et al., 2003; Minn et al., 2005), two issues
arise. In a small subgroup (~5%) of tumor cases, a primary tumor is not
detectable despite a metastasized disease state (Hunter et al., 2008). Second,
the progression model predicts that the aggressive genotype in the metastatic
subpopulation would exist the lifetime of the secondary tumor but studies have
shown some of these subpopulations degrade to a lower level metastatic
capability after multiple regenerations (Harris et al., 1982). Thus, given these
discrepancies, alternative models have been proposed.

1.4.1.2. Transient Compartment Model
The transient compartment model, also known as the dynamic
heterogeneity model, was proposed by Weiss in 1990 to partially explain the
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difference in metastatic aggressiveness between the primary and secondary
tumors (Weiss, 1990). This model suggests that instead of only primary tumor
subpopulations acquiring metastatic potential, all the primary tumor cells acquire
metastatic properties and either position or random events (e.g. epigenetics)
allow for specific cells to fully metastasize (Weiss, 1990). While some studies
support this model (Kerbel et al., 1984; Stopper et al., 1992) the transient
compartment model fails to explain the clonal nature of metastases since random
epigenetic events dictate the portions of primary tumor that are capable of
metastasizing, thus not appearing clonal (Hunter et al., 2008).

1.4.1.3. Fusion Model
While more of a theory than a model, the fusion model attempts to explain
why tumor-derived epithelial cells are able to metastasize (Hunter et al., 2008).
The fusion model converges on a hypothesis that metastatic tumor cells gain
lymphoid features via nuclear transduction with myeloid cell fusion or uptake of
circulating tumor DNA by myeloid cells (García-Olmo and García-Olmo, 2001).
Cellular fusion is a normal human function (i.e. fertilization, myocytes in muscle
fibers, osteoclasts, etc) and while there are studies supporting this model, they
are riddled with cofounders (Busund et al., 2003; Pratt et al., 1989). Additionally,
there are no studies supporting this model in human tumors thus, this model has
lower support within the cancer community than most other models mentioned
here (Hunter et al., 2008).
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1.4.1.4. Gene Transfer Model
Similar to the fusion model, the gene transfer model is based on horizontal
gene transfer. In short, this model suggests that circulating tumor cell DNA is
taken up by stem cells at the secondary sites, not circulating cells (García-Olmo
et al., 2004) thus, metastasis results from de novo tumor synthesis rather than
from primary tumors. Organ specific affinities of metastases is not explained by
this model nor is it possible that a significant amount of the proposed circulating
DNA would be taken up in the same organ in order to form a solid tumor (Hunter
et al., 2008). For these reasons and more, the gene transfer model is the least
popular at this time.

1.4.1.5. Early Oncogenesis Model
The early oncogenesis model resembles parts of the transient
compartment model. Microarray studies within the last decade or so have
identified protein expression profiles that can predict which tumors can or cannot
metastasize (Nuyten et al., 2006; Ramaswamy et al., 2003; van ’t Veer et al.,
2002; Wang et al., 2005a). These profiles generally include the bulk of the tumor,
thus suggesting the whole tumor has potential to metastasize (transient
compartment model) but may be dominated by a highly metastatic subpopulation
within the tumor that is masked by the bulk of the tumors' expression (Hunter et
al., 2008). Therefore, it has been proposed that metastatic ability is decided
early in oncogenic progression, thus giving a similar protein expression profile to
the bulk of the tumor. Similar issues arise with this model as they did in the
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transient compartment model. This model suggests the majority of the tumor is
capable of metastasis, but secondary tumor site invasion is lower in clinical
observations than what is suggested by this model. Additionally, the microarray
data neither confirms nor denies metastatically aggressive subpopulations within
the primary tumor (Hunter et al., 2008).

1.4.1.6. Genetic Predisposition Model
The Hunter laboratory of cancer biology and genetics at the National
Cancer Institute has piloted the genetic predisposition model, which is based on
how the genetic background of the primary tumor affects its ability to metastasize
(Lifsted et al., 1998). This model suggests that inherited polymorphisms
influence gene expression not only in normal tissue but in tumors as well,
possibly allowing for a predisposition toward metastatic capabilities. The Hunter
laboratory also suggests possible prediction of tumor development and
metastatic capability once a metastatic predictive gene expression signature is
established, as the inherited polymorphisms would be present in all tissues, not
just cancerous ones, therefore making it possible to predict and possible prevent
cancer occurrence (Hunter et al., 2008). The Hunter laboratory is currently
exploring this proposal in vivo (Yang et al., 2005). While none of the metastasis
theories completely explain the phenomenon, it is possible that parts of each
model are true and remain to be proven or disproven.
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1.4.2. Metastatic Initiation
Metastasis initiation is characterized by the cancer cells undergoing
epithelial-to-mesenchymal transition (EMT), invasion through the primary tumor
environment toward the blood, and the bone microenvironment (for those
cancers prone to metastasize in the bone, such as breast cancer). Epithelial
carcinomas that metastasize typically develop physiological alterations, have
changes in cell-to-cell adhesion, and alter how they attach to the extracellular
matrix (ECM), among other changes (Hanahan and Weinberg, 2011).

1.4.2.1. Epithelial to Mesenchymal Transition
EMT is the process where epithelial cells become mesenchymal-like by
losing their epithelial characteristics. This mesenchymal-like profile increases
cancer cell invasiveness (Kallergi et al., 2011). Induction of EMT is associated
with activation of the Wnt/β-catenin signaling pathway (Prasad et al., 2009).
Glycogen synthase kinase 3 inhibition and nuclear β-catenin are markers of the
Wnt/β-catenin pathway activation and are often correlated with poor prognosis of
breast cancer patients (Kim et al., 2002; Logullo et al., 2010). Several markers
are established in the EMT pathway with some of the most established markers
being epithelial-cadherin (E-cadherin), Twist (E-cadherin's repressor), neuronalcadherin (N-cadherin), fibronectin, and vimentin.
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1.4.2.1.1. E-cadherin
The CDH1 gene on chromosome 16q22.1 encodes the E-cadherin protein,
a calcium-dependent, transmembrane adhesion, glycoprotein (McVeigh et al.,
2013). E-cadherin, as its name indicates, is found mainly in epithelial cells and
interacts with cytoskeleton actin and thus has a role in regulating cellular
differentiation, growth, migration, and adhesion (Buda and Pignatelli, 2011).
Specific to its' cell adhesion function, E-cadherin typically interacts with an
assortment of catenins within the cytoplasm, thus maintaining its' interaction with
actin filaments (Pötter et al., 1999). The catenin-binding domain is highly
conserved and consists of 72 amino acids on E-cadherins carboxyl terminus
(Pötter et al., 1999). Within the catenin-binding domain are eight serine residues
and when phosphorylated, allow for catenin-binding therefore inducing the
expected cell-adhesion properties (Stappert and Kemler, 1994). The
juxtamembrane domain, located past the transmembrane domain but within the
intracellular part of E-cadherin is said to function independently to suppress cell
motility (Chen et al., 1997). Therefore, the intracellular tail of E-cadherin not only
dictates cytoplasmic protein interactions but also mediates cadherin functions
(Pötter et al., 1999). A variety of additional factors influence expression and
function of the E-cadherin-catenin system in humans such as, epidermal growth
factor (EGF), tumor growth factor-β (TGF-β), cyclic AMP (cAMP), and androgens
among other factors (Pötter et al., 1999).
Loss of E-cadherin causes loss of epithelial cells apical-basal polarity and
cellular adhesion, characteristics of the EMT transition. While this transition is
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necessary for proper embryonic development, wound healing, and fibrosis, it also
initiates tumor progression to metastasis (Lee et al., 2006; Thiery et al., 2009).
E-cadherin loss is well documented in breast cancer and loss of the CDH1 gene
function is considered a high-risk mutation for breast cancer susceptibility (Berx
and Van Roy, 2001; Deng et al., 2012; McVeigh et al., 2013; Rakha et al., 2005;
Sarrió et al., 2004; Singhai et al., 2011; Vincent-Salomon and Thiery, 2003). In
fact, carriers of CDH1 mutations have a 40-50% breast cancer risk compared to
non-carriers and E-cadherin down regulation predicts poor patient prognosis
(Schrader et al., 2008). E-cadherin down regulation leads to decreased cell
adhesion, which decreases the integrity of breast epithelial cell morphology to a
more mesenchymal-like morphology (Taylor et al., 2011; Wendt et al., 2011).
This mesenchymal-like phenotype allows for continued breast cancer
progression and furthers metastatic initiation.

1.4.2.1.2. Vitamin D Induced Expression of E-cadherin in Breast Cancer
E-cadherin has been shown to be increased by 1,25(OH) 2 D (van Roy and
Berx, 2008). In breast cancer EMT, E-cadherin expression is suppressed, thus
contributing to the mesenchymal-like phenotype (Taylor et al., 2011; Wendt et al.,
2011). 1,25(OH) 2 D treatment caused a time (12-72 hours of 100 nM) and dose
dependent (1-100 nM for 72 hours) increase of E-cadherin expression, which
decreased metastatic potential in MDA-MB-231 breast cancer cells (Lopes et al.,
2012). Given the in vitro effects of 1,25(OH) 2 D to increase E-cadherin, studies in
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in vivo models should be pursued next to see 1,25(OH) 2 D's effect on EMT
inhibition.

1.4.2.1.3. Vimentin
The VIM gene on chromosome 10p13 codes for the vimentin protein, a
type III intermediate filament. Type III intermediate filaments are found in a
variety of human tissues and cells such as endothelium, muscle, glia, fibroblasts,
astrocytes, and leukocytes (Chung et al., 2013). The intermediate filament
proteins are regulated post-translationally via acetylation, ubiquitination,
sumolyation, O-glycosylation, and phosphorylation, most of which are reversible
(Chung et al., 2013). Specifically, vimentin plays an important role in maintaining
cell shape, cytoskeleton communication, organization, and migration and is
predominately expressed during embryogenesis (Dave and Bayless, 2014). Slug,
H-RAS, Akt, adenomatous polyposis coli (APC), and linker of nucleoskeleton and
cytoskeleton activate vimentin to promote cell migration, while specific miRNAs
(i.e. mir-138,mir-30a) and methylenetetrahydrofolate dehydrogenase 2 inhibit this
function (Chung et al., 2013). Therefore, vimentin plays a crucial role in cancer
cell communication and migratory ability leading to metastasis.
In breast cancer EMT, the cancerous epithelial cells switch from a keratindominated IF system to a vimentin-dominated intermediate filament system
(Chung et al., 2013). Vimentin works as a mesenchymal intermediate filament to
assist in epithelial cell migration, thus increasing invasive potential
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(Caruso and Stemmer, 2011; Kallergi et al., 2011). It is also one of the most
highly expressed EMT markers in a study using MCF10CA1a metastatic breast
cancer cells (Battula et al., 2012; Caruso and Stemmer, 2011). Moreover,
studies show increased vimentin expression is associated with increased cancer
cell motility (Chu et al., 1993, 1996; Hendrix et al., 1997) and is a poor prognostic
factor in breast carcinomas (Battula et al., 2012; Caruso and Stemmer, 2011;
Kallergi et al., 2011). Further supporting this observation are multiple studies
with vimentin alterations in human breast cancer cell lines, which showed a
decreased migration effect upon siRNA/shRNA treatments (McInroy and Määttä,
2007; Rogel et al., 2011; Vuoriluoto et al., 2011), suggesting vimentin is indeed a,
if not the, major player in cancer cell motility. This increased expression may be
exacerbated by down regulation of mir-30a and mir-138 in tumors, which
generally functions to inhibit vitmentin motility functions (Cheng et al., 2012;
Yamasaki et al., 2012).

1.4.2.1.4. Vitamin D Induced-Decrease of Vimentin in Breast Cancer
There is some evidence that vitamin D may regulate vimentin expression.
Vitamin D-binding protein-derived macrophage activating factor treatments on
MCF-7 breast cancer cells showed significantly lower vimentin expression (Pacini
et al., 2012). This suggests that vitamin D may have a role in down regulation of
vimentin and therefore EMT inhibition. Several gaps in knowledge remain
regarding the role of vitamin D in regulating vimentin in breast cancer.
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While there is only one study examining vitamin D-related proteins
regulation of vimentin in breast cancer, several studies support vitamin D
regulation of vimentin in prostate and colorectal cancer. A significant decrease in
vimentin mRNA abundance was seen in DLD-1 and HCT116 colorectal cancer
cell lines treated with 1 µM of 1,25(OH) 2 D for 24 and 48 hours (Findlay et al.,
2014). Similarly, RWPE-W99 prostate cancer cells had a dose dependent
decrease in vimentin protein expression shown by Western blot and with
immunohistochemistry when treated with increasing doses of 1,25(OH) 2 D (10-9 to
10-6) (Tokar and Webber, 2005). Further, as the dose of 1,25(OH) 2 D increased,
the percentage of invasive cancer cells decreased (Tokar and Webber, 2005).
Together, these studies provide evidence to support further exploration of the
role of 1,25(OH) 2 D regulated vimentin expression in breast cancer progression.

1.4.2.1.5. N-cadherin
The CDH2 gene on chromosome 18q11.2 codes for the N-cadherin
protein, a calcium-dependent, transmembrane adhesion, glycoprotein. Ncadherin is found in a variety of tissues such as muscle, neurons, endothelial
cells, cardiomyocytes, and mesenchymals. Main functions of N-cadherin
includes establishment of left-right asymmetry, early embryo development,
nervous system synapse function, and cell-cell adhesion. Similar to E-cadherin,
N-cadherin is part of the type 1 classical cadherin family (Sun et al., 2014). It has
a small cytoplasmic domain, a membrane anchoring domain, and a large
extracellular domain with five repeats. Within the large extracellular domain,
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calcium ions are required to stabilize the links between the extracellular repeats,
with the first repeat allowing for interaction between N-cadherins on separate
cells thus facilitating its' classical cell-cell adhesion function (Sun et al., 2014).
Similar to E-cadherin, the cytoplasmic tail of N-cadherin binds to proteins of the
catenin family (Sun et al., 2014). Binding of the catenins allows for N-cadherin to
interact with other cell membrane proteins to form proper cell-cell junctions. Ncadherin-catenin interaction is altered by tyrosine phosphorylation (Lilien and
Balsamo, 2005). Cyclin dependent kinase 5, non-receptor tyrosine kinases, and
receptor tyrosine kinases all associate with N-cadherin adhesion as
phosphorylators, causing dissociation of the catenin-cadherin complex (Castaño
et al., 2007; Lilien and Balsamo, 2005; Schuman and Murase, 2003).
Conversely, dephosphorylation stabilizes the N-cadherin-catenin complex
through receptor tyrosine phosphatase, and non-receptor phosphatase (Balsamo
et al., 1998; Müller et al., 1999).
In breast cancer EMT, N-cadherin expression is increased concurrently
with decreased E-cadherin expression (Hazan et al., 1997; Sigurdsson et al.,
2011). It is thought that N-cadherin and the cell surface receptor fibroblast
growth factor (FGF), interact and cause invasiveness by increasing matrix
metallopeptidase-9 (MMP-9) through sustained MAPK-ERK activation (Kim et al.,
2000; Suyama et al., 2002). Tumor aggressiveness and metastatic potential
was associated with N-cadherin expression in invasive breast cancer biopsies
(Nagi et al., 2005). High N-cadherin expression was significantly associated with
triple negative breast cancer patients who also had metastasis compared to
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those that did not (Nakagawa et al., 2011). Additional evidence comes from a
clinical cohort of 574 breast cancer patients where those with above the median
N-cadherin expression had a statistically significant shorter relapse-free period
compared to those below it (Saadatmand et al., 2013). Therefore, it is possible
that higher N-cadherin expression in breast cancer may contribute to tumor
progression and metastasis.

1.4.2.1.6. Vitamin D Induced-Decrease of N-cadherin in Breast Cancer
Currently, only one study investigates the role of 1,25(OH) 2 D regulation of
N-cadherin. Treatment of 100 nM of 1,25(OH) 2 D for 24, 48, 72, and 96 hours
resulted in a significant decrease in N-cadherin protein expression in MDA-MB453, MDA-MB-361, and BT-474 metastatic breast cancer cell lines (PendásFranco et al., 2007). While these results are promising, the results need to be
replicated to establish a correlation between 1,25(OH) 2 D treatments and
decreased N-cadherin expression in breast cancer.

1.4.2.1.7. Fibronectin
The FN1 gene on chromosome 2q34 encodes for the ECM glycoprotein.
Fibronectin is involved in a host of functions such as wound healing, blood
coagulation, immunity, embryo development, cell adhesion, and metastasis
(Pankov and Yamada, 2002). Within the extracellular matrix and at the cell
surface, fibronectin is either dimeric or multimeric and has the potential to
produce 20 separate transcript variants due to its three regions of alternative
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splicing (Pankov and Yamada, 2002; Sabatier et al., 2013). In the last few years,
studies have suggested that fibronectin is the most pivotal extracellular matrix
organizer (Sabatier et al., 2013). For example, collagen type 1, TSP-1, and
latent TGF-beta-binding protein-1 require fibronectin for their proper assembly
and without such, may lead to developmental abnormalities among other issues
(Dallas et al., 2005; Liu et al., 1995; Sottile and Hocking, 2002). Additionally,
fibronectin is a ligand for many integrin receptors, which are heterodimeric cellsurface receptors that link the intracellular cytoskeleton and extracellular matrix,
thus acting as signaling mediators between the extracellular space and the cell
interior (Pankov and Yamada, 2002). Integrins regulate these signals through
secondary molecules such as focal adhesion kinase (FAK), integrin-linked kinase
(ILK) and more (Hehlgans et al., 2007). Consequently, cell shape, adhesion,
polarity, survival, migration, differentiation and proliferation are indirectly
regulated by fibronectin (Hehlgans et al., 2007).
In breast cancer EMT, fibronectin expression is significantly increased.
Fibronectin has long been known as a marker for EMT (Ignotz and Massagué,
1986) and is also associated with tumor aggressiveness (Bae et al., 2013).
Breast cancer cells undergoing EMT had an increased fibronectin expression
coupled with decreased E-cadherin (as expected) compared to breast cancer
cells that were inhibited from proceeding to EMT (Trimboli et al., 2008).
Additionally, increased tumor expression of fibronectin is linked to poor patient
prognosis and a tumor size >10 mm
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(Bae et al., 2013; Gorczyca et al., 1993; Ioachim et al., 2002). Currently, no
literature exists examining the role of 1,25(OH) 2 D regulation of fibronectin
expression in breast cancer.

1.4.2.2. Metastatic Invasion Into the Blood
Thus, the combination of these EMT associated protein expressions;
decreased E-cadherin, and increased N-cadherin, fibronectin, and vimentin, lead
to increased breast cancer metastasis. EMT is one of the steps of metastatic
initiation, but several additional changes must occur in order for the cancer cells
to acquire full metastatic ability. Once the cancer cells have acquired their
mesenchymal phenotype they must also be able to invade the surrounding tissue
and eventually make it to the blood stream. MMP-9, and bone morphogenic
proteins-2 and -7 (BMP-2, BMP-7) are factors with emerging evidence that they
are involved in cancer invasion to a new cancer site; in this case, breast to bone.
MMP's are known to be capable of degradating extracellular matrix and
basement membrane during normal cell and tissue processes. Over expression
of MMP-9 in metastatic breast cancer cells correlates with invasiveness in the
new site, bone (Cox et al., 2012). Reinforcing this hypothesis, another study
showed MMP-9 was highly expressed and associated with increased
degradation of extracellularmatrix and collagen in both the MCF-7 breast cancer
line and U937 lymphoma cell line (Chimal-Ramírez et al., 2013).
Additionally, CD44, a key regulator of epithelial cell environment, is
commonly over expressed in invasive breast cancers (So et al., 2013). A study
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by So et al. (2013) tested how the vitamin D analog, Gemini, affected
MCF10DCIS basal-like human breast cancer cells and decreased expression of
CD44. This knock down of CD44 lead to decreased MMP-9 mRNA abundance
in the MCF10DCIS line suggesting that vitamin D analogs, thus perhaps
1,25(OH) 2 D, play a role in preventing extracellular matrix degradation which may
inhibit invasion to the bone (So et al., 2013). Studies in the bone are needed to
clarify 1,25(OH) 2 D's precise role on MMP-9.
BMP-7 has known roles in locomotion, chemotaxis, and cell proliferation in
early bone development (Glait-Santar et al., 2012) and assists in cartilage and
bone formation. BMP-7 is up regulated and promoted cancer cell growth,
migration, and metastasis to bone in the highly bone marrow metastatic breast
cancer cell line, 4T1E/M3 (Sakai et al., 2012). In the same study, BMP-7 knock
down in 4T1E/M3 cells caused decreased proliferation, invasion, and migration of
the breast cells to the bone marrow (Sakai et al., 2012). Micro-calcifications,
which occur in early breast cancer and in the breast cells metastasized to bone,
are used as a detection method for early stage breast cancer. Increased
mineralization and calcification of the breast cancer cells occurred in murine
mammary adenocarcinoma cell line, 4T1, when cultured with an osteogenic
cocktail media containing a BMP-2 supplement, suggesting BMP-2 may assist in
tumor development beyond the bone (Cox et al., 2012). Despite substantial
research of BMP-7 in relation to breast cancer, there are no studies concerning
the 1,25(OH) 2 D regulation of BMP-7 or of BMP-2. Considering BMP's and
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1,25(OH) 2 D's prominent roles in bone formation, it is important for future studies
to research their interaction in breast cancer metastasis.

1.4.2.3. Metastatic Marrow Mobilization
Bone is the most common site of breast cancer metastasis (Hess et al.,
2006). The bone microenvironment, which is a milieu of growth factors,
osteoclasts, and osteoblasts, plays a pivotal role in survival of metastatic breast
cancer cells (Chiang and Massagué, 2008). Chemokine (C-C motif) ligand 2 (Ccl2) is one of the best documented controllers involved in the bone
microenvironment (Chiang and Massagué, 2008). Ccl-2, a chemokine with
immunoregulatory, inflammatory, and chemotaxis roles, is also regulated by
1,25(OH) 2 D. Foundational studies show Ccl-2 promotes angiogenesis and acts
on tumor cells to create an attractive microenvironment rich in growth factors
(Salcedo et al., 2000). Co-culturing of pre-osteoblastic and breast
adenocarcinoma cells, to mimic metastatic breast cancer, resulted in increased
Ccl-2 expression in the pre-osteoblastic cells (Glait-Santar et al., 2012). This
suggests that Ccl-2 creates an attractive microenvironment in bone for breast
cancer cells undergoing metastatic initiation to adhere (Glait-Santar et al., 2012).
MCF-7 breast cancer cells transfected with the Fokl polymorphism (VDRff) vector
confirmed the expected increase in Ccl-2 expression (Alimirah et al., 2011).
Treatment with 1,25(OH) 2 D resulted in a significant decrease of Ccl-2 , indicating
a decrease in metastatic potential (Alimirah et al., 2011). More studies
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investigating the impact of 1,25(OH) 2 D regulation in the bone microenvironment
are needed, including the role of breast cancer cell Ccl-2 expression.

1.4.3. Metastatic Progression
Metastatic progression is marked by breast cancer cell extravasation from
the blood into the new cancer site, angiogenesis at the new site, and immune
evasion of the forming micro-tumors.

1.4.3.1. Extravasation
Extravasation is the process of tumor cells traveling through the
bloodstream, exiting the blood vessels, and heading to the new tumor site in the
bone (Chiang and Massagué, 2008). TGF-β and cyclooxygenase-2 (COX-2) are
two established factors involved in extravasation with new results emerging
rapidly. TGF-β suppresses tumorigenesis and promotes cell and tissue
differentiation. In breast cancer, the TGF-β tumor suppressor function is reduced,
thus increasing tumorigenesis. Loss of this TGF-β tumor suppressor function has
been noted to assist in the movement of breast cancer cells to the bone (Chiang
and Massagué, 2008). Once the breast cancer cells are established, the
mutated TGF-β controls several factors, including E-cadherin, that further
promote breast cancer metastasis (Proietti et al., 2011; Taylor et al., 2011). A
10-fold increase in TGF-β expression inhibited further cancer cell growth in MCF7 breast cancer cells when treated for 72 hours with 1,25(OH) 2 D (Proietti et al.,
2011). The results of this study suggest that 1,25(OH) 2 D's mechanism of action
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is through TGF-β's control of Smads, downstream factors which influence cancer
cell proliferation and hormonal responses (Proietti et al., 2011). Additional
studies detailing 1,25(OH) 2 D's mechanism of action in enhancing the TGF-β
tumor suppressor function are needed.
COX-2 plays an intimate role in tissue inflammatory responses and can be
regulated by 1,25(OH) 2 D. In breast cancer, COX-2 has an emerging role in
enhancing cancer cell movement from breast to bone. One study demonstrated
that eliminating COX-2 action decreased or prevented movement of breast tumor
cells to bone (Valcárcel et al., 2011). A significant decrease in COX-2
expression was observed when nude mice with MCF-7 breast cancer cell
xenograft were treated with 1,25(OH) 2 D compared to those treated with vehicle
(Swami et al., 2011). Another study employed similar MCF-7 xenografts but
included male nude mice as well (Swami et al., 2012). Consistent with the
previous study, the results showed a significant decrease in COX-2 mRNA when
both 1,25(OH) 2 D intravenous injections and diet supplements were given (Kim et
al., 2003; Swami et al., 2012). 1,25(OH) 2 D induced COX-2 down regulation,
which may lead to decreased inflammatory signals and reduced directional
signaling that breast cancer cells follow in order to extravasate. Future studies
should focus on up and down-stream factors of COX-2 in order to identify the
exact mechanism of action in relation to 1,25(OH) 2 D inhibited breast cancer
extravasation.
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1.4.3.2. Vascular Remodeling and Secondary Site Angiogenesis
Vascular endothelial growth factor (VEGF) promotes angiogenesis at the
new tumor site and may be regulated by 1,25(OH) 2 D. Angiogenesis is the
growth of blood vessels to the cells implanted in the bone site to provide nutrients.
VEGF is a glycosylated protein that stimulates endothelial cell growth, causing
new blood vessel formation and mediating vascular permeability. In breast
cancer, VEGF is increased and causes increased angiogenesis to the tumor site,
allowing blood to bring the necessary nutrients for its growth (Folkman, 1971;
Syed Khaja et al., 2013). Distant metastases over express VEGF, which is
linked to patient prognosis as shown by microarray analysis of original breast
tumors, nearby metastases (i.e. rib), and distant metastases (i.e. liver, brain) of
human biopsy samples (Hu et al., 2009). The authors hypothesized it was the
increased VEGF that promoted de novo blood vessel formation to new tumors in
the patients analyzed (Hu et al., 2009). Although there are studies exploring the
role of 1,25(OH) 2 D in regulating VEGF in the original breast tumor, none exist for
in the metastases (Mantell et al., 2000; Ben-Shoshan et al., 2007). It is possible
that 1,25(OH) 2 D has an effect on VEGF-stimulated angiogenesis based on
original breast tumor studies but this is an area needing greater research,
particularly using 3D in vitro and animal, models.

1.4.3.3. Immune Evasion
Chemokine (C-C motif) ligand 5 (Ccl-5) and an array of inflammatory
factors are emerging factors thought to be responsible for new tumor site
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immune evasion but few studies involving 1,25(OH) 2 D are available. Immune
evasion is required to protect the tumor from being recognized and attacked by
the body's immune system. Ccl-5 and related inflammatory factors generally act
as chemoattractants for eosinophils and helper-T cells as part of
immunoregulatory processes. High levels of Ccl-5 as well as increased TNF-α,
Ccl-2, and interlukein-1β (IL-1β) were found in breast cancer patient tumor
samples (Soria et al., 2011). The same study further proposes that the combined
expression of Ccl-2 and Ccl-5 and/or TNF-α and IL-1β, promotes breast cancer
formation and relapse (Soria et al., 2011). No literature was found directly
investigating the role of vitamin D on Ccl-5 in breast cancer. Although one recent
study examined the role of vitamin D on Ccl-5 and showed that vitamin D
increased Ccl-5 expression and optimized innate immune function in nondiseased cattle (Nelson et al., 2010). Another study looked at vitamin D
treatment on EAE mice and found it caused increased Ccl-5 as well as a variety
of other inflammatory factors (Subramanian et al., 2012). Although these two
studies showed vitamin D to increase Ccl-5, this vitamin D-induced Ccl-5
increase appeared to normalize immunofunctionality in both (Nelson et al., 2010;
Subramanian et al., 2012). Therefore, vitamin D may act on Ccl-5 in breast
cancer and have an immunoregulatory role that inhibits the tumor cells from
immune evasion but further research is needed to confirm these observations.
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1.4.4. Metastatic Perturbation in Bone
Metastatic perturbation, or continued growth and disruption of normal
tissue, begins after the new tumor has formed and encompasses new site
proliferation as well as immunofunction. Secondary tumor site cancer cell
proliferation requires angiogenesis for nutrient and energy delivery. In normal
tissues, interluken-11 (IL-11) provides proliferation assistance of megakaryocyte
progenitor cells and hematopoietic stem cells as well as stimulation of T-cell
development. In bone metastases, bone is resorbed to create space for the
growing tumor. As osteoclasts break down the bone, osteocytes release immune
mediator signals, which may play a role in tumor metastasis immunofunction. A
foundational study by Hunt et al. (2001) established IL-11 as a mediator of
osteoclastogenesis and osteolytic bone metastasis, allowing for further bone
resorption, therefore promoting bone tumor growth and proliferation (Hunt et al.,
2001). IL-11 can lead to stimulation of RANKL, therefore perturbing osteoclast
synthesis and promoting continued bone degradation for tumor growth (Ren et al.,
2013). A recent study showed that high IL-11 levels were associated with
number of metastases, increased tumor size, age, and pain score in breast
cancer patients (Ren et al., 2013). Additionally, patient survival rates were
significantly lower in patients with increased IL-11 levels (Ren et al., 2013).
While IL-11 has long been identified as an assistant in new tumor site
proliferation, no literature exists on its interaction with 1,25(OH) 2 D. 1,25(OH) 2 D
has an established bone building role, thus its effects on bone
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synthesizers/degraders, RANKL, and IL-11, need to be investigated in the
context of breast cancer metastasis to bone.
Endothelin-1 (EDN-1) plays a dual role as a vasoconstrictor and an
affecter of the central nervous system and is additionally one of the only
identified factors that may be involved in local immune function within breast to
bone metastasis. Immunofunction occurs as the new bone metastases progress
and begin to secrete their own immune responses and/or modulate those of the
hosts immune system. Specifically in breast cancer, EDN-1 has a role in
macrophage and lymphocyte infiltration therefore supporting the
immunofunctional actions of the new tumors (Jewell et al., 2010). EDN-1 is also
involved in earlier stages of metastatic growth but in the inflammatory processes
of those tumors. Tumor mass, bone metastases, immune cell infiltration, and
tumor mass leukocytes were significantly decreased when EDN-1 inhibitors were
given to mice with stage 4 (advanced/metastatic) breast cancer (Jewell et al.,
2010). This finding suggests there is communication between the hosts immune
system and tumor cell microenvironment which dictates tumor growth in bone
(Jewell et al., 2010). Currently, there is no data on 1,25(OH) 2 D regulation of
EDN-1 in breast cancer metastasis.

1.4.5. Chemoresistance to Vitamin D in Breast Cancer
VDR is expressed in normal mammary epithelium both in cells and in
tissues (Lopes et al., 2010). A paradox occurs when considering breast cancer
and vitamin D: as 25(OH)D increases, risk for breast cancer incidence decreases;
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conversely, as breast cancer aggressiveness increases, 1,25(OH) 2 D signaling
decreases. This paradox is characterized by three main players: varied VDR
expression, loss of CYP27B1 expression (codes for 1α-hydroxylase), and overexpression of CYP24A1 (codes for 24-hydroxylase).

1.4.5.1. Variation of VDR
Multiple studies have shown that as cancer progression continues,
1,25(OH) 2 D signaling is attenuated (Lopes et al., 2010, 2012; Matilainen et al.,
2010; Yagmurdur et al., 2009). This may be due to the trend of decreasing VDR
in breast tumors compared to normal tissue. In vitro, ex vivo, and in vivo studies
have all shown a decrease in VDR expression in breast cancer compared to their
normal counter parts (Banwell et al., 2006; Escaleira and Brentani, 1999; Lopes
et al., 2010). Similarly, our own laboratory showed that C3H10T1/2 mouse
fibroblast cells transfected with H-ras had reduced VDRE transcriptional activity
compared to the untransfected cells, suggesting 1,25(OH) 2 D signaling through
the VDR is disrupted in some cancers (Stedman et al., 2003).
Furthermore, over 470 single-nucleotide polymorphisms (SNPs) of VDR
exist (McCullough et al., 2009). Prior studies suggest a link between breast
cancer incidence and VDR polymorphisms but results are mixed (Huang, 2014).
A recent meta-analysis examining the Fok1, Bsm1, Taq1, Apa1, Cdx2, and
PolyA VDR polymorphisms concluded their link to breast cancer risk, if any, is
small (Huang et al., 2014). Specifically, the Fok1, Apa1, Cdx2, and Poly-A
polymorphisms have a insignificant role in breast cancer risk while Bsm1 and
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Taq1 may play a role but many additional studies are needed before that link is
confirmed (Huang et al., 2014).

1.4.5.2. Loss of CYP27B1 Activation
The CYP27B1 gene codes for 1α-hydroxylase, the enzyme which
produces 1,25(OH) 2 D. As mentioned in sections 1.1.1.1. and 1.1.1.3., 1αhydroylase is commonly found in the kidney as well as multiple extra-renal
tissues including the breast (Friedrich et al., 2006; Townsend et al., 2005). A
study by Kemmis and Welsh showed a greater than 70% reduction in CYP27B1
mRNA and protein abundance upon SV40 T-antigens and H-rasV12 oncogene
transfection in human mammary epithelial cell lines (Kemmis and Welsh, 2008).
Further, a study comparing MCF-10 breast epithelial cells to MCF-7 breast
cancer cells showed the MCF-7 cells produced CYP27B1 splice variants which
create non-functional 1α-hydroxylases (Fischer et al., 2007). While there is
evidence for reduced activation of CYP27B1 in breast cancer tissues, these
studies remain controversial as other studies show opposing results (de Lyra et
al., 2006; Townsend et al., 2005).

1.4.5.3. Overexpression of CYP24A1 Activation
The CYP24A1 gene codes for 24-hydroxylase, the enzyme that gives rise
to 1,24,25-trihydroxvitamin D and leads to its degradation. Multiple studies show
this enzyme is significantly increased in breast cancer tissues compared to
normal tissue
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(Albertson et al., 2000; Fischer et al., 2009; Lopes et al., 2010; Matilainen et al.,
2010; Townsend et al., 2005). Therefore, even if VDR and 1α-hydroxylase are
present and active, the predominate role of 24-hydroxlyase will target
1,25(OH) 2 D for degradation, indicating a dysregulation in signaling in breast
cancer even if only one of the three proteins are under-/over-expressed.
However, together with the potential decrease in VDR and CYP27B1, these
findings give even further evidence for attenuated 1,25(OH) 2 D signaling in some
breast cancers. Thus, alternative treatments, such as vitamin D analogs, may
preferably help control breast cancer progression (Chiang et al., 2014; El
Abdaimi et al., 2000; Filip et al., 2010; O’Kelly et al., 2006; So et al., 2013;
Valrance and Welsh, 2004).

1.4.6. Vitamin D Analogs for Breast Cancer
Vitamin D analogs are proposed to have similar anti-cancer effects to
1,25(OH) 2 D without the side effects of disturbing calcium metabolism at high
doses. Another issue occurs if patients are not given bisphosphonates, a
common treatment for patients with metastatic breast cancer, but are given high
1,25(OH) 2 D doses, which can cause toxic hyper- or hypo-calcemia (Amir et al.,
2010; Simmons et al., 2009). Thus, vitamin D analogs attempt to combat the
negative side effects of both long term bisphosphonate use as well as
1,25(OH) 2 D-induced calcium metabolism imbalance.
One vitamin D analog that has been of interest for many years, EB1089,
exerts anti-cancer effects similar to vitamin D when studied in mice. One

54
EB1089 study showed several positive effects when injected in nude mice
xenografted with MDA-MD-231 breast cancer (El Abdaimi et al., 2000). Injected
mice had decreased osteolytic bone metastases and bone tumor burden, as
seen by histomorphometric exams, as well as increased survival rates, showing
that the vitamin D analog can exert anti-cancer effects (El Abdaimi et al., 2000).
Interestingly, the EB1089 injections did not induce the classic vitamin D response
of increased apoptosis in cancer but this did not alter survival rate of the mice (El
Abdaimi et al., 2000). Normo-calcemia remained for injected mice, giving hope
for EB1089 as an anti-cancer agent with little or no side effects (El Abdaimi et al.,
2000).
PRI-2208 and PRI-2209, two well researched vitamin D analogs, have
been tested in both in vitro and in vivo breast cancer models. Inhibition of cell
proliferation and decreased tumor growth occurred with both PRI-2208 and PRI2209 separately in treated MCF-7 breast cancer cells (Filip et al., 2010). Tumor
growth inhibition occurred only with the PRI-2208 analog but both analogs
caused a decrease in lung metastases number when tested in female C57B1/6
mice injected with mouse Lewis Lung Carcinoma (LLC) (Filip et al., 2010).
Additionally, both PRI-2208 and PRI-2209 treatment did not alter serum calcium
levels (Filip et al., 2010). Both PRI-2208 and PRI-2209 analogs show promise to
slow or treat cancer with few calcemic side effects but will require more studies to
determine their impact. The future for vitamin D analogs is bright but much
research needs to be completed to confirm these preliminary studies.
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1.5. Lipid Metabolism
Lipids are one of three macronutrients along with proteins and
carbohydrates. Lipids include glycerides, phospholipids, sterols, waxes, and fatsoluble vitamins. While each class has individual functions, the common
biological function is to provide cell structure, signaling, and store and synthesize
energy (Subramaniam et al., 2011). Additionally, lipids play a role in multiple
human disease states such as obesity, cardiovascular diseases, diabetes, and
cancer. Humans use various anabolic and catabolic pathways to synthesize and
break down lipids as the bodies needs alter but how this is accomplished varies
on the chemical structure of each lipid.

1.5.1. Functions of Specific Lipid Classes
The commonalities between all classes includes their hydrophobicity and
are generally mostly hydrocarbons. However, each lipid class has a different
structure and thus performs varying functions within the realm of energy
metabolism.

1.5.1.1. Fatty Acids
Fatty acids contain long hydrocarbon chains with a carboxylic acid
terminus, and can range from 2 to 49 carbons long (Rezanka and Sigler, 2009).
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In order to make a lipid, these fatty acid chains link with a backbone structure
such as glycerol, creating a mono-, di-, or tri-acylglyercol. The amount of
hydrogens connected to the long carbon tails determines if each fatty acid is
saturated or unsaturated. Saturated fatty acids maintain a relatively linear
structure, and contain all single bonds where as unsaturated fatty acids are bent
due to the cis- or trans- double bond at the sight of unsaturation.
The balance between synthesis and degradation of triacylglycerols and
fatty acids is determined by a number of factors. In a normal healthy human
being, this balance is predominately determined by energy need; where
degradation occurs when energy is needed, most often during starvation or
exercise; and synthesis typically occurs in excess energy states or altered tissue
status such as cancer, diabetes, or genetic disorders of lipid metabolizing
proteins(Campbell and Reece, 2008). Lipogenic pathways include fatty acid
synthesis, cholesterogenesis, sphingomyelin and phospholipid synthesis, among
others.
Fatty acid synthesis and degradation are similar processes in reverse.
Fatty acid synthesis begins with an activated acyl group and an activated malonyl
group, which undergo a condensation reaction to form a four-carbon fragment.
This four-carbon fragment is then reduced, dehydrated, and reduced again to
produce a hydrocarbon chain with the final product being butyryl CoA.
Elongation continues by adding (through condensation reactions) activated
malonyl coA groups until palmitate (a 16-carbon fatty acid) is synthesized (Berg
et al., 2007). After palmitate production, additional elongation and de-saturation
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can occur through special enzymes located on the cytoplasmic face of the
endoplasmic reticulum. Conversely, fatty acid degradation is the reverse of the
synthetic process. An activated fatty acid (with an activated acyl group) is
oxidized to form a double bond which is next hydrated to become a hydroxyl.
The hydroxyl is once again oxidized but into a ketone, which is cleaved by
coenzyme A to produce acetyl coA and a fatty acid with two less carbons (Berg
et al., 2007). Degradation continues until the original fatty acid is completely
converted to all acetyl CoA units.
The process of β-oxidation leads to the degradation of the activated fatty
acids for energy in a stepwise fashion. Before fatty acids can be oxidized for
energy, they must be linked to coenzyme A via thioester bonding. This bonding
occurs on the outer mitochondrial membrane, activating the fatty acid. Upon
activation, the fatty acids translocate across the inner mitochondrial membrane
by conjugating with carnitine. The acyl group from coenzyme A transfers to the
hydroxyl group on carnitine to form acyl-carnitine, which is catalyzed by carnitine
palmitoyl transferase 1 (CPT1) on the outer membrane. Once conjugated, the
acyl-carnitine carries the fatty acid across the inner mitochondrial membrane into
the mitochondrial matrix via translocase (Berg et al., 2007). On the matrix side,
the acyl group is transferred back to coenzyme A by CPT2. The fatty acid can
next begin degradation in the mitochondrial matrix through a serious of four
repeating reactions: oxidation of the β-carbon, hydration, oxidation, and thiolysis.
As a result, the fatty acid is shortened by two carbons and flavin adenine
dinucleotide (hydroquinone form) (FADH 2 ), nicotinamide adenine dinucleotide
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(NADH), and acetyl CoA are synthesized. This sequence of reactions repeats
until the fatty acid is completely broken down into acetyl CoA and energy
metabolites (Campbell and Reece, 2008). For example, complete β-oxidation of
16-carbon palmitoyl CoA becomes eight acetyl CoA molecules, seven FADH 2 ,
seven NADH, and 7 hydrogen ions. The NADH molecules enter complex 1 of
the electron transport chain, known as NADH dehydrogenase, which oxidizes
NADH to NAD and pumps the hydrogen molecule into the intermembrane space
of the mitochondria. Similarly, FADH 2 molecules enter complex 2, known as
succinate dehydrogenase, and is oxidized to FAD. The two removed hydrogen's
are shuttled to complex 3, cytochrome b, where one is pumped into the
intermembrane space. The last hydrogen is pumped through the fourth and final
complex, creating a proton gradient. This gradient causes the hydrogen's to
translocate through the ATP-synthase protein, which powers the synthase to
convert ADP + inorganic phosphate to ATP. In the palmitate example, complete
oxidation of this molecule would result in 106 ATP molecules (Campbell and
Reece, 2008). Unsaturated and odd-chain fatty acids require additional steps
beyond typical β-oxidation to complete degradation.
Unsaturated odd-numbered carbon fatty acids are degraded using just the
isomerase enzymes, converting the double bonds again to the trans-Δ2-double
bond (Berg et al., 2007). Additionally, saturated odd-number carbon fatty acids
have a altered degredation. Rather than the two acetyl CoA molecules being
produced in typical β-oxidation, odd-number fatty acids produce one acetyl CoA
molecule and one propionyl CoA. Propiony CoA enters the TCA cycle by
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conversion into succinyl CoA via a carboxylase enzyme (Berg et al., 2007). Oddchain and unsaturated fatty acids require additional steps to the traditional βoxidation pathway but ultimately produce ATP as well.
As with proteins, lipid structure determines their function. Fatty acids and
the fats they create (triglycerides, etc) are mainly for energy storage in the form
of lipid droplets in adipose tissue. Fat storage is not just for energy but it also
allows for insulation, cushioning of organs, and protection. Non-stored fatty acids
are used as building blocks for glycolipids and phospholipids, which are vital
components to cell membrane structure (Campbell and Reece, 2008).
Cells other than just adipocytes contain lipid droplets that often serve as
an individual energy reserve. Cells can utilize their lipid droplet for energy
production, signaling, or membrane alterations and synthesis (Zechner et al.,
2009). The ability to mobilize tri-, di-, and mono-glycerides from the lipid droplet
depends on lipases and lipid droplet surface proteins such as perilipin 2 (PLIN2),
adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL), which
will be discussed in detail in a later section 1.5.2.3..

1.5.1.2. Cholesterol
Cholesterol is part of a larger lipid family known as the sterols.
Cholesterol has a tetra-cyclic ring structure with an iso-octyl side chain attached
at carbon 17 (Ikonen, 2008). Cholesterol has a multitude of functions including
cell membrane structure, hormone and bile acid precursor, signal transduction,
embryonic development, lipoprotein synthesis, and nervous system functionality.
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In humans, the brain has the highest cholesterol content over any other organ
(Ikonen, 2008). The main function of cholesterol is to alter cell membrane fluidity
by interacting with membrane phospholipids (Ohvo-Rekilä et al., 2002). Similarly,
it assists in membrane organization by regulating membrane proteins and lipid
rafts (Maxfield and van Meer, 2010).
De novo cholesterol synthesis is a 26 step process but can be broken
down into three main steps. Step one, in the cytoplasm, is formation of
isopentenyl pyrophosphate from acetyl CoA, this molecule is an active isoprene
unit and is the core building block of cholesterol. Within the first step, acetoacetyl
CoA is reduced to mevalonate via HMG-CoA reductase, synthesis of mevalonate
is the rate-limiting step in cholesterol synthesis. Step two condenses six
isopentenyl pyrophosphate molecules into squalene in the endoplasmic reticulum.
The last step, three, is cycling squalene until its tetracylic product is converted
into cholesterol, which also takes place in the endoplasmic reticulum.
Cholesterol can either stay in its natural form or go on to become a steroid
hormone, bile acid, or fat soluble vitamins (A, D, E, and K) (Berg et al., 2007).
Cholesterols are stored in an esterified form which is synthesized via acyl-CoA
cholesterol acyltransferase 1 (ACAT1), the cholesterol ester is stored within the
intracellular lipid droplet where it can be released and utilized if needed.
Cholesterol esters are not part of cell membranes, rather they are packed into
intracellular lipid droplets which are released when needed for membranes,
hormone synthesis, and/or lipoprotein synthesis (Athenstaedt and Daum, 2006).
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Cholesterol is not degraded for energy but can be excreted in the feces through
bile acid (Campbell and Reece, 2008).
Regulation of cholesterol synthesis occurs via four main pathways, all of
which involve controlling HMG CoA reductase (Berg et al., 2007). First,
phosphorylation of the enzyme decreases its activity which occurs when there
are low levels of ATP. Second, translation of the enzyme mRNA can be inhibited
by non-sterol metabolites derived from mevalonate or high dietary cholesterol.
Third, the enzyme can be degraded through ubiquitination or proteolysis. Fourth,
the rate of the enzymes mRNA transcription can be altered. This alteration is
controlled by the sterol regulatory element binding protein (SREBP), which
associates on the endoplasmic reticulum when inactive and is associated with
SREBP-cleavage activating protein (SCAP), a cholesterol sensor molecule (Berg
et al., 2007). Additionally, insulin inducing gene 2 (Insig2) associates with
SREBP and binds to SCAP and anchors the complex onto the endoplasmic
reticulum (Stipanuk, 2006). When cholesterol levels are low, SCAP guides
SREBP to the Golgi apparatus utilizing the help of Cop-II proteins. Within the
Golgi, SREBP is cleaved by a MMP and serine protease. The released DNAbinding domain (N-terminus) translocates into the nucleus and binds to the sterol
regulator element (SRE) of the HMG-CoA reductase gene and several other
cholesterol synthetic genes, and enhances their transcription. Conversely, when
cholesterol levels are high, the release of SREBP from the endoplasmic
reticulum is inhibited and the cleaved DNA-binding domain of SREBP in the
nucleus degrades, thus inhibiting further synthesis (Stipanuk, 2006).
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1.5.1.3. Phospholipids
Another abundant lipid class is phospholipids. Their structure resembles
fatty acids in that two long fatty acid tails connected to a glycerol backbone. A
negatively charged phosphate group attaches to the third glycerol hydroxyl group.
Alterations in the types of phospholipids come from differing chain length of the
fatty acids attached, saturation of the fatty acid, and the molecules that may be
linked to the phosphate group (such as choline or serine) (Campbell and Reece,
2008).
Synthesis of phospholipids begins with production of phosphatidate, also
known as diacylglycerol 3-phosphate (Figure 2). Synthesis of phosphatidate
occurs in the endoplasmic reticulum and the outer mictochondrial membrane and
is formed mainly by reduction of dihydroxyacetone phosphate or through glycerol
phosphorylation. Adding two fatty acids to the reduced dihydroxyacetone
phosphate/phosphorylated glycerol next creates phosphatidate. However,
addition of only one chain yields a lysophosphatidate (Berg et al., 2007). Next,
either an activated diacylglycerol or an activated alcohol combine to form their
characteristic lipid. For example, ethanolamine can be phosphorylated to create
active phosphorylethanolamine which is further altered into
phosphatidylethanolamine (PE). Additionally, the phospholipids can interchange
their functional groups to become phosphatidylcholines (PCs),
phosphatidylserines (PSs), and phosphatidylinositols(PIs).
Phospholipids are known for their amphipathic character via their
hydrophilic head and hydrophobic body, thus making them the perfect constituent
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for cell membranes. In water, phospholipids self-assemble into bilayers to shield
their hydrophobic tails, thus creating a boundary between the cellular cytosol and
the external environment. This lipid bilayer is necessary for the structure of all
cells as it as it is a barrier with selective permeability (Campbell and Reece,
2008). Cell membrane permeability can be altered a number of ways, one being
the phospholipid composition. If all the fatty acids in the phospholipid bilayer are
saturated, no kinks or gaps in the bilayer will occur. If there are unsaturated fatty
acids, the bilayer will have altered fluidity, permeability, and morphology.
Therefore, phospholipid content in the cell membrane lipid bilayer may determine
cell fate as it can alter the ability for foreign substances to enter, signaling
capacity, as well as morphology of the cell (Campbell and Reece, 2008).
Functions of phospholipids span beyond lipid bilayers and into signal
transduction, typically as intracellular second messengers. The most common
example is that of the G-protein coupled receptor response by phophatidylinositol
(4,5)-bisphosphonate, which is split into two intra-cellular messengers: inositol1,4,5-triphophosphate and diacylglycerol by phospholipase C (Campbell and
Reece, 2008). These second messengers act on multiple physiological
pathways such as calcium release for muscle contraction and activation of
protein kinase C which leads to changes in chemotaxis, opioid sensitivity, cell
proliferation, and cell survival
(Jiang et al., 1997; Lyon and Tesmer, 2013; Mathews et al., 2008; Newton, 2010;
Penniston et al., 2014; Woodcock et al., 2009). PI's, are most often signaling
molecules but are also part of the cell lipid bilayer, typically on the cytosolic side.
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Additionally, PI's can alter cell motility, invasiveness, proliferation, and actin
cytoskeleton (Corda et al., 2012). PS's are mostly found in brain tissue myelin
and parts of the cell membrane. PS's are also involved in blood coagulation,
apoptosis regulation, bone formation, and neuron survival (Lentz, 2003; Leventis
and Grinstein, 2010). PC's are the most abundant phospholipids in plants and
animals and are the largest constituent of the cell lipid bilayer. Furthermore, PC's
are a component of lipoproteins, thus they are the most abundant phospholipid in
the circulating plasma (Cole et al., 2012). PC is also thought to be involved in
minor signaling pathways in the nucleus and comprises part of human lung
surfactant (Goss et al., 2013). Lastly, PE's are the third most abundant
phospholipid in plants and animals, accumulating particularly in the liver, brain,
and mitochondria, thus playing a large role in cell membrane composition (Vance
and Tasseva, 2013). Specifically, PE is thought to have a major role in inhibiting
negative amino acids from entering the cytoplasm, thus maintaining the positively
charged intracellular space.

1.5.1.4. Sphingolipids and Ceramides
A second subclass of phospholipids are sphingolipids, which are
structurally similar to phospholipids but in lieu of a glycerol backbone,
sphingosine is used. Additionally, the sphingosine molecule itself contains a long
hydrocarbon chain with a terminal amino group. A fatty acid is next linked to the
sphinosine backbone by forming an amide bond with the amino group (Campbell
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and Reece, 2008). The sphingolipid group includes ceramides and
sphingomyelins among other highly complex lipid moitites.
Sphingolipids are formed through the condensation of palmitoyl CoA and
serine to form 3-ketosphinganine. This product is then further reduced to
dihydrosphingosine, followed by conversion into ceramide (Berg et al., 2007).
Ceramides consist of a sphingosine backbone with its' amino group attached to a
fatty acid. The terminal hydroxyl group of the sphingosine is also adjustable
depending on its location and function. An example of this is in nerve fibers
where the sphingosine has a PC attached to comprise part of the myelin sheath
around the nerve axon (Stipanuk, 2006).
Ceramides often have a sphingoid base linked to a fatty acid and are only
found in trace levels, as they are mainly an intermediate of complex sphingolipid
metabolism. As the central molecule in sphingolipid metabolism, ceramides can
be synthesized through multiple pathways but is most often synthesized from
palmitoyl CoA and serine de novo (Saddoughi et al., 2008). Ceramides are
frequently found as part of lipid rafts in the cell membrane but their highest
accumulation occurs in the outer-most epidermis layer (skin) and function in
conjunction with cholesterol and free fatty acids to form a protective barrier
(Bouwstra and Ponec, 2006). Additionally, ceramides are second messengers in
signal transduction during stressful situations (Stancevic and Kolesnick, 2010).
Ceramides are particularly important in apoptosis initiation but the exact
mechanism is currently under investigation (Young et al., 2013).
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Sphingomyelins are compromised of a ceramide with a PC side chain.
Sphingomyelins are the second most abundant phospholipid, just below the
abundance of PC's, with the greatest amount found in the cell membrane (Slotte,
2013). Furthermore, they serve as a part of the sphingomyelin cycle which
serves to synthesize a multitude of ceramide and sphingolipid derivatives, some
of which function as intracellular messengers as well as cell membrane
constructs (Merrill, 2011). Lastly, sphingomyelins may have a role in iron
transport into cells as it is required for transferrin internalization (Slotte, 2013).
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Figure 1.1 Simplified overview of lipid metabolism.
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Figure 1.2 Simplified Overview of Advanced Lipid Metabolism
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1.5.2. Lipid Pathways in Breast Cancer
It is well established that cancer cells undergo a switch to a greater rate of
glycolysis, labeled the Warburg effect, thus it is possible that alterations in lipid
metabolism occur as well. In fact, a lipogenic phenotype is associated with
cancer progression and is thought to provide survival and growth advantages
(Louie et al., 2013; Swinnen et al., 2006). Changes in several lipid classes and
moitites such as cholesterol (Moon et al., 2014), ceramides (Saddoughi et al.,
2008), PIs (Altomare et al., 2004; Yan et al., 2009), and sphingosin-1-phosphate
(Van Brocklyn et al., 2002) have been linked to various cancers. These lipid
alterations, particularly that of the cell membrane, can lead to changes in
membrane fluidity, ligand-receptor interactions, endocytosis, antigen presentation,
lipid-lipid/lipid-protein interactions, and micro-domain formation (Escribá et al.,
2008). Lastly, lipids also act as second messengers which control cell
proliferation, apoptosis, division, and inflammation among other roles (Emoto and
Umeda, 2000). Therefore, the lipogenic phenotype of cancer suggests these
pathways are altered, possibly promoting cancer progression.

1.5.2.1. Fatty Acids in Breast Cancer
Several studies have shown that malignant cells utilize free fatty acids at a
greater rate than non-malignant cells, which are usually esterified to glycerol
backbones in lipid droplets (Prentki and Madiraju, 2008). It is hypothesized that
these fatty acids are employed as energy sources via β-oxidation, or as
substrates for lipid membrane synthesis (Fernandis and Wenk, 2009). While it is
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well established that breast cancers have increased fatty acid levels, a debate
remains whether that increase is due to increased exogenous uptake or
endogenous synthesis. While there is evidence to support both sides of the
argument, the fact remains that increased fatty acids in breast cancer are
associated with a variety of pro-breast cancer effects such as decreased survival
(Liu et al., 2011), increased proliferation (Louie et al., 2013; Rysman et al., 2010),
increased migration (Antalis et al., 2010), metastasis (Vazquez-Martin et al.,
2008) and more. Additionally, β-oxidation may be altered as studies show an
increase in carnitine palmitoyltransferase 1a (CPT1a) in breast cancer,
suggesting an increase in mitrochondrial fatty acid update for β-oxidation, thus
energy production (Sanchez-Alvarez et al., 2013; Shen et al., 2013).

1.5.2.1.1. Fatty Acid Synthase
Fatty acid synthase (FAS) is the second and final committed step in fatty
acid synthesis. The FAS enzyme catalyzes nearly 40 reactions within separate
domains of its active homodimer structure. Thus, it is an efficient process rather
than having different enzymes for each intermediate and also allows for greater
control of fatty acid synthesis via regulating the FAS enzyme (Stipanuk, 2006).
FAS activity is high in the fed state and low in the fasted state with transcriptional
regulation as well as protein expression levels (Stipanuk, 2006). It is the only
human protein that can perform intracellular reductive de novo synthesis of long
chain fatty acids, thus it is major target for control of lipid synthesis (Notarnicola
et al., 2012).
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It is well established that FAS is up regulated in many cancers, including
breast cancer (Antalis et al., 2011; Currie et al., 2013; Menendez and Lupu, 2007;
Menendez et al., 2004; Qiao et al., 2003; Vazquez-Martin et al., 2008; Wang et
al., 2012; Yang et al., 2003). Further, an association between up regulated FAS
and increased fatty acid levels in breast cancer has been established (Menendez
and Lupu, 2007). Breast tumor associated FAS up regulation possibly follows
two paths: Ras activation and/or PI3K activation. MCF10A human breast cells
transformed with H-ras oncogene had increased FAS due to up regulation of
MAPK and PI3K signaling as determined through inhibitor studies (Yang et al.,
2003). MAPK/PI3K up regulation is induced by multiple cell surface receptors
such as receptor tyrosine kinase, epidermal growth factor receptor, and HER2,
which eventually causes increased FAS transcription. It has been further
suggested that the increased FAS may act on cell surface HER2 as positive
feedback, therefore maintaining the high levels of FAS and thus fatty acids in the
cancer cells (Vazquez-Martin et al., 2008). Since increased FAS in breast
cancer is associated with poor prognosis, it is an appealing target for therapeutic
intervention (Puig et al., 2009). Inhibition of FAS has been shown to cause
multiple cell-death inducing effects such as inhibition of pro-apoptotic proteins
(Menendez et al., 2005a, 2005b), inhibition of DNA replication (Liu et al., 2002;
Pizer et al., 1998), disturbance of membrane function (Menendez et al., 2005b;
Nagy et al., 2002), end-product starvation, malonyl-CoA toxicity (Pizer et al.,
2000; Thupari et al., 2001), and p53 regulated metabolic stress (Menendez and
Lupu, 2007; Menendez et al., 2005b). While FAS is an appealing therapeutic

72
target for breast cancer treatment, animal models treated with FAS inhibitors had
adverse side effects, therefore more research is needed prior to clinical
application (Loftus, 2000)(Loftus et al., 2000).

1.5.2.1.2. Vitamin D and FAS
While there are no studies exploring 1,25(OH)2 D's regulation of FAS
expression in breast cancer, there are a few studies in prostate cancer. FAS was
significantly decreased in a cDNA microarray in LNCaP prostate cancer cells
when treated with 10 nM of 1,25(OH) 2 D for 24 hours (Qiao et al., 2003). This
observation was as there was a significant decrease in FAS mRNA abundance at
6, 24, and 48 hours of 1,25(OH) 2 D treatment (Qiao et al., 2003). Further
investigation by this laboratory group determined a potential mechanism of action
of 1,25(OH) 2 D regulation of FAS. They propose 1,25(OH) 2 D increases the
expression of fatty-acid-CoA ligase 3 (FACL3), leading to an increase in long
chain fatty acyl-coAs, which are natural inhibitors of FAS, thus decreasing the
enzymes' expression (Qiao and Tuohimaa, 2004). A similar mechanism may
occur in breast cancer cells, but this remains to be elucidated.

1.5.2.1.3. Stearoyl-CoA Desaturase 1
Stearyol-CoA Desaturase 1 (SCD1) converts saturated fatty acids into
unsaturated fatty acids and is anchored to the endoplasmic reticulum (Enoch et
al., 1976). SCD1 is up regulated by the PI3K/mTOR pathway, insulin, and
growth factors but is not effected by estrogen or leptin (Holder et al., 2013).
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SCD1 plays a role in balancing the ratio of unsaturated verse saturated fatty
acids that are attached to phospholipids. Thus, modification of SCD1 may lead
to alterations in membrane fluidity and therefore cell survival and proliferation
(Mauvoisin et al., 2013).
Increased SCD1 activity is associated with increased breast cancer risk as
well as multiple other cancers (Holder et al., 2013). Additionally, the balance
between unsaturated and saturated fatty acids, often controlled by SCD1, was
said to predict breast cancer incidence in preliminary epidemiological studies
(Chajès et al., 1999, 2008). Specific mono-unsaturated and saturated fatty acid
chains on PCs were found to be significantly higher in breast tumor biopsy
samples compared to normal tissue and correlated with increased SCD1
expression, suggesting high SCD1 may be the culprit for synthesizing the
tumorigenic lipid classes (Ide et al., 2013). Further, inhibition of SCD1 caused a
decrease in proliferation and survival of breast cancer cells (Morgan-Lappe et al.,
2007; Scaglia et al., 2009). In relation to EMT, decreased SCD1 expression is
thought to be involved in maintaining the epithelial phenotype of primary breast
cancer cells, thus inhibiting EMT (Mauvoisin et al., 2013). Lastly, patients with
ER+ and/or PR+ and/or HER2+ breast cancer have the highest SCD1 expression
compared to triple negative tumors, and also have a significantly shorter relapsefree time and overall survival, though the exact mechanism is currently under
investigation (Holder et al., 2013). There no studies examining the role of
1,25(OH) 2 D regulation of SCD1 expression or activity in any cancer lines to my
knowledge.
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1.5.2.1.4. Carnitine Palmitoyl Transferase 1a
As referenced in the lipid metabolism section, CPT1a controls the
entrance of long-chain fatty acids into the mitochondrial inner membrane space
where they undergo β-oxidation. CPT1a is indirectly regulated by the adenosine
monophosphate-activated protein kinase (AMPK). AMPK phosphorylation
inhibits upstream lipogenic enzymes such as acetyl-coA carboxylase (ACC),
which causes a decrease in malonyl CoA levels, thus decreasing fatty acid
synthesis. Malonyl CoA is an inhibitor of CPT1a, thus when it is decreased,
CPT1a is activated and begins transferring fatty acids for β-oxidation.
CPT1a mRNA abundance is increased in MCF-7 and MDA-MB-231 breast
cancer cells compared to 184B5 normal breast cells (Linher-Melville et al., 2011).
Immunohistochemistry of breast invasive ductal carcinomas (IDCs) showed
specific nuclear localization of the CPT1a protein compared to normal breast
tissue (Mazzarelli et al., 2007). Additionally, histone deacetylase (HDAC) activity
was significantly higher in the MCF-7 cells compared to the MCF-12F. Therefore,
the authors tested HDAC and CPT1a with their results suggesting CPT1a could
function as a recruiter for HDAC proteins in order to silence regulatory genes in
cancer (Mazzarelli et al., 2007). There no studies examining the role of
1,25(OH) 2 D in regulating CPT1a expression or activity in any cancer lines to my
knowledge.
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1.5.2.2. Cholesterol in Breast Cancer
Further, the cholesterol pathway is altered in breast cancer. Statin
treatment, which inhibits endogenous cholesterol synthesis, in breast cancer
cells caused cell cycle arrest, suggesting cholesterol is a required component of
cancer cell replication (Gray-Bablin et al., 1997; Rao et al., 1998). There is a
trend of altered lipoprotein profiles in breast cancer patients, with those in
advanced stages showing low cholesterol levels, a documented phenomenon in
these patients (Furberg et al., 2004; Kritchevsky and Kritchevsky, 1992;
Potischman et al., 1991). It is hypothesized that cancer cells have an increased
demand for cholesterol as it is necessary for membrane formation, signaling, and
lipid rafts, thus the low cholesterol levels seen in advanced patients are due to
the cancer, not a cause of cancer (Danilo et al., 2013). Cholesterol accumulation
may be associated with an estrogen receptor status as in vitro models have
shown increased proliferation in ER- breast cancer cell lines compared to the
ER+ lines (Antalis et al., 2010).
An increased estrogen status is associated with increased breast cancer
risk, it is possible that cholesterol exerts some of its effects indirectly through its'
precursor, estrogen, which is an activator of pathways such as ERK1/2 (Yager
and Davidson, 2006). Additionally, cholesterol can travel through the blood
within lipoproteins, which have been shown to induce proliferation, migration, and
signaling pathways that promote breast cancer such as Ras (Grewal et al., 2003)
and Akt (Mineo et al., 2003; Seetharam et al., 2006). Lastly, cholesterol is a
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major part of lipid rafts which are known to assist in regulating cell apoptosis,
invasion, and migration (Danilo et al., 2013; George and Wu, 2012; Murai, 2012).

1.5.2.2.1. Insulin Inducing Gene 2
Insig2, discovered in 2002, is associated with the endoplasmic reticulum
membrane and assists in controlling cholesterogenesis from a transcriptional
level (Yabe et al., 2002). Insig2 associates with SREBP and binds to SCAP and
anchors the complex onto the endoplasmic reticulum (Stipanuk, 2006). When
cholesterol levels are low, SCAP guides SREBP to the Golgi apparatus utilizing
the help of Cop-II proteins. Within the Golgi, SREBP is cleaved by an MMP and
serine protease. The released DNA-binding domain (N-terminus) translocates to
the nucleus and binds to the SRE of the HMG-CoA reductase gene and several
other cholesterol synthetic genes, and enhances their transcription. Conversely,
when cholesterol levels are high, the release of SREBP from the endoplasmic
reticulum is inhibited by Insig2 and the cleaved DNA-binding domain of SREBP
in the nucleus degrades, thus inhibiting further synthesis. Expression of Insig2 is
at a low but constant level and does not depend on SREBPs, but does require
the presence of sterols (Goldstein et al., 2006; Yabe et al., 2002).
While no studies currently exist examining the expression or role of Insig2
in breast cancer, there are some studies in pancreatic and colon cancer. Insig2
has been identified as a negative prognostic marker for colon cancer based on
in vitro studies (Li et al., 2008). The results of the suggest found that increased
Insig2 expression lead to increased colon cancer cell invasion, proliferation,
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growth, and apoptosis inhibition (Li et al., 2008). Similarly, Insig2 expression is
also increased in pancreatic cancer cell lines, especially in hypoxic states
(Kayashima et al., 2011). Pancreatic cancer cells with Insig2 knockdown
resulted in a significant decrease of proliferation and invasion, suggesting Insig2
has a role in these processes (Kayashima et al., 2011). While the trend appears
to be increased Insig2 expression is linked to cancer progression, its role within
breast cancer remains to be determined. The only known link between
1,25(OH) 2 D and Insig2 is the discovery of a VDRE in the promoter region of the
Insig2 gene in pre-adipocyte cells (Lee et al., 2005). No other studies were
found linking 1,25(OH) 2 D and Insig2 in any cancer.

1.5.2.2.2. Acyl-CoA Cholesterol Acyltransferase 1
As mentioned before, ACAT1 esterifies free cholesterol to a cholesterol
ester for neutral storage within a cell. When cholesterol concentrations increase,
a negative feedback loop causes inhibition of HMG CoA reductase, therefore
reducing cholesterol production. This HMG CoA reductase decrease causes
increased ACAT1 activity, shuttling the remaining free cholesterol into storage.
Few studies have examined the role of ACAT1 in breast cancer despite
the known lipogenic phenotype in progressing cancer. A study comparing the
ER+ breast cancer cell line, MCF-7 to the ER- lines, MDA-MB-231 and MDA-MB436 showed a significantly greater number of cytoplasmic lipid droplets in the ER
negative cell lines compared to the ER+ line (Antalis et al., 2010). From this, it
was determined that the ER- cancer lines had a significantly increased mRNA,
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protein expression, and activity of ACAT1 as well as increased low density
lipoprotein (LDL) update, which stimulated proliferation. When ACAT was
inhibited in these cell lines, proliferation was significantly reduced in the ER- lines
(Antalis et al., 2010). Similarly, MDA-MB-231 breast cancer line grown in a
lipoprotein depleted media, resulted in decreased lipid droplet formation and a
significant decrease in cell migration (Antalis et al., 2010). When LDL was
restored to the media, the cancer cell was able to migrate, suggesting a
differential but important role for LDL and ACAT1 in ER+/- breast cancer
progression (Antalis et al., 2011). There no studies examining the role of
1,25(OH) 2 D on ACAT1 expression or activity in any cancer lines.

1.5.2.3. Intracellular Lipid Storage in Breast Cancer
Accumulation of lipid droplets in breast cancer comes as no surprise with
their lipogenic phenotype. Lipid droplets consists of more than just lipids but also
protein kinases, enzymes, and regulatory membrane proteins, and are regulated
through cell signaling. Lipid droplets can be 'activated', leading to influences on
intracellular lipid metabolism, inflammatory mediation, and membrane synthesis,
therefore suggesting that lipid droplets are more organelle-like than a benign
structure (Bozza and Viola, 2010).
Free fatty acids in the cell cytoplasm are toxic, thus hydrolyzing them into
triglycerides and packing them into lipid droplets for storage is optimal. In breast
cancer, it is hypothesized that the lipid droplets not only serve as an energy
reservoir but also protect the cell from lipid toxicity. Peroxisome proliferator-
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activated receptor-gamma (PPARγ) activation stimulates conversion of free fatty
acids to triglycerides for storage, thus protecting the cell from lipotoxicity and
death (Kourtidis et al., 2009). Specifically, PPARγ-binding protein (PBP) coactivates with PPARγ activation leading to increased transcription of lipogenic
genes. Particularly, this co-activation increases nuclear receptor family 1, group
D, member 1 (NR1D1), a recently identified cancer survival promoter, ATP-citrate
lyase (ACLY), FAS, and up to 30 additional lipogenic genes (Kourtidis et al.,
2010; Wang et al., 2012).
Eicosanoids, a type of signaling lipids, are found in high concentration
within lipid droplets of normal epithelial and cancerous cells (Plotkowski et al.,
2008). Further, multiple studies have linked increased lipid droplet formation to
increased eicosanoid synthesis (Accioly et al., 2008; Bozza et al., 1997; Pacheco
et al., 2002). Human group X secreted phospholipase A2 (hGX sPLA 2 ), releases
fatty acids from membranes and lipoproteins. In invasive breast cancer cells
(MDA-MB-231), hGX sPLA2 induces lipid droplet formation, proliferation, and
survival, even during serum depletion (Pucer et al., 2013). From this, it is clear
that intracellular lipid droplets in breast cancer play a pivotal role in cancer cell
survival, proliferation, inflammation, and more.

1.5.2.3.1. Perilipin 2
PLIN2, which is also known as adipose differentiation-related protein
(ADRP/ADFP), is found on the surface of lipid droplets in nearly all cell types and
is regulated by hypoxia inducible factor (HIF) and the PPAR family
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(Matsubara et al., 2011; McIntosh et al., 2012). Many studies suggest this
protein is expressed early within adipocyte differentiation and has a role in
cellular lipid exchange, lipid accumulation, droplet structure, and ultimately cell
proliferation in majority of normal cell types (McIntosh et al., 2012). Further,
PLIN2 promoted accumulation of droplet core lipids, cholesterol esters and
triglycerides, as well as droplet surface lipids, PCs, PSs, and sphingomyelins
(McIntosh et al., 2012). Together, this data suggests that PLIN2 can regulate
lipid droplet composition and lipid exchange through direct protein-lipid
interactions on the surface of the droplet.
It has been suggested that lipid droplets in cancer may function as
specialized sites of signaling to induce inflammatory responses intracellularly
(Bozza and Viola, 2010). One study suggests there is a direct association
between the amount of lipid droplets and PLIN2 mRNA abundance in MDA-MB231 breast cancer cells (Pucer et al., 2013). Additionally, PLIN2 is one of the
only diagnostic markers for the rare secretory carcinoma breast cancer (Osako et
al., 2013). There no studies examining the role of 1,25(OH) 2 D in regulating
PLIN2 expression or activity in any cancer lines.

1.5.2.3.2. Adipose Triglyceride Lipase
ATGL, also called Desnutrin or iPLA 2 , is coded from the Patatin-like
phospholipase domain containing 2 (PNPLA2) gene. ATGL is most often found
in adipose tissue and on intracellular lipid droplets where it preferentially
hydrolyzes triacylglycerides to diacylglycerides. In ATGL-knockout mice there is
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systemic lipid accumulation, severe fat deposition, myopathy, increased cold
sensitivity, and leukocyte malformation (Jordans anomaly), suggesting a
pertinent role for ATGL in normal systemic function (Zechner et al., 2009). The
mechanisms of ATGL regulation are not yet elucidated, but it is hypothesized that
they interact with perilipins and other lipid droplet proteins (Listenberger et al.,
2007). In fact, the only known ATGL up-regulator is comparative gene
identification-58, which increases activation of ATGL five-fold, but the mechanism
of this effect has not been elucidated (Zimmermann et al., 2009).
The only data on ATGL expression in breast cancer is by Gnerlich et al.
(2013) who showed that ATGL expression is not altered based on breast tumor
size or node size (Gnerlich et al., 2013). ATGL is involved in the majority of
cancers through its role in cancer-associated cachexia, the uncontrolled loss of
adipose and muscle tissue. To test ATGLs role in cachexia, researchers
implanted xenografts of LLC cells or B16 melanoma cells in C57BL/6 wild type
and AGTL knock-out (Das et al., 2011). The knockout of ATGL lead to
decreased fatty acid mobilization, retention of muscle and adipose tissues, thus
preventing cancer-associated cachexia in these mice (Das et al., 2011). There
no studies examining the role of 1,25(OH) 2 D regulation of ATGL expression or
activity in any cancer lines.

1.5.2.3.3. Hormone Sensitive Lipase
HSL is the next step of lipolysis after ATGL hydrolysis of a triacylglyceride
to a diacylglyceride. The short-form HSL preferentially hydrolyzes
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diacylglyceridess to monoacylglycerides in adipose and other tissues. The longform HSL, found mainly in steroidogenic tissues, converts cholesterol esters to
free cholesterol for steroid hormone production, particularly on the intracellular
lipid droplets. HSL is activated by protein kinase A, ERK, Glycogen Synthase
Kinase-4, and AMPK and is regulated both pre- and post-transcriptionally via
phosphorylation (Lampidonis et al., 2011). The phosphorylated HSL then
translocates from the cell cytoplasm to the lipid droplet surface where it
preferentially degrades diacylglycerides to monoacylglycerides or cholesterol
ester to free cholesterol (Egan et al., 1992).
Similar to Insig2, literature supporting or negating a role of HSL in breast
cancer does not currently exist. However, similar to ATGL, HSL is suggested to
play a role in cancer-associated cachexia. HSL mRNA abundance is increased
two fold in the adipose tissue of cancer patients compared to non-diseased and
also directly correlated with the serum free fatty acid level (Thompson et al.,
1993). Further, gastrointestinal cancer patients with cachexia had a 50%
increase in gene expression and two times the protein expression of HSL in their
adipocytes compared to gastrointestinal cancer patients without cachexia
(Agustsson et al., 2007). Therefore, it is possible that cancer-associated
cachexia in this group is due to the significant increase in HSL and that perhaps
cachexia can be prevented with HSL inhibitors. There are no studies examining
the role of 1,25(OH) 2 D regulation of HSL expression or activity in any cancer
lines.
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1.5.2.4. Phospholipids and Complex Glycerolipids in Breast Cancer
Shifts in phospholipids have also been noted in breast cancer. The
synthesizing enzyme and precursors to phosphatidic acid, a precursor for de
novo phospholipid synthesis, are increased in breast cancer compared to normal
tumors (Brockmöller et al., 2012). Other studies show that phosphatidic acid,
upon Ras- or PI3K-activated cleavage by phospholipase D 2 , is a major activator
of the MAPK and Akt signaling pathways, which increase cancer cell survival
(Yalcin et al., 2010). Increased phospholipids may be the cause of increased
PI3K signaling seen in breast cancer which ultimately leads to changes in cell
growth and transformation. Increased choline flux into PC's and other lipids is
also noted in breast cancer tumor cells (Ridgway, 2013). Breast cancer cells
under metabolic stress respond by significantly increasing PE production,
suggesting it as a survival mechanism (Zhu and Bakovic, 2012). Additionally,
several PI moities, which indirectly regulate GTPases, are dysregulated in breast
cancer, suggesting their aberrant signaling may contribute to cancer progression
(Wang et al., 2005b). Lastly, in human biopsy samples, specific long chain PC's
(PC(30:0), PC(32:1), etc) are up regulated in patients with below median
prognosis (Hilvo et al., 2011).
Sphingolipids have an emerging role in breast cancer progression. Their
core, ceramide, is a pro-apoptotic sphingolipid which can go on to form
sphingosine-1-phosphate (S1P), a pro-survival sphingolipid (Saddoughi et al.,
2008). This suggests sphingolipids play a major role in determining cancer cell
survival. In vitro models have confirmed that S1P is linked to breast cancer
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progression by regulating cancer cell survival and growth (Nava et al., 2002;
Sarkar et al., 2005). Furthermore, sphingomyelin synthesis activates the
cleavage of diacylglycerol, an intracellular second messenger, from PC, which
activates protein kinase C, a pro-proliferative kinase (Saddoughi et al., 2008).
Perhaps most importantly, increased levels of glucosylceramide, a product of
ceramide, is associated with development of breast cancer drug resistance,
further inducing cancer survival (Ogretmen and Hannun, 2004).
While there is literature on lipid metabolism in cancer, how 1,25(OH) 2 D
may regulate lipid metabolism in any cancer, particularly the breast, has few
studies. A lipogenic phenotype is associated with an increase in cancer
aggressiveness, thus lipid metabolism is an appealing therapeutic target for
breast cancer. Additionally, 1,25(OH) 2 D down-regulated FAS mRNA abundance
in prostate cancer cells, which may lead to decreased aggressiveness. FAS,
SCD1, CPT1a, Insig2, ACAT1, PLIN2, ATGL, and HSL are among the many lipid
metabolism enzyme of interest for therapeutic targets but few studies exam their
function within breast cancer, and even fewer, if any, studies look at 1,25(OH) 2 D
regulation of these enzymes. The understanding of lipid metabolism in breast
cancer and the potential regulatory role of 1,25(OH) 2 D in breast cancer lipid
metabolism remains incomplete at this time.
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2.1. Abstract
It has been established that 1,25-dihydroxyvitamin D (1,25(OH) 2 D) can
alter glycolysis and the Krebs cycle of breast cancer cells (Jiang et al., 2010;
Zheng et al., 2013) but little information is available on 1,25(OH) 2 D's alterations
of lipid metabolism in breast cancer cells. The purpose of this study was to
determine if there was an effect of 1,25(OH) 2 D on proteins that regulate lipid
metabolism in MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a epithelial
breast cancer cells. While no significant effects were seen at 24 hours of
treatment with 10 nM of 1,25(OH) 2 D, several changes were see at 48 hours with
the most significant effects in the MCF10CA1a line. With 48 hour treatment of
1,25(OH) 2 D there was a significant increase of fatty acid synthase (FAS), acetylCoA acetyltransferase 1 (ACAT1), insulin-inducing gene 2 (Insig2), perilipin 2
(PLIN2), and a non-significant trend towards an increase in stearoyl-CoA
desaturase 1 (SCD1) in the MCF10CA1a line. Additionally, there was a nonsignificant trend towards a decrease in carnitine palmitoyl transferase 1a
(CPT1a), adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL).
Lipid accumulation was greater in the MCF10CA1a compared to the other
MCF10A cell lines as shown by oil red O staining. 1,25(OH) 2 D treatment caused
a non-significant trend towards a decrease in total triglyceride concentration in
the MCF10CA1a cells. Additionally, a multitude of alterations
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upon 1,25(OH) 2 D treatment were noted in specific phospholipids,
sphingomyelins, and ceramides using MS-MS. Together, these results suggest
that 1,25(OH) 2 D alters lipid metabolism by increasing lipid storage and
decreasing lipid degradation in epithelial breast cancer cells.

2.2. Introduction
In 2013, it is estimated that 232,340 people will be diagnosed and 39,620
will die of breast cancer in the United States alone (PDQ Screening and
Prevention Editorial Board, 2014). It is well established that cancer cells undergo
a switch to increased glycolysis, termed the Warburg effect, thus it is probable
that alterations in lipid metabolism occur as well. In fact, a lipogenic phenotype is
associated with cancer progression and is thought to provide survival and growth
advantages (Louie et al., 2013; Swinnen et al., 2006). Changes in several lipid
classes and moieties such as cholesterol (Moon et al., 2014), ceramides
(Saddoughi et al., 2008), phophotidylinositols (Altomare et al., 2004; Yan et al.,
2009), and sphingosine-1-phosphate (S1P) (Van Brocklyn et al., 2002) have
been linked to various cancers. These lipid alterations, particularly that of the cell
membrane, can lead to changes in membrane fluidity, ligand-receptor
interactions, endocytosis, antigen presentation, lipid-lipid/lipid-protein interactions,
and microdomain formation (Escribá et al., 2008). Lipids also act as second
messengers which control cell proliferation, apoptosis, division, and inflammation
among other roles (Emoto and Umeda, 2000). Therefore, the lipogenic
phenotype of cancer cells suggests these pathways that regulate lipid
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metabolism are altered, possibly promoting cancer progression. Specifically in
breast cancer, increased fatty acids are associated with a variety of pro-breast
cancer effects such as decreased survival (Liu et al., 2011), increased
proliferation (Louie et al., 2013; Rysman et al., 2010), increased migration
(Antalis et al., 2011), metastasis (Vazquez-Martin et al., 2008).
1,25(OH) 2 D is proposed to be a chemopreventive agent for breast cancer.
Epidemiological studies link increased UV exposure, thus vitamin D levels,
and/or adequate oral vitamin D intake, to a decreased prevalence of breast
cancer (Garland et al., 2007). Additionally, there is an association between
decreased breast cancer prognosis and low serum 25-hydroxyvitamin D
(25(OH)D), the vitamin D status marker (Kermani et al., 2011; Peterlik et al.,
2009). Many studies have shown that the active form of vitamin D, 1,25(OH) 2 D,
exerts inhibitory effects on primary breast tumors through reducing angiogenesis
and proliferation and increasing apoptosis of the cancer cells (Hanahan and
Weinberg, 2011). Our own laboratory has shown that 1,25(OH) 2 D can attenuate
the Warburg effect in breast cancer cells (Jiang et al., 2010; Zheng et al., 2013),
therefore it is possible that 1,25(OH) 2 D may also attenuate lipid metabolism that
promotes breast cancer progression.
A multitude of enzymes regulate lipid metabolism and are shown to be
altered in a cancerous state. FAS is the second and final committed step in fatty
acid synthesis. Additionally, it is the only human protein that can perform
intracellular reductive de novo synthesis of long chain fatty acids, thus it is major
target for control of lipid synthesis (Notarnicola et al., 2012). It is well established
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that FAS is up-regulated in many cancers, including breast cancer (Menendez
and Lupu, 2007). Since increased FAS in breast cancer is associated with poor
prognosis, it is an appealing target for therapeutic intervention (Puig et al., 2009).
While there are no studies examining if 1,25(OH) 2 D can affect expression of FAS
in breast cancer, there are limited studies in prostate cancer. FAS was
significantly decreased in LNCaP prostate cancer cells when treated with 10 nM
of 1,25(OH) 2 D for 24 hours, as shown with microarray and RT-PCR (Qiao et al.,
2003). A similar effect may occur in breast cancer cells but this remains to be
elucidated.
SCD1 plays a role in balancing the ratio of unsaturated versus saturated
fatty acids which are utilized as components of the cell membrane attached to
phospholipids. Thus, modification of SCD1 may lead to alterations in membrane
fluidity and therefore cell survival and proliferation (Mauvoisin et al., 2013).
Increased SCD1 activity is associated with increased breast cancer risk as well
as multiple other cancers (Holder et al., 2013). Inhibition of SCD1 caused a
decrease in proliferation and survival of breast cancer cells (Morgan-Lappe et al.,
2007; Scaglia et al., 2009). In relation to the epithelial-to-mesenchymal transition
(EMT) stage of metastasis, decreased SCD1 expression is projected to be
involved in maintaining the epithelial phenotype of primary breast cancer cells,
thus inhibiting EMT (Mauvoisin et al., 2013). Currently, there are no studies
examining the role of 1,25(OH) 2 D in regulating SCD1 expression or activity in
breast cancer.
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CPT1a controls the entrance of long-chain fatty acids into the
mitochondrial inner membrane space where they undergo β-oxidation. CPT1a
mRNA abundance is increased in MCF-7 and MDA-MB-231 breast cancer cells
compared to 184B5 normal breast cells (Linher-Melville et al., 2011). However,
there are no studies examining the role of 1,25(OH) 2 D regulation of CPT1a
expression in any cancer types.
Insig2 is associated with the endoplasmic reticulum membrane with sterolregulatory element binding protein (SREBP) and SREBP-cleavage activating
protein (SCAP), which together control cholesterogenesis at a transcriptional
level (Yabe et al., 2002). Expression of Insig2 is at a low but constant level and
does not depend on SREBPs but does require the presence of sterols in a
normal healthy individual (Goldstein et al., 2006; Yabe et al., 2002). While no
studies currently exist examining the expression or role of Insig2 in breast cancer,
there are some studies in pancreatic and colon cancer. Increased Insig2
expression lead to increased colon cancer cell invasion, proliferation, growth, and
apoptosis inhibition (Li et al., 2008). Similarly, pancreatic cancer cells with Insig2
knockdown resulted in a significant decrease of proliferation and invasion
(Kayashima et al., 2011). The only known link between 1,25(OH) 2 D and Insig2 is
the discovery of a VDRE in the promoter region of the Insig2 gene in
preadipocyte cells (Lee et al., 2005). No other studies were found linking
1,25(OH) 2 D and Insig2 in any cancer types.
ACAT1 ubiquitously esterifies free cholesterol to a cholesterol ester for
neutral storage within a cell. When cholesterol concentrations increase, a
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negative feedback loop causes inhibition of HMG CoA reductase, therefore
ceasing cholesterol production. This HMG CoA reductase decreased causes
increased ACAT1 activity, shuttling the remaining free cholesterol into storage.
Few studies examined the role of ACAT1 in breast cancer despite the known
lipogenic phenotype in progressing cancer. Despite this, one study showed that
ACAT1 inhibition resulted in decreased breast cancer cell proliferation. Currently,
there are no studies examining the role of 1,25(OH) 2 D in regulation of ACAT1
expression or activity in any cancer types.
PLIN2, also known as adipose differentiation-related protein
(ADRP/ADFP), is located on the surface of lipid droplets in nearly all cell types.
Current research suggests that PLIN2 can regulate lipid droplet composition and
lipid exchange through direct protein-lipid interactions on the surface of the
droplet. It is well established that cancerous cells express a lipogenic phenotype,
thus it is probable that lipid droplet size and number are subsequently increased,
and therefore possible that PLIN2 is also regulated. Despite this, few studies
have examined PLIN2 regulation in cancerous states although one study
suggests there is a direct association between the amount of lipid droplets and
PLIN2 mRNA levels in MDA-MB-231 breast cancer cells (Pucer et al., 2013).
Additionally, PLIN2 is one of the only diagnostic markers for the rare secretory
carcinoma breast cancer (Osako et al., 2013). Currently, no studies examining
the role of 1,25(OH) 2 D in regulating PLIN2 expression or activity in any cancer
type.
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ATGL is located in adipose tissue and on intracellular lipid droplets where
it preferentially hydrolyzes triacylglycerides to diacylglycerides. In ATGL
knockout mice there is whole-body lipid accumulation, severe fat deposition,
myopathy, increased cold sensitivity, and leukocyte malformation (Jordans
anomaly), suggesting a pertinent role for ATGL in normal systemic function
(Zechner et al., 2009). The only data on ATGL expression in breast cancer is by
Gnerlich et al. (2013) who showed that ATGL expression is not altered based on
breast tumor size or node size (Gnerlich et al., 2013). Knockout of ATGL led to
decreased fatty acid mobilization and retention of muscle and adipose tissues,
thus preventing cancer-associated cachexia in mice (Das et al., 2011). Again,
there are no current studies examining the role of 1,25(OH) 2 D in regulating ATGL
expression or activity in any cancer type.
HSL controls the next step of lipolysis after ATGL which is the hydrolysis
of a triacylglyceride to a diacylglyceride. The short-form HSL preferentially
hydrolyzes diacylglycerides to monoacylglycerides in adipose and other tissues.
The long-form HSL, located mainly in steroidogenic tissues, converts cholesterol
esters to free cholesterol for steroid hormone production, particularly on the
intracellular lipid droplets. Similar to Insig2, literature on HSL in breast cancer
does not currently exist. However, similarly to ATGL, HSL is suggested to play a
role in cancer-associated cachexia. HSL mRNA level is increased two-fold in the
adipose tissue of cancer patients compared to non-diseased and also directly
correlated with the serum free fatty acid level (Thompson et al., 1993).
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Additionally, there are no studies examining the role of 1,25(OH) 2 D regulation of
HSL expression or activity in any cancer type.
Clearly there is little research on the effects of 1,25(OH) 2 D regulation of
lipid metabolism in models of breast carcinogenesis and metastasis. In this
study, a range of normal to metastatic epithelial breast cells were utilized as a
model of progressive carcinogenesis and metastasis to examine the function of
1,25(OH) 2 D in regulation of specific lipid metabolism enzymes (FAS, CPT1a,
PLIN2, HSL, ATGL, ACAT1, SCD1, Insig2) and lipid moieties. The hypothesis of
this study is that 1,25(OH) 2 D decreases lipid metabolism and sequesters the
lipids. The results of these studies will provide information that will help the
development of breast cancer prevention strategies.

2.3. Materials and Methods
2.3.1. Chemicals and Reagents
1,25(OH) 2 D was purchased from Biomol (Plymouth Meeting, PA).
Dulbecco's modified Eagle medium (DMEM/F-12), horse serum, trypsin-EDTA,
oil red O, para-formaldehyde, and penicillin/streptomycin were purchased from
Life Technologies, Gibco-BRL (Grand Island, NY). Cholera toxin was from
Calbiochem (Darmstadt, Germany). Trypan blue, insulin, epidermal growth factor,
hydrocortisone, and 3-(4,5-dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide
(MTT) were purchased from Sigma-Aldrich (St. Louis, MO). Bovine serum
albumin was purchased from EMD Milipore (Billerica, MA). Whatman thin layer
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chromatography (TLC) plates Reagent A and B for BCA were purchased from
Thermo Scientific (Rockford, IL). The Non-polar lipid mix B for TLC standards
was purchased from Matreya LLC (Pleasant Gap, PA). Triglyceride assay
reagents and lipid mix standard were purchased from Wako Diagnostics
(Richmond, VA). Tri-Reagent was purchased from Molecular Research Center,
Inc. (Cincinnati, OH). Dimethyl sulfoxide (DMSO) was purchased from Avanto
Performance Materials (Center Valley, PA). ROX dye and SYBR Green Brilliant
II and III were purchased from Agilent Technologies (Santa Clara, CA). Rnasin,
Random Primers, Oligo DT, XTP Random Nucleotide Mix, MMLVRT, and MMLVRT 5x Buffer were purchased from Promega (Madison, WI).

2.3.2. Cell Culture
MCF10A and MCF10A cells stably transfected with the Harvey ras
oncogene (MCF10A-ras) were cultured in DMEM/F12(1:1) supplemented with 5%
horse serum, 1% penicillin-streptomycin, 50 μg/L cholera toxin, 50 mg/L
hydrocortisone, 10 mg/L insulin, and 20 μg/L epidermal growth factor in a
humidified environment at 37C with 5% carbon dioxide. Cells were maintained in
linear (2D) growth, and frozen back in 85% supplemented media, 5% DMSO,
and 10% heat-inactivated fetal bovine serum (HI-FBS). 1,25(OH) 2 D was given to
cells in 100% sterile ethanol with a final concentration of less than 1%.
The MCF10CA1h and MCF10CA1a cells were gifts from Dr. Julia
Kirshner, Purdue University. Both cell lines were cultured in DMEM/F12 (1:1)
supplemented with 5% horse serum and 1% penicillin-streptomycin in a
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humidified environment at 37oC with 5% carbon dioxide. Cells were maintained
in linear (2D) growth and frozen in 85% supplemented media, 5% DMSO and 10%
HI-FBS for storage. 1,25(OH) 2 D was given to cells in 100% ethanol with a final
concentration less than 1%.

2.3.3. Real Time-Polymerase Chain Reaction
MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were treated
with either vehicle (100% ethanol) or 10 nM of 1,25(OH) 2 D for 48 hours prior to
harvest. RNA was harvested and isolated using TriReagent following the
manufacturer's instructions. The total isolated RNA was reverse transcribed
using a reverse transcription mixture: Rnasin, Random Primers, Oligo DT, XTP
Random Nucleotide Mix, MMLVRT, and M-MLVRT 5x Buffer. After this, the
cDNA was quantified and real-time PCR was completed with Brilliant II or Brilliant
III SYBR Green QPCR Master Mix. The abundance of the mRNA of interest was
determined via the threshold cycle (Ct) value and normalized to 18S mRNA
abundance. Results were expressed as arbitrary units and were considered
significant if P<0.05. Primers utilized were purchased from Integrated DNA
Technologies (Coralville, IA) :
-18S
Forward: 5'-TTAGAGTGTTCAAAGCAGGCCCGA-3'
Reverse: 5'-TCTTGGCAAATGCTTTCGCTCTGG-3'
-ACAT1:
Forward: 5'-TGGGCAATGGAGTCTTACTCTGCT-3'
Reverse: 5'-AAACAGCTGGCTCCAAATCAGGGA-3'
-ATGL:
Forward: 5'-CAGACAACCTGCCACTCTATG-3'
Reverse: 5'-GTATCCCTGCTTGCACATCT-3'
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-CPT1a:
Forward: 5'-GGATCCTGGACAATACC-3'
Reverse: 5'-CAGGGAGTCTCTATAAC-3'
-FAS:
Forward: 5'-AGTTCACGGACATGGAGCACAACA-3'
Reverse: 5'-ATGGTACTTGGCCTTGGGTGTGTA-3'
-HSL:
Forward: 5'-CTCTCCAAGTGTGTCAG-3'
Reverse: 5'-GGGTTCTTGACTATGGG-3'
-Insig2:
Forward: 5'-TGGTCCAGTGTAATGCGGTGTGTA-3'
Reverse: 5'-GACCACAGTTGCCAAGAAGCCAAT-3'
-PLIN2:
Forward: 5'-AGCCAACAGACCATTTCTCAGCTC-3'
Reverse: 5'-TTAAAGGAGGCAGCATTGCGGAAC-3'
-SCD1:
Forward: 5'-CCCACCTACAAGGATAAG-3'
Reverse: 5'-CTGGCAGAGTAGTCATAG-3'
2.3.4. Lipid Extraction for Lipid Analysis
MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were
cultured in DMEM/F:12(1:1) as described above in triplicate 60mm dishes and
treated with either vehicle or 10 nM 1,25(OH) 2 D for 48 hours. Twenty-four hours
after the last treatment, cells were washed with 1x Tris-buffered Saline (TBS)
containing 0.2% Bovine Serum Albumin (BSA) and then again with only 1x TBS.
A 3:2 ratio of hexane to isopropanol was added to each dish and placed on a
shaker for 30 minutes at room temperature. After incubation, the solution was
transferred to glass test tubes. The organic solution wash and extraction were
repeated a second time. Test tubes with lipid extractions were capped,
parafilmed, and stored at 4oC until analysis by TLC, gas chromatography (GC),
or colorimetric analysis. Remaining dishes were allowed to dry and 3 mL of 0.1
N NaOH was added to each dish and incubated over night at room temperature
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in order to solubilize the proteins. The protein solution was transferred into
polystyrene tubes and stored at -20oC until BCA assay.

2.3.5. Triglyceride Colorimetric Analysis
Following lipid extraction, the organic fraction was dried with nitrogen,
washed with 1% Triton-X, vortexed to dissolve the lipids, and dried again with
nitrogen. Cells were washed with 2% Triton-X and vortexed to dissolved the
lipids, followed by incubation for 15 minutes in 37oC. After incubation, an
equivalent ratio of water was added to the tubes and incubated for 15 minutes in
37oC. Samples were aliquoted in 2 µl triplicates into a 96-well plate. A serial
dilution of the Lipid Mix Standard was employed. Reagent Color A (180 µl) was
added to all wells and the plate was incubated for 5 minutes at 37oC. Reagent
Color B (60 µl) was added to all wells and the plate was incubated for 15 minutes
at 37C. Absorbance was measured at 600 nm wavelength by spectrophotometer
and corrected to protein concentration determined by BCA. Results were
expressed as mg of triglycerides per µg of protein, averaged for each treatment
group and cell line.

2.3.6. Thin Layer Chromatography
Following the lipid extraction, the samples were dried with nitrogen. A
glass chromatography chamber was equilibrated with a 80:20:1
hexane:ether:acetic acid solution and a sheet of filter paper. After drying,
samples and the non-polar lipid mix B for TLC standards were reconstituted in a
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small amount of chloroform, per manufacturer's instructions. Standards and
samples were spotted and completely dried in 5 µl intervals on a Whatman TLC
plate until 20 µl was reached for each sample. Once complete, the plate was
placed into the equilibrated glass chamber until the solvent line was one inch
from the top of the plate. The plate was removed and allowed to dry and placed
inside a solid phase iodine chamber until band staining was strong. The TLC
plate was removed, photographed, and allowed to evaporate until no color
remained. The plate was stored in a dark, cool, room temperature area for revisualization as needed.

2.3.7. Oil Red O Staining
MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were
cultured in DMEM/F:12(1:1) as described above in triplicate 60 mm dishes with
and without cover slips on the bottom, and treated with either vehicle or 10 nM
1,25(OH) 2 D for 48 hours. Twenty-four hours after the last treatment, the media
was aspirated and cells were washed once with PBS and fixed using 4% paraformaldehyde for 15 minutes at room temperature. Cells were washed three
times with phosphate buffered saline (PBS) and once with 60% isopropanol. A
3:2 ratio of 1% Oil Red O in isopropanol to water was then added to the cells and
incubated at room temperature for 20 minutes. Cells were washed once with 60%
isopropanol, three times with PBS, and once with water. The 60 mm dishes were
sealed with parafilm; cells grown on cover slips were inverted onto slides and
sealed around the edges with clear nail polish.
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2.3.8. Lipid Extraction for MS-MS Analysis
MCF10CA1a cells were cultured in DMEM:F12(1:1) as described above in
triplicate 60 mm dishes and treated with either vehicle or 10 nm 1,25(OH) 2 D for
48 hours, harvested and replated, and treated for an additional 96-hours.
Twenty-four hours after the last treatment, cells were washed with 1x TBS with
0.2% BSA, followed by washing with 1x TBS. A lysis buffer cocktail was added
to each plate and incubated at room temperature for 5 minutes. Plates were
scraped and aliquoted into glass tubes. A methanol-chloroform (3:5) mixture was
added to each tube and incubated for 30 minutes at room temperature on a
shaker. After incubation, the tubes were centrifuged to separate polar and nonpolar fractions, being careful to not aspirate the cell pellet. Fractions were
harvested and aliquoted into separate corresponding glass tubes, dried with
nitrogen, and stored in -80oC until analysis.

2.3.9. Mass Spectrometry
Positive and negative node mass spectrometry was performed on each
polar sample via the LTQ-Orbitrap XL-Nano LC-high resolution hybrid ion trap
(Thermo Orbitrap) machine at Purdue Discovery Park, Bindley Bioscience (West
Lafayette, IN). Parameters for analysis were as follows:
Molecular weight difference: 0; maximum number of modifications: 0;
centralization: yes; LC peak width: 10; minimum effective retention time:
0.5; maximum effective retention time: 38.0; minimum noise-to-signal
ratio: 0.3; m/z variation: 0.007; retention time variation: 0.4 minutes; peak
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frequency cut off: 60; minimum fraction of sample in which a peak must be
detected in control sample: 0.66; minimum fraction of samples in which a
peak must be detected in treatment sample: 0.3; mass tolerance: 0.2; Ttest threshold: 0.05.

2.3.10. Bicinchoninic Acid Assay (BCA)
BCA assay was utilized for the colorimetric detection of the total protein
concentration of a sample. A standard curve was created utilizing increasing
concentrations of BSA . Samples were placed in triplicate on the plate, a mixture
of Reagent A to Reagent B (50:1) was put in each well and the plate was
incubated in the dark for 30 minutes at 37oC. Colorimetric detection was
quantified by spectrophotometer at 592 nm wavelength (Powerwave, Biotek
Instruments Inc, Winooski, VT).

2.3.11. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] Assay
MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were
cultured in DMEM/F:12(1:1) as described above in a 24-well plate and were
treated with either vehicle or 10nM 1,25(OH) 2 D for 48 hours. Twenty-four hours
after the last treatment, the media was aspirated and a 0.5 mg/mL of MTT
working mix was added to each well and incubated in the dark for 2 hours at
37oC. After incubation, DMSO was added and thoroughly mixed in each well and
the plate was incubated in the dark for 5 minutes at 37oC. Afterwards, the plate
was tapped to assist in dissolving the solutes and the solution was aliquoted in
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duplicate into a 96-well plate and quantified at 570 nm with a 700 nm reference
wavelength via spectrophotometer (Powerwave, Biotek Instruments Inc.,
Winooski, VT).

2.3.12. Statistical Analysis
Values presented are means ± SEM. Student T-tests and ANOVA were
performed using SAS 9.2 or 9.3. Data was considered statistically significant
with a p-value of P<0.05. MS-MS samples were processed through the Purdue
OMICS Pipeline database.

2.4. Results
To determine if 1,25(OH) 2 D alters lipid metabolism, MCF10A, MCF10Aras, MCF10CA1h, and MCF10CA1a cells were treated with vehicle or 10 nM of
1,25(OH) 2 D for 24 or 48 hours and mRNA abundance determined. Twenty-four
hour treatment of all four cell lines resulted in no significant differences among
ACAT1, FAS, Insig2, or PLIN2 in any of the cell lines. Following 1,25(OH) 2 D
treatment for 48 hours, ACAT1 levels were significantly increased (p=0.007) in
MCF10CA1a cells with a non-significant trend towards an increase (p=0.06) in
the MCF10A cells (Figure 2A). Similarly, FAS (p=0.004) (Figure 2B), Insig2
(p=0.03) (Figure 2C), and PLIN2 (p=0.01) (Figure 2D) were all significantly
increased in the MCF10CA1a cells with no significant differences or trends in the
other three cell lines. In contrast, there were non-significant trends towards
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decreases in HSL (p=0.08) (Figure 2E), ATGL (p=0.08) (Figure 2F), and CPT1a
(Figure 2G) in the MCF10CA1a cells. No change was seen in SCD1 mRNA
levels in any cell line (Figure 2H).
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Figure 2. mRNA abundance of vehicle and 1,25(OH) 2 D treated MCF10A,
MCF10A-ras, MCF10CA1h, and MCF10CA1a cells. All cells were treated for 48
hours with either vehicle or 1,25(OH) 2 D (10 nM). A representative quantification
of the mRNA abundance is shown for each lipid metabolism enzyme, indicated
with vehicle (open bars) and 1,25(OH) 2 D treatment (black bars). Values are
expressed as lipid enzyme mRNA relative to 18S mRNA for each sample relative
to vehicle control. Results are expressed as mean ± SEM. (n ≥ 3). Bars with
common letter subscripts are not significantly different (p<0.05). 2A. ACAT1; 2B.
FAS; 2C. Insig2; 2D. PLIN2; 2E. HSL; 2F. ATGL; 2G. CPT1a; 2H. SCD1.
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Due to these alterations in lipid metabolism enzymes, oil red O staining
and TLC were performed to visually assess the differences between cytoplasmic
lipid droplet accumulation and lipid classes, respectively, with 48 hours of
1,25(OH) 2 D treatment. Upon oil red O staining, it was apparent that lipid
accumulation was increased in the metastatic cell line (Figure 3), specifically,
visual assessment determined that the size and number of lipid droplets
increased, thus agreeing with the conjecture that aggressive cancer is
characterized with a lipogenic phenotype. Differences in oil red O staining were
difficult to visually assess between vehicle and 1,25(OH) 2 D treatment therefore,
TLC was performed to better identify differences. Visual assessment of the
iodinated plates showed a slight increase in cholesterol with 1,25(OH) 2 D
treatment in the MCF10A cells, but a decrease in cholesterol with 1,25(OH) 2 D
treatment in the MCF10A-ras and MCF10CA1a cells lines (Figure 4).
Additionally, visual assessment showed that 1,25(OH) 2 D treatment increased
free fatty acids, as represented by the oleic acid standard, in both the MCF10Aras and MCF10CA1a cell lines while no changes were seen with the
MCF10CA1h cell line (Figure 4).
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Figure 3. Oil red O staining of vehicle and 1,25(OH) 2 D treated MCF10A,
MCF10A-ras, MCF10CA1h, and MCF10CA1a cells. All cells were treated for 48
hours with either vehicle or 1,25(OH) 2 D (10 nM). A representative image of the
oil red O staining is shown for each cell line and treatment.
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Figure 3. TLC of vehicle and 1,25(OH) 2 D treated MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells. All
cells were treated for 48 hours with either vehicle or 1,25(OH) 2 D (10 nM). Standards are listed along the far left
column and are designated by the "S" on the x-axis. A test spot was done on the far left and is labeled "T". A
representative image of the TLC plate is shown for each cell line and treatment.
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The same samples used to perform the TLC were tested for total
triacylglyceride content relative to their protein concentration. While the only
significant difference between treatment groups was in the MCF10A-ras cells
(P=0.03), there were no significant differences between the treatment groups in
the other three cell lines upon 48 hours of vehicle or 1,25(OH) 2 D. Despite this, it
was again observed that there was a significant increase in triglycerides as the
cell line aggressiveness increased (Figure 5).
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Figure 5. Triglyceride colorimetric analysis of vehicle and 1,25(OH) 2 D treated
MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells. All cells were
treated for 48 hours with either vehicle or 1,25(OH) 2 D (10 nM). A representative
quantification of the triglyceride colorimetric analysis is shown, indicated with
vehicle (open bars) and 1,25(OH) 2 D treatment (black bars). Values are
expressed as average milligrams of triglycerides per treatment group relative to
the average milligrams of protein per the same treatment group for each sample
relative to vehicle control. Results are expressed as mean ± SEM. (n ≥ 3). Bars
with common letter subscripts are not significantly different (p<0.05).
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To identify the specific lipids that were altered with 48 hour 1,25(OH) 2 D
pretreatment, replating, and subsequent 96 hour 1,25(OH) 2 D treatment, MS-MS
was performed on MCF10CA1a cells. The negative and positive spray together
produced over 400 significant changes (P ≤ 0.01) in individual lipid moieties.
Significant increases in some phosphotidylinositols (PIs), phosphotidylchoines
(PCs), phosphotidylethanolamines (PEs), and sphingomyelins with long chain
fatty acids attached (data not shown) were seen in the 1,25(OH) 2 D treated group.
Additionally, there were significant decreases in some glucosylceramides, also
with long chain fatty acids attached. Overall, majority of the significantly altered
lipids upon 1,25(OH) 2 D treatment were those with long chain fatty acids attached.
The analysis of these changes is ongoing in our laboratory.
To assure our differences were not a result of changes in cell viability, an
MTT assay was performed on all four cells lines with vehicle or 10 nM of
1,25(OH) 2 D for 48 hours prior to harvest. While there was a trend towards a
decrease in number of live cells with 1,25(OH)2 D treatment in all the lines, only
the MCF10A line had a statistically significant decrease (P=0.0006) (Figure 6).

145

6
Cell Number Relative to Vehicle

2.5

Vehicle
1,25(OH)2D
2.0

1.5

1.0

0.5

*

0.0

MCF10CA1a

Figure 6. MTT assay of vehicle and 1,25(OH) 2 D treated MCF10CA1a cells. All
cells were treated for 48 hours, harvested and replated, and treated for an
additional 96 hours with either vehicle or 1,25(OH) 2 D (10 nM). A representative
quantification of the MTT assay is shown, indicated with vehicle (open bars) and
1,25(OH) 2 D treatment (black bars). Values are expressed as cell number of
each sample relative to vehicle control. Results are expressed as mean ± SEM.
(n ≥ 5). Statistical significance is defined as P<0.05.
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2.5. Discussion
In the current study, the effect of 1,25(OH) 2 D treatment on lipid
metabolism enzyme mRNA abundance was explored in epithelial breast cancer
cell lines including untransformed MCF10A, H-ras oncogene transfected
MCF10A-ras, to aggressive MCF10CA1h, and metastatic MCF10CA1a cells.
Together these cell lines represent a model for breast cancer progression. This
study is the first to examine how 1,25(OH) 2 D may regulate FAS, SCD1, CPT1a,
Insig2, ACAT1, PLIN2, ATGL, and HSL in metastatic breast cancer. The results
show that 10 nM of 1,25(OH) 2 D did not have significant effects at 24 hours but
upon 48 hours of treatment, several alterations were noted. Specifically, in the
metastatic MCF10CA1a line, there were significant increases in FAS, ACAT1,
Insig2, and PLIN2, which suggests there is an increase in cholesterol storage
(ACAT1) and lipid storage (PLIN2) as well as a decrease in synthesis of new
cholesterol (Insig2). Increased FAS may indicate increased triglyceride synthesis
as well. Additionally, a trend towards a decrease in CPT1a, HSL, and ATGL,
was observed. These results suggest that lipolysis of the stored lipids is
decreased (HSL, ATGL) and that β-oxidation may also be decreased (CPT1a).
No effects were seen in SCD1 expression, suggesting that the balance of
saturated and unsaturated fatty acids within a cell may not be significantly altered
in metastatic breast cancer. Together these results suggests that 1,25(OH) 2 D
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may shift lipid metabolism toward storage and decrease lipolysis and β-oxidation
in metastatic MCF10CA1a cells. Therefore, 1,25(OH) 2 D may inhibit cancer cell
growth and/or metastasis by shifting lipids usually needed for signaling, energy,
or proliferation, into storage. While these endpoints remain to be tested, it is
clear 1,25(OH) 2 D has a consistent effect on several enzymes involved with lipid
metabolism.
Visual increases in lipid droplets and fatty acids were seen as cell line
aggressiveness increases. While visual alterations of cells treated with
1,25(OH) 2 D were not detectable, trends between cell lines were seen in levels of
cytoplasmic lipid droplet accumulation by oil red O, and in levels of lipids
separated by TLC. The visual trend of increased lipid droplets confirms the
notion that increasing cancer aggressiveness is associated with increased
cytoplasmic lipid accumulation (Louie et al., 2013; Swinnen et al., 2006).
Additionally, the visual increase in oleic acid in the MCF10CA1a cells suggests
specific lipid moieties are altered within cancer progression. Interestingly, total
triglycerides were significantly increased only in the MCF10A-ras line upon
1,25(OH) 2 D treatment while MCF10CA1a cells had a trend towards a decrease.
Although this decrease does not agree with the significant increase in FAS
mRNA abundance, it may suggest that FAS is synthesizing fatty acids for
alternative lipid synthesis such as phospholipids, sphingomyelins, cholesterols,
etc.
Therefore, lipidomics of the MCF10CA1a cells was performed on samples
treated with either vehicle or 10 nM of 1,25(OH) 2 D. Preliminary analysis
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performed by laboratory member, Tomasz Wilmanski, identified potential
differences in several lipid moieties. There were significant decreases in
glucosylceramides concurrently with significant increases in PCs, PEs, PIs, PSs,
and sphingomyelins containing long-chain fatty acids in the 1,25(OH) 2 D treated
cells compared to vehicle. This suggests that lipid metabolism is shifted toward
phospholipid and SM synthesis upon 1,25(OH) 2 D treatments and may explain
the trend towards a decrease of TAG but increased FAS. To our knowledge, this
is the first study examining the effects of 1,25(OH) 2 D regulation of the
abundance of advanced lipid moieties. Increased phospholipids may lead to a
multitude of changes within a cancer cell such as altered cell membrane
permeability and fluidity. It is also probable that there are changes in signaling
transduction pathways as both phospholipids and sphingomyelins have both
been identified as intracellular messengers. While the results of recent studies
have shown that increased PCs (Hilvo et al., 2011; Ridgway, 2013), PEs (Zhu
and Bakovic, 2012), and PIs (Wang et al., 2006) may be linked to cancer cell
survival signaling, it is known that treatment with 1,25(OH) 2 D induces apoptosis
(Pileczki et al., 2012; Simboli-Campbell et al., 1996) and growth inhibition
(García-Quiroz et al., 2013; Suetani et al., 2012). Thus, since lipidomics
revealed an increase in phospholipid abundance, MTT was performed to identify
if MCF10CA1a did indeed have decreased viability. The normal MCF10A cells
had a significant decrease in viability but there was only a trend towards a
decrease in the metastatic MCF10CA1a cells. Together these results suggest
that 1,25(OH) 2 D exhibits moderate growth inhibition in metastatic cells but
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perhaps this is driven more by alterations in neutral lipid availability and not
phospholipid abundance. Alternatively, the increase in phospholipids may shift
intracellular signaling for decreasing the invasive potential of the cancer cell (see
chapter 3).

2.6. Conclusions
To our knowledge, this is the first study to examine how 1,25(OH) 2 D
regulates FAS, SCD1, CPT1a, Insig2, ACAT1, PLIN2, ATGL, and HSL as well as
the abundance of lipid moieties in metastatic breast cancer. Overall, our results
suggest that 1,25(OH) 2 D may shift lipid metabolism toward storage and decrease
lipolysis as indicated by decreased lipases and CPT1a concurrently with
increased FAS, Insig2, ACAT1, and PLIN2. Furthermore, the results show that
1,25(OH) 2 D further increases phospholipids and sphingomyelins while causing a
slight decrease in cell viability suggesting the altered lipids may alternatively
used for signaling and not proliferation. Together, these results suggest
1,25(OH) 2 D alters the lipid metabolism within metastatic epithelial breast cancer
cells in vitro.
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3.1. Abstract
It is known that 1,25-dihydroxyvitamin D (1,25(OH) 2 D) exerts anti-cancer
effects on primary breast tumors (Welsh, 2004) but the role of 1,25(OH) 2 D in
metastasis has yet to be determined. The purpose of this study was to
determine if there was an effect of 1,25(OH) 2 D on epithelial-to-mesenchymal
transition (EMT) protein markers and cell viability in MCF10CA1a metastatic
epithelial breast cancer cells. To identify the impact of 1,25(OH) 2 D regulation of
EMT and metastasis of breast epithelial cells to bone we employed a
reconstructed metastasis (rMET) model. Upon 1,25(OH) 2 D treatment in the
upper well of the rMET model, which recapitulates the mammary environment,
mammospheres were visually smaller but not statistically significant upon
quantification, compared to vehicle treated cells. Similarly, 3-(4,5dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) assays had a nonsignificant trend towards a decrease in the amount of viable cells between
treatments in 3D. Additionally, the total number of cells to metastasize and
survive in the bone marrow conditioned media (BMCM) and reconstructed bone
matrix (rBM) were significantly reduced in the 1,25(OH) 2 D group versus vehicle.
To determine the impact of 1,25(OH) 2 D regulation of EMT, the mRNA
abundance of markers of EMT in the upper well was determined. A significant
increase in vimentin and fibronectin mRNA abundance, both markers of EMT,
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was seen following 48 hours of 10 nM of 1,25(OH) 2 D treatment compared to
vehicle in 2D cell culture. Additionally, mRNA abundance of epithelial-cadherin
(E-cadherin), which is decreased during EMT, had a trend towards an increase
while neuronal-cadherin (N-cadherin) was unchanged. Immunofluorescent
staining of the upper well mammospheres for E-cadherin, vimentin, perilipin 2
(PLIN2) proteins, co-stained with neutral lipid stain, Bodipy, and the nuclear stain,
4',6-diamidino-2-phenylindole (DAPI), were completed. Although a visual
difference employing the Zeiss microscope showed little difference between
treatments, confocal images are being obtained and analyzed by our laboratory
to more carefully assess the differences in protein expression. Together, these
results suggest that 1,25(OH) 2 D decreases breast to bone metastasis by altering
viability in the BMCM and rBM as well as alterations in mRNA abundance of
characteristic EMT protein proteins in metastatic epithelial breast cancer cells,
therefore decreasing cancer aggressiveness.

3.2. Introduction
In 2013, it is estimated that 232,340 people will be diagnosed and 39,620
will die of breast cancer in the United States alone (PDQ Screening and
Prevention Editorial Board, 2014). Of those diagnosed with breast cancer, 32%
will have spread to lymph nodes and another 5% to distant sites with 84.4% and
24.3% survival rates at five years, respectively. Compared to a 98.6% survival
rate of patients with breast tumors without metastasis at diagnosis, it is clear
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metastasis of the tumor is correlated with increased mortality (Centers for
Disease Control and Prevention). While there are several non-modifiable breast
cancer risk factors such as age, gender, and genetics, it may be possible to
prevent breast cancer progression and/or metastasis by altering other factors.
Thus, additional research is needed to determine alternative propositions for
breast cancer progression and/or metastasis prevention.
1,25(OH) 2 D has support as a chemopreventive agent for breast cancer.
Epidemiological studies link increased UV exposure, thus vitamin D levels,
and/or adequate oral vitamin D intake, to a decreased prevalence of breast
cancer (Garland et al., 2007). Additionally, there is an association between
decreased breast cancer prognosis and low serum 25-hydroxyvitamin D
(25(OH)D), the vitamin D status marker (Kermani et al., 2011; Peterlik et al.,
2009). Many studies have shown 1,25(OH) 2 D's inhibitory effects on primary
breast tumors through reduced angiogenesis and proliferation with increased
apoptosis of the cancer cells (Hanahan and Weinberg, 2011). New literature has
begun to explore the role of 1,25(OH) 2 D in prevention of breast cancer
metastasis to the bone.
Metastasis initiation is affected by the cells undergoing EMT, invasion
through the primary tumor environment toward the blood, and the bone
microenvironment (for those cancers prone to metastasize in the bone, such as
breast cancer). Epithelial carcinomas that metastasize typically develop
physiological alterations, a process where epithelial cells become mesenchymallike by losing their epithelial characteristics, called EMT. This mesenchymal-like
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profile increases cancer cell invasiveness (Kallergi et al., 2011). Several proteins
are associated with EMT with some of the most established being decreased Ecadherin, and increased vimentin, N-cadherin, and fibronectin.
E-cadherin, a transmembrane adhesion glycoprotein has roles in cellular
migration and adhesion (Buda and Pignatelli, 2011). E-cadherin loss is well
documented in breast cancer and causes loss of epithelial cells apical-basal
polarity and cellular adhesion, characteristics of the EMT transition. Specifically,
its' down regulation leads to decreased cell adhesion which decreases the
integrity of breast epithelial cell morphology to become more mesenchymal-like
morphology (Taylor et al., 2011; Wendt et al., 2011). E-cadherin has been
shown to be increased by 1,25(OH) 2 D (van Roy and Berx, 2008). Treatment
with 1,25(OH) 2 D caused a time (12-72 hours of 100 nM) and dose dependent 1100 nM for 72 hours) increase of E-cadherin expression, which decreased
metastatic ability in MDA-MB-231 breast cancer cells (Lopes et al., 2012).
Vimentin, an intermediate filament protein, plays an important role in
maintaining cell shape, communication, organization, and migration (Davies and
Samuels, 2010). Studies show increased vimentin expression is linked to
increased cancer cell motility (Chu et al., 1993, 1996; Hendrix et al., 1997) and is
a poor prognostic factor in breast carcinomas (Battula et al., 2012; Caruso and
Stemmer, 2011; Kallergi et al., 2011). Currently there are no studies
investigating the role of 1,25(OH) 2 D regulation of vimentin expression in breast
cancer.
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N-cadherin, a calcium-dependent, transmembrane, adhesion glycoprotein,
has a role in cell adhesion and neuronal development. In breast cancer EMT, Ncadherin expression is increased co-currently with decreased E-cadherin
expression (Hazan et al., 1997; Sigurdsson et al., 2011). Tumor aggressiveness
and metastatic potential was associated with N-cadherin in invasive breast
cancer biopsies (Nagi et al., 2005). Additionally, high N-cadherin expression was
significantly associated with triple negative breast cancer patients who also had
metastasis compared to those that did not (Nakagawa et al., 2011). Currently,
only one study investigated the role of 1,25(OH) 2 D regulation of N-cadherin
expression. Treatment with 100 nM of 1,25(OH) 2 D for 24, 48, 72, and 96 hours
resulted in a significant decrease in N-cadherin protein expression (PendásFranco et al., 2007).
Fibronectin is involved in a host of functions, two of which include cell
adhesion and metastasis (Pankov and Yamada, 2002). Fibronectin has long
been positively associated with EMT in cancer (Ignotz and Massagué, 1986) and
is also associated with tumor aggressiveness (Bae et al., 2013). Additionally,
increased tumor expression of fibronectin is linked to poor patient prognosis and
a tumor size >10 mm (Bae et al., 2013; Gorczyca et al., 1993; Ioachim et al.,
2002). Unfortunately, no literature exists examining the role of 1,25(OH) 2 D in
regulation of fibronectin expression in breast cancer.
Thus, it is likely the combination of decreased E-cadherin, and increased
N-cadherin, fibronectin, and vimentin, lead to increased breast cancer metastasis.
Treatment with 1,25(OH) 2 D increased E-cadherin expression and decreased N-

161
cadherin expression, likely decreasing EMT potential, and therefore metastasis
initiation (Lopes et al., 2012; Pacini et al., 2012). Weak or no literature exists on
the role of 1,25(OH) 2 D in regulation of vimentin and fibronectin expression.
The effects of 1,25(OH) 2 D regulation of E-cadherin, N-cadherin, vimentin,
and fibronectin has not been well researched in models of breast carcinogenesis
and metastasis. In the current study, metastatic breast epithelial cells were
utilized as a model of carcinogenesis and metastasis to examine the function of
1,25(OH) 2 D in regulation of E-cadherin, N-cadherin, vimentin, and fibronectin.
The hypothesis of this study is that 1,25(OH) 2 D inhibits metastasis and increases
E-cadherin, while simultaneously decreasing N-cadherin, vimentin, and
fibronectin in metastatic epithelial breast cancer cells. These results will
contribute to understanding how 1,25(OH) 2 D acts on the breast tissue throughout
cancer, specifically during EMT.

3.3. Materials and Methods
3.3.1. Chemicals & Reagents
1,25(OH) 2 D was purchased from Biomol (Plymouth Meeting, PA).
Penicillin/streptomycin, RPMI 1640, Alexa-488, Alexa-680, DAPI, Triton-X, fetal
bovine serum, L-glutamine, and the Viability Live/Dead kit for mammalian cells
were from Life Technologies, Gibco-BRL (Grand Island, NY). Vectashield was
purchased from Vector Laboratories Incorporated (Burlingame, PA). HEPES,
alpha-MEM, sodium bicarbonate, phosphate buffered solution (PBS), calcium
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chloride, and Puromycin were from Sigma-Aldrich (St. Louis, MO). Matrigel, 0.8
micron transmembrane inserts, Rat tail collagen 1, Cell Recovery Solution, were
purchased from BD Biosciences (San Jose, CA). Bodipy lipid droplet stain was a
gift from Dr. Kim Buhman, Nutrition Science, Purdue University. Tri-Reagent was
purchased from Molecular Research Center, Inc. (Cincinnatti, OH). Primary antimouse antibodies for E-cadherin and VIM were purchased from Cell Signaling
Technologies (Beverly, MA). PLIN2 primary anti-mouse antibody was purchased
from Abcam (Cambridge, MA). Dimethyl sulfoxide (DMSO) was purchased from
Avanto Performance Materials (Center Valley, PA). Saponin, bovine serum
albumin, and Fibronectin were purchased from EMD Milipore (Billerica, MA).
Reagent A and B for BCA were purchased from Thermo Scientific (Rockford, IL).
ROX dye and SYBR Green Brilliant II and III were purchased from Agilent
Technologies (Santa Clara, CA). Rnasin, Random Primers, Oligo DT, XTP
Random Nucleotide Mix, MMLVRT, and M-MLVRT 5x Buffer were purchased
from Promega (Madison, WI). 10% Neutral Buffered Formalin (NBF) was
purchased from VWR International (Radnor, PA). Aqua-Hold II Pap Pen was
purchased from Scientific Device Laboratory (Des Plaines, IL).

3.3.2. Cell Culture
MCF10CA1a and MCF10CA1a-GFP were gifts from Dr. Julia Kirshner,
Biological Sciences, Purdue University. Both cell lines were cultured in
DMEM/F12 (1:1) supplemented with 5% horse serum and 1% penicillinstreptomycin in a humidified environment with 5% carbon dioxide. Cells were
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maintained in linear (2D) growth and frozen back in 85% supplemented media, 5%
DMSO and 10% heat-inactivated fetal bovine serum (HI-FBS). When using the
MCF10CA1a-GFP cells, two to three Puromycin treatments (2-5 µg/mL) were
given prior to plating in order to eliminate cells without the GFP present.
1,25(OH) 2 D was given to cells in 100% sterile ethanol with a final concentration
less than 1%.
Fetal mesenchymal stem cells (FnMSC), were a gift from Dr. Julia
Kirshner, Purdue University, who received them originally from Dr. Caroletta
Glackin, Beckman Research Institute and City of Hope National Medical Center
(Gutova et al., 2008). FnMSC cells were cultured in alpha-MEM supplemented
with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine. Cells were
maintained in linear (2D) growth and frozen back in a 9:1 ratio of FBS:DMSO.

3.3.3. Real Time-Polymerase Chain Reaction (RT-PCR)
MCF10CA1a cells were treated with either vehicle (100% ethanol) or 10
nM of 1,25(OH) 2 D for 48 hours replated and treated for an additional 96 hours,
prior to harvest. RNA was harvested and isolated using TriReagent following the
manufacturer's instructions. The total isolated RNA was reverse transcribed
using a reverse transcription mixture: Rnasin, Random Primers, Oligo DT, XTP
Random Nucleotide Mix, MMLVRT, and M-MLVRT 5x Buffer. After this, the
cDNA was quantified and real-time PCR was completed with Brilliant III SYBR
Green QPCR Master Mix. The abundance of the mRNA of interest was
determined via the threshold cycle (Ct) value and normalized to 18S mRNA
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abundance. Results were expressed as arbitrary units and were considered
significant if P<0.05. Primers utilized were purchased from Integrated DNA
Technologies (Coralville, IA) :
-18S
Forward: 5'-TTAGAGTGTTCAAAGCAGGCCCGA-3'
Reverse: 5'-TCTTGGCAAATGCTTTCGCTCTGG-3'
-E-Cadherin:
Forward: 5'-GAAGAGAGACTGGGTTATTC-3'
Reverse: 5'-GTGAGAGAAGAGAGTGTATG-3'
-Fibronectin:
Forward: 5'-GGAGATTCATGGGAGAAGTATG-3'
Reverse: 5'-GACCACTTGAGCTTGGATAG-3'
-N-Cadherin:
Forward: 5'- CATCATCATCCTGCTTATCC-3'
Reverse: 5'-ATAGTCCTGGTCTTCTTCTC-3'
-Vimentin:
Forward: 5'-CTCGTCACCTTCGTGAATAC-3'
Reverse: 5'-CGTTGATAACCTGTCCATCTC-3'
3.3.4. 3D Reconstructed Metastatic Model (Figure 7)
MCF10CA1a or MCF10CA1a-GFP cells were cultured in media described
above in triplicate 60mm dishes and were treated with either vehicle or 10 nM
1,25(OH) 2 D for 48 hours. MCF10CA1a-GFP cells were not used during any
experiments containing fluorescent staining. Twenty-four hours after the last
treatment, cells were harvested and plating density was calculated by trypan blue
for culture in 24-well plate 8µm transmembrane inserts. rMET set up begins with
the reconstructed bone, which consist of two solid layers: reconstructed
endosteum (rEND) and rBM without hyaluronic acid. rEND components include
5.32 parts of fibronectin (1 mg/mL), 1 part rat tail collagen type I (2 mg/mL,
diluted via 100 mM HEPES in sterile 1x PBS), and 62.8 parts of sterile 1x PBS.
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rEND was coated on the bottom of each 24-well plate and incubated at 37oC with
5% CO 2 and humidity for one hour. rBM components include 3.72 parts of
Matrigel, 2.43 parts of Fibronectin (1 mg/mL), and 1 part rat tail collagen I (2
mg/mL diluted via 100 mM HEPES in sterile 1x PBS). rBM was evenly layered
on top of the rEND and again incubated at 37oC with 5% CO 2 and humidity for
one hour. Cells were plated at 50,000 cells/insert within Matrigel in the 8 µm
transmembrane inserts and incubated at 37oC in 5% CO 2 and humidity for 30-45
minutes. Transwells were placed into wells containing the reconstructed bone
and the bottom well was filled with 1 mL/well of 80% bone marrow growth media
(BMGM) and 20% bone marrow conditioned media (BMCM). BMGM has a base
of RPMI 1640 and contains 20% FBS, 1% penicillin-streptomycin, 10-6 M dilution
of sodium succinate and hydrocortisone, and a 6.2 x 10-4 M dilution of calcium
chloride. The BMCM was acquired by seeding the FnMSC cells at a 1.8 x 106
density in a T-75 flask with 10 mL of BMGM. On day two, the cells were 80-90%
confluent and the media was aspirated, cells were rinsed once with sterile
calcium magnesium free-PBS (CMF-PBS), and 15 mL of fresh BMGM was
added to the flask. On day four, the media was collected into conical tubes,
centrifuged to remove cells and debris, and sterile filtered through a 0.2 µm filter,
thus creating BMCM. If not immediately used, BMCM was frozen in -80oC.
FnMSC cells used for BMCM creation are then discarded. The transwell
containing the MCF10CA1a/MCF10CA1a-GFP cells received 500 µl/insert of
mammary epithelial growth media (MEGM). MEGM consists of RPMI 1640 with
1% horse serum and 1% penicillin-streptomycin. rMET model was incubated at
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37oC in humidity and 5% CO 2 and treatments of either vehicle (100% ethanol) or
10 nM of 1,25(OH) 2 D were given every 24 hours for seven days, if treatment was
longer, 50:50 BMCM media change occurred on day eight. Cells were imaged
every two to three days using Axiovision 4.8.2 SP software for the Zeiss
microscope.
Twenty-four hours after the last treatment, the MEGM media on the
transmembrane inserts was aspirated and cells were washed once with PBS.
Cell Recovery Solution (62 µl,CRS) was added to each transmembrane and
incubated for 10 minutes at room temperature. The solution was transferred into
tubes and an additional 93 µl of CRS was added to each tube and the mix was
incubated for another hour and 45 minutes in 4oC. After incubation, the cell
samples were centrifuged, supernatant was aspirated, and cells were
resuspended in a low volume of sterile PBS. Cells were immunofluorescently
stained on slides.
BMGM/BMCM media that was in the wells containing reconstructed bone
was aspirated, centrifuged, and live versus dead cells were manually counted
with trypan blue. Cells that had migrated from the Matrigel layer in the
transmembrane insert into the layers of the reconstructed bone were either
photographed or stained for viability or immunoflluorescence.

3.3.5. Mammosphere Diameter Measurements
On the day of harvest, the upper well was imaged at 20x magnification in
the center of the edge closest to the viewer in each well. Axiovision 4.8.2 SP
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software on the Zeiss microscope provided a scale of 100 μm which was used to
manually measure the center-most mammosphere of each image to the closest
whole number. Mammosphere sizes were averaged per treatment group and
were relative to vehicle.

168

7

Figure 7. rMET model set up.
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3.3.6. Live/Dead Viability Assay for Mammalian Cells
Cells stained for viability were those that had migrated from the upper well
(reconstructed breast) and had burrowed into the rBM in the wells of the 24-well
plates. After the BMCM media was removed, cells were quickly washed once
with 1x PBS. Live stain, Calceinin AM (CAM), and dead stain, Ethidium
homodimer-1 (EthD-1), were diluted to 2 µM and 4 µM in 1x PBS, respectively
and added to each well. The plate was covered and incubated for 35 minutes in
the dark at 37oC. Immediately after the incubation, the stains were quantified
using a microplate reader (Synergy H1 Hybrid Reader, Biotek Instruments Inc,
Winooski, VT) and the cells were immediately imaged using Axiovision 4.8.2 SP
on the Zeiss microscope.

3.3.7. Immunofluorescent Staining
Immunofluorescent staining was completed in both the harvested
transwell breast mammospheres, spotted on slides, and the intact reconstructed
bone in the well. Protocol for intact staining was completed within the well, and
the protocol for harvested cells was in tubes or on glass slides as indicated.
For cells harvested from upper well (reconstructed breast), cells were
rinsed twice with PBS and if in tubes; centrifuged between each wash. Cells
were fixed using 10% neutral buffered formalin for 15 minutes at room
temperature, and if in tubes, they were centrifuged after incubation. Neutral
buffered formalin was removed and cells were washed twice with PBS in the
same manner as prior. For the cells in tubes, they were spotted onto glass
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plates that were outlined with a Aqua-Hold II Pap pen to prevent spills over the
sides of the slide. All samples were permeabilized; E-cadherin and vimentin
samples were permeabilized with 0.1% Triton-X in PBS; PLIN2 and Bodipy
samples were permeabilized with 0.1% Saponin in PBS, for 10 minutes at room
temperature. Samples were blocked over night using 1% BSA in PBS in the dark
with humidity at 4oC. The next day (day two), the blocking solution was removed,
samples were washed three times with PBS, and primary antibodies were added
with only one antibody per sample. Antibodies used were E-cadherin (1:200),
vimentin (1:50), and PLIN2 (1:50). All antibodies were in 1% BSA-PBS solution
and incubated with the samples overnight in the dark with humidity at 4oC.
Primary antibodies were removed the following day (day 3) and samples were
washed three times with PBS. Secondary antibodies, Alexa-488 (1:500) and
Alexa-680 (1:500) were added one per sample for one hour at room temperature,
in the dark. Simultaneously, samples being tested for PLIN2 were incubated with
lipid droplet stain, Bodipy (10 µg/mL), along with secondary antibody Alexa-680
(1:500). Dependent on the combination of staining necessary, the combination
of Alexa dyes altered per experiment. Typically, Alexa-488 was utilized for Ecad and Alexa-680 was utilized for vimentin; but if co-staining with Bodipy, Alexa680 had to be utilized for E-cad so they were contrasting colors. After the
incubation time, the secondary antibodies and Bodipy were removed, samples
were washed twice with PBS, and the nuclear stain, DAPI (1:25) was added to
every sample for 8-10 minutes at room temperature in the dark. After the
incubation, DAPI solution was removed, samples were washed twice with PBS,
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and one drop of Vectashield was added, and a coverslip was placed on top.
Samples were imaged immediately after (<24 hours) using Axiovision 4.8.2 SP
and stored in the dark at 4oC when not in use.

3.3.8. 3-(4,5-dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Assay (MTT)
MCF10CA1a cells were cultured in the rMET model as described above in
a 24-well plate and were treated with either vehicle or 10 nM 1,25(OH) 2 D.
Twenty-four hours after the last treatment, the media was aspirated and a 0.5
mg/mL MTT working mix was added to each transwell and incubated in the dark
for 2 hours at 37oC. After incubation, cells were harvested out the Matrigel using
CRS as previously described. DMSO was added and thoroughly mixed in each
well, the plate was incubated in the dark for 5 minutes at 37oC. The plate was
tapped to assist in dissolving the solutes and the solution was aliquoted in
duplicate into a 96-well plate and quantified at 570 nm with a 700 nm reference
wavelength via spectrophotometer (Powerwave, Biotek Instruments Inc.,
Winooski, VT).

3.3.9. Statistical Analysis
Values presented are means ± SEM. T-tests and ANOVA were performed
in SAS 9.2 or 9.3. Data was considered statistically significant with a p-value of
P<0.05.
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3.4. Results
In order to determine if 1,25(OH) 2 D alters E-cadherin, N-cadherin,
vimentin, and fibronectin mRNA abundance in MCF10CA1a cells, cells were
treated with vehicle or 10 nM of 1,25(OH) 2 D and mRNA abundance determined.
mRNA abundance showed that E-cadherin had an trend towards an increase
(P=0.09) (Figure 8A), N-cadherin was unchanged (P=0.31) (Figure 8B), and
vimentin (P=0.001) (Figure 8C) and fibronectin (P=0.0001) (Figure 8D) were
significantly increased by 1,25(OH) 2 D compared to vehicle after 48 hour pretreatment followed by re-plating and an additional 96 hour treatment in
MCF10CA1a cells.
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Figure 2. mRNA abundance of vehicle and 1,25(OH) 2 D treated MCF10CA1a
cells. All cells were treated for 48 hours, harvested, replated and treated for an
additional 96 hours with either vehicle or 1,25(OH) 2 D (10 nM). A representative
quantification of the mRNA abundance is shown for each protein, indicated with
vehicle (open bars) and 1,25(OH) 2 D treatment (black bars). Values are
expressed as mRNA of interest, relative to 18S mRNA for each sample, relative
to vehicle control. Results are expressed as mean ± SEM. (n ≥ 3). Statistical
significance was defined as *P < 0.05. 8A. E-cadherin; 8B. N-cadherin; 8C.
Fibronectin; 8D. Vimentin.
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In order to determine the role of 1,25(OH) 2 D in the metastatic cell invasion
and viability, the in vitro rMET model was utilized. No change in mammosphere
size in the reconstructed breast portion of the 1,25(OH) 2 D treated cells within the
transwell was noted compared to vehicle (Figure 9A and 9B). Similarly, a nonsignificant trend towards a decreases was present in the 1,25(OH) 2 D treated
samples assessed through by MTT (P=0.001) (Figure 10). Furthermore, there
was a significant decrease in the number of live cells and number of dead cells in
the BMCM of the 1,25(OH) 2 D treated wells compared to vehicle according to
trypan blue exclusion counts (P=0.004) (Figure 11). Microplate reading of the
rBM live/dead viability stains showed a significant decrease in live cells upon
1,25(OH) 2 D treatment (Figure 12). Additionally, a significant decrease was seen
in the dead cells compared to the live cells, though there was no difference in the
amount of dead cells between treatment groups (Figure 12).
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Figure 9. Representative figures of mammosphere sizes in the reconstructed
breast matrix (upper well) of the 3D model. All cells were treated for 48 hours in
2D prior to replating in 3D for 7 days with either vehicle of 1,25(OH) 2 D (10 nM)
treatment. Representative images are shown (9A) and values are expressed as
average µm diameter of treated mammospheres relative to the average µm
diameter of vehicle control mammospheres (9B). Results are expressed as
mean ± SEM. (n≥3). Images are 20x magnification with 5ms of exposure with a
brightfield filter.
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Figure 10. MTT assay of vehicle and 1,25(OH) 2 D treated MCF10CA1a cells from
upper well (reconstructed breast) of the rMET model. All cells were treated for
48 hours in 2D prior to plating in 3D for 7 days with either vehicle of 1,25(OH) 2 D
(10 nM). A representative quantification of the MTT assay is shown, indicated
with vehicle (open bars) and 1,25(OH) 2 D treatment (black bars). Values are
expressed as average cell number of each sample relative to vehicle control.
Results are expressed as mean ± SEM. (n ≥ 3).
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Figure 11. Trypan blue exclusion quantifications of live versus dead MCF10CA1a
cells in the BMCM of the 3D model. All cells were treated for 48 hours in 2D prior
to plating in 3D for 7 days with either vehicle of 1,25(OH) 2 D (10 nM) treatments.
After harvest, BMCM was centrifuged, supernatant removed, and pellet was
resuspended in 7-10 µl of PBS. Quantifications shown are indicated with vehicle
(open bars) and 1,25(OH) 2 D treatment (black bars). Values are expressed as
absolute average cell counts. Results are expressed as mean ± SEM. (n≥3).
Bars with common letter subscripts are not significantly different (p<0.05).
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Figure 12. Quantified fluorescence of live versus dead metastasized
MCF10CA1a cells in the rBM of the 3D model treated with vehicle or 1,25(OH) 2 D.
All cells were treated for 48 hours in 2D prior to plating in 3D for 7 days with
either vehicle of 1,25(OH) 2 D (10 nM) treatments. At day 7 of the 3D model, the
rBM was washed and stained with 2 µM calcein AM (live) and 4 µM Ethidium
homodimer-1 (dead). A representative quantification of the microplate values are
shown, indicated with vehicle (open bars) and 1,25(OH) 2 D (black bars). Values
are expressed as absolute average of treatment groups. Results are expressed
as mean ± SEM. (n ≥ 3). Bars with common letter subscripts are not significantly
different (p<0.05).
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In order to determine the role of 1,25(OH) 2 D regulation on the expression
of E-cadherin, vimentin, and PLIN2 protein in metastasis, the rMET model was
again utilized. The upper reconstructed breast portion and the rBM cells were all
immunostained to show their protein expression as well as DAPI for nuclear
location and Bodipy for neutral lipid droplet location. No visual differences in Ecadherin (Figure 13), vimentin (Figure 14), and lipid droplets or PLIN2 (Figure 15)
were noted between the treatments in either location.
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Figure 1. Immunofluorescent staining of the upper reconstructed breast portion
and rBM for E-cadherin. Blue staining is DAPI, representing the nucleus. Ecadherin is the green stain (Alexa-488). The representative images of the
reconstructed breast portion are 20x magnification, and the rBM images are 10x
magnification; all images are uniformly sharpened.
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Figure 14. Immunofluorescent staining of the upper reconstructed breast portion
and rBM for vimentin. Blue staining is DAPI, representing the nucleus. Vimentin
is the pink-red stain (Alexa-680). The representative images of the reconstructed
breast portion are 20x magnification, and the rBM images are 10x magnification;
all images are uniformly sharpened.
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Figure 15. Immunofluorescent staining of the upper reconstructed breast portion
and rBM for lipid droplets and PLIN2. Blue staining is DAPI, representing the
nucleus. Lipid droplets are green (Bodipy) and PLIN2 is the pink-red stain
(Alexa-680). The representative images of the reconstructed breast portion are
20x magnification, and the rBM images are 10x magnification; all images are
uniformly sharpened.
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3.5. Discussion
In the current study, the effect of 1,25(OH) 2 D treatment on breast to bone
cancer metastasis in vitro was explored in MCF10CA1a metastatic breast
epithelial cells in a rMET model. The results determined that 1,25(OH) 2 D had no
significant impact in regulating the mammosphere diameter (Figures 3A and 3B)
and 1,25(OH) 2 D caused a trend towards a decrease in the viability of the cells
within the reconstructed breast compartment after 48 hours of 10 nM 1,25(OH) 2 D
2D pre-treatment and subsequent 3D treatment for seven days. These results
do not strongly confirm 1,25(OH) 2 D's role in inhibiting proliferation and/or
inducing apoptosis within breast cancer as previously established (García-Quiroz
et al., 2013; Simboli-Campbell et al., 1996) but may upon replication of the
experiment.
Recent evidence suggests 1,25(OH) 2 D may play a role in inhibiting
metastasis of cancer cells. In the current studies, 1,25(OH) 2 D not only inhibited
growth in the reconstructed breast but significantly decreased survival of
metastatic breast cancer cells in the BMCM and reconstructed bone matrix
compared to vehicle control after 48 hours of 10 nM 1,25(OH) 2 D 2D pretreatment and subsequent 3D treatments for seven days in the breast matrix 3D
component only. It is probable that the 1,25(OH) 2 D treated cells that do make it
through the membrane and into the BMCM have increased pro-apoptotic
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signaling, thus inhibiting their ability to implant in the reconstructed bone.
Furthermore, our results show that even the 1,25(OH) 2 D treated cells that
implant in the rBM are significantly fewer than the vehicle control cells. Together,
these results suggest that 1,25(OH) 2 D action causes alterations within the
primary site(breast) but the effects extend far past the primary location of
exposure and into distant sites, such as the bone. This further emphasizes the
importance of 1,25(OH) 2 D treatment of the primary tumor to inhibit metastasis.
More recently, literature suggests 1,25(OH) 2 D may inhibit EMT (Tan, 2007;
Lopes, 2012)(Lopes et al., 2012; Tan et al., 2007), therefore decreasing and/or
inhibiting metastasis. Specifically, Lopes and colleagues showed that 100 nM of
1,25(OH) 2 D treatment for 72 hours caused a significant increase of E-cadherin
protein expression in aggressive breast cancer cells (Lopes et al., 2012). Few
studies have explored the role of 1,25(OH) 2 D in regulation of N-cadherin,
vimentin, and fibronectin, the other important characteristic proteins of EMT. In
the current study, 10 nM of 1,25(OH) 2 D lead to a trend toward an increase of Ecadherin mRNA abundance compared to vehicle control at 48 hours of 2D pretreatment and subsequent 96 hour 2D treatment after re-plating (in order to
mimic the rMET model) in MCF10CA1a cells. On the other hand, 1,25(OH) 2 D
significantly induced vimentin and fibronectin mRNA abundance but had no effect
on N-cadherin mRNA abundance compared to vehicle control utilizing the same
cell line and treatment conditions. While our E-cadherin results agree with those
of Lopes (Lopes et al., 2012) and Van Roy (van Roy and Berx, 2008) the
concurrent results of increased vimentin, fibronectin and unaltered N-cadherin
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suggest 1,25(OH) 2 D inhibition of metastasis is not through regulation of EMT
alone. To test the expression of the EMT proteins in the reconstructed bone
matrix, immunofluorescent staining of E-cadherin, vimentin, and DAPI was
implemented but significant differences between treatment groups were not seen
based on visual analysis. This may be explained by the heterogeneous nature of
cancerous tumors and the immunostained cells maybe those that are
1,25(OH) 2 D resistant and therefore would not show differences in expression.
Even so, 1,25(OH) 2 D lead to a trend towards a decrease in the number of live
cells in the breast and a significant decrease in the number of live cells in the
bone components, suggesting 1,25(OH) 2 D treatment for metastasis inhibition is
an effective intervention.
As stated in chapter 2, increased cancer aggression is associated with
increased cytoplasmic lipid droplet accumulation (Louie et al., 2013; Swinnen et
al., 2006), which was confirmed in our studies and was altered by 1,25(OH) 2 D
treatment. Preliminary testing of lipid involvement in metastasis was performed
via immunofluorescent staining in the rBM with Bodipy, for neutral lipids, and
perilipin 2 (PLIN2), a lipid droplet associated protein that has a role in regulating
entrance and exit of triacylglycerides and cholesterol esters from cytoplasmic
lipid droplets. Visual assessment did not show any differences between
treatments in lipid droplet accumulation or PLIN2 protein expression in the rBM.
However, this could be attributed to the heterogeneous nature of cancerous
tumors and the immunostained cells may be those that are1,25(OH) 2 D resistant
and therefore would not show differences in expression. Our laboratory will
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continue to explore the role of 1,25(OH) 2 D regulation of lipid metabolism in
metastasis.

3.6. Conclusions
Overall, the results of the current studies support that 1,25(OH) 2 D
decreases breast cancer metastasis in metastatic breast cancer cells. Further,
our results reveal a vital role in 1,25(OH) 2 D treatment at the primary location
(breast) as inhibition was moderately observed at the breast site as well as the
distal bone even in the absence of direct 1,25(OH) 2 D treatment in the bone
compartment. Additionally, our results suggest the mechanism of 1,25(OH) 2 D
inhibition of metastasis may not be strictly through EMT alterations as
1,25(OH) 2 D treatment showed the expected increase in E-cadherin but
unexpected increases in vimentin and fibronectin as well. Further, alterations
were not seen between the treatment groups upon immunofluorescent staining of
the cells implanted in the rBM suggesting the heterogeneous nature of tumor
cells may include 1,25(OH) 2 D resistant cells that successfully metastasize. Our
experiments exploring the link between increased lipids and metastatic breast
cancer did not appear to be effected by 1,25(OH) 2 D treatment according to
immunofluorescent staining. This again supports the theory that 1,25(OH) 2 D
resistant cells exist within the MCF10CA1a cell line. Together these results
support that 1,25(OH) 2 D inhibits metastasis but the exact mechanism remains to
be elucidated and remains of interest to our laboratory.
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CHAPTER 4 FUTURE DIRECTIONS

4.1. Summary
Vitamin D via sunlight or diet is associated with a decreased risk in breast
cancer in human epidemiological studies (Garland et al., 2007; Mohr et al., 2014).
It is well known that the active form of vitamin D, 1,25-dihydroxyvitamin D
(1,25(OH) 2 D), can reduce proliferation, inhibit angiogenesis, promote
differentiation, and promote apoptosis in primary breast tumors via regulation of
gene expression (García-Quiroz et al., 2013; Mantell et al., 2000; SimboliCampbell et al., 1996). In this thesis, we explored the novel regulation of
1,25(OH) 2 D in factors that are essential to breast cancer progression and
metastasis, including mRNA abundance of several lipid metabolism regulating
enzymes; and employed a novel 3D reconstructed metastasis model to explore
the role of 1,25(OH) 2 D in metastasis from breast to bone in vitro.

4.1.1. Lipid Metabolism
A lipogenic phenotype is associated with cancer progression and is
thought to provide survival and growth advantages (Louie et al., 2013; Swinnen
et al., 2006). Changes in lipid classes have also been observed and likely lead
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to changes in membrane fluidity, ligand-receptor interactions, endocytosis,
antigen presentation, lipid-lipid/lipid-protein interactions, microdomain formation,
and second messenger signaling (Emoto and Umeda, 2000; Escribá et al., 2008).
Specifically in breast cancer, increased fatty acids are associated with a variety
of pro-breast cancer effects such as decreased survival (Liu et al., 2011),
increased proliferation (Louie et al., 2013; Rysman et al., 2010), increased
migration (Antalis et al., 2011), metastasis (Vazquez-Martin et al., 2008), and
more.
Many studies have shown 1,25(OH) 2 D's inhibitory effects on primary
breast tumors through reduced angiogenesis and proliferation with increased
apoptosis of the cancer cells (Hanahan and Weinberg, 2011). Our own
laboratory has shown that 1,25(OH) 2 D can attenuate the Warburg effect in breast
cancer cells (Zheng et al., 2013), therefore it is possible that 1,25(OH) 2 D may
also attenuate the pro-breast cancer lipid metabolism. For our studies, we used
a model for multistage carcinogenesis of breast cancer which includes
untransformed MCF10A cells, Harvey-ras transfected MCF10A-ras cells,
aggressive MCF10CA1h cells, and metastatic MCF10CA1a cells.
The MCF10A cell line series originated from a benign breast tissue biopsy
from a female with fibrocystic disease whose cells were immortalized (Santner et
al., 2001). The immortalized cells that grew as attached cells were labeled,
MCF10A cells, and are used as a normal breast tissue control in many studies,
including our own. The transformed MCF10A-ras line, also called MCF10AneoT,
was created by transfection of the activated Harvey-ras oncogene and
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represents cancer initiation (Imbalzano et al., 2009). The MCF10A-ras cells were
then cycled through immuno-compromised mice via repeated selection for
progressively more aggressive tumor formation in the xenograft tumors
(Imbalzano et al., 2009). The most aggressive cells from organoids were
immortalized and labeled MCF10CA1h and are a recognized malignant cell line
representative of malignant breast cancer (Santner et al., 2001). The most
aggressive cells from trocar transplantation were immortalized and labeled
MCF10CA1a and are a recognized malignant cell line representative of
metastatic breast cancer (Santner et al., 2001). Since the MCF10A cell line is
derived from the same genetic background, variation between cell lines is
decreased thus making it easier to identify genetic differences between the lines,
potentially allowing for identification of crucial genetic changes that may allow
cancer development (Santner et al., 2001). Together, the MCF10A cell line
series provides a complete spectrum of breast cancer cells from the normal,
MCF10A, to the fully malignant, metastatic, MCF10CA1a cells.
Certain lipid metabolism enzymes were significantly altered upon
1,25(OH) 2 D treatment in our studies. Our RT-PCR results show that 1,25(OH) 2 D
did not have significant effects at 24 hours but upon 48 hours of treatment
several alterations were noted in the metastatic MCF10CA1a line. There were
no significant differences between treatment groups of any enzyme tested in the
MCF10A, MCF10A-ras, and MCF10CA1h cell lines. However, in the
MCF10CA1a cell line, after 48 hours of 10 nM of 1,25(OH) 2 D treatment in 2D, we
saw significant increases in FAS, ACAT1, Insig2, and PLIN2 mRNA abundance,
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concurrently with a trend towards a decrease in CPT1a, ATGL, and HSL mRNA
abundance but no effect in SCD1 mRNA abundance. Together these suggest
that 1,25(OH) 2 D may shift lipid metabolism toward storage and may also
decrease lipolysis through inhibition of lipases and decreasing mitochondrial βoxidation. Additionally, since no effect was seen on SCD1 mRNA abundance
upon 1,25(OH) 2 D treatment, the balance of saturated and unsaturated fatty acids
within a cell may not be significantly altered.
We also demonstrated that a lipogenic phenotype was associated with an
increased aggressiveness in the MCF10A cell line. Oil red O staining, thin layer
chromatography (TLC), and triglyceride analysis all demonstrated the greatest
amount of lipids in the most aggressive cell line (MCF10CA1a). Lipidomics was
employed to further explore the regulatory effects of 1,25(OH) 2 D in specific lipid
classes in MCF10CA1a cells. We noted significant increases in some
phosphotidylinositols's (PIs), phosphotidylcholines (PCs),
phosphotidylethanolamine's (PEs), and sphingomyelin's with longer than usual,
long chain fatty acids attached as well as significant decreases in some
glucosylceramides with long chain fatty acids attached. This suggests that lipid
metabolism is shifted toward phospholipid and sphingomyelin synthesis upon
1,25(OH) 2 D treatments.
Together, we believe this data suggests that 1,25(OH) 2 D may shift lipid
metabolism toward storage, decrease β-oxidation, and alter phospholipid
abundance in the MCF10CA1a cells. Subsequently, 1,25(OH) 2 D may cause
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MCF10CA1a cells to decrease proliferation by sequestering lipids in storage and
altering survival signaling by shifting phospholipid synthesis.

4.1.2. Metastasis
Breast cancer metastasis significantly decreases patient survival rate
compared to non-metastatic breast cancer patients, thus it is important to identify
measures that prevent metastasis (Centers for Disease Control and Prevention).
1,25(OH) 2 D has established inhibitory effects on primary breast tumors and new
literature suggests 1,25(OH) 2 D may also have a role in preventing breast cancer
metastasis to the bone through inhibition of the epithelial-to-mesenchymal
transition (EMT) (Hanahan and Weinberg, 2011). Several proteins are
associated with the EMT pathway with some of the most established markers
being epithelial-cadherin (E-cadherin), neuronal-cadherin (N-cadherin),
fibronectin, and vimentin. E-cadherin is found mainly in epithelial cells and
interacts with cytoskeleton actin and thus has a role in regulating cellular
differentiation, growth, migration, and adhesion (Buda and Pignatelli, 2011).
Loss of E-cadherin causes loss of epithelial cells apical-basal polarity and cellular
adhesion, characteristics of the EMT transition. E-cadherin loss is also well
documented in breast cancer and mutations in its coding gene, CDH1, increase
breast cancer risk up to 50% (Schrader et al., 2008). N-cadherin functions
include establishment of left-right asymmetry, early embryo development,
nervous system synapse function, and cell-cell adhesion. In breast cancer EMT,
N-cadherin expression is increased and has been associated with increased
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tumor aggressiveness and metastatic potential (Hazan et al., 1997; Kim et al.,
2000; Sigurdsson et al., 2011; Suyama et al., 2002). Fibronectin is involved in a
host of functions such as wound healing, blood coagulation, immunity, embryo
development, cell adhesion, and metastasis (Pankov and Yamada, 2002).
Fibronectin has long been known as a marker for EMT (Ignotz and Massagué,
1986) and is also associated with tumor aggressiveness (Bae et al., 2013), poor
patient prognosis, and a tumor size > 10mm (Bae et al., 2013; Gorczyca et al.,
1993; Ioachim et al., 2002). Vimentin plays an important role in maintaining cell
shape, cytoskeleton communication, organization, and migration and is
predominately expressed during embryogenesis (Dave and Bayless, 2014). In
breast cancer EMT, vimentin is significantly increased and is associated with
increased cancer cell motility and poor patient prognosis (Battula et al., 2012;
Caruso and Stemmer, 2011; Chu et al., 1993, 1996; Hendrix et al., 1997; Kallergi
et al., 2011). We hypothesized that 1,25(OH)2 D increases E-cadherin,
decreases N-cadherin, vimentin, fibronectin and decreases the number of cells
able to successfully metastasize and survive into the reconstructed bone matrix.
To test our hypotheses, the effect of 1,25(OH) 2 D treatment on breast to
bone cancer metastasis in vitro was explored in MCF10CA1a metastatic breast
epithelial cells in a 3D reconstructed metastasis model. After 48-hour 2D pretreatment and 7 day 3D treatment of 1,25(OH)2 D there was a trend towards a
decrease in the number of viable cells in the reconstructed breast matrix, and a
significant decrease in the number of live cells in the bone marrow conditioned
media (BMCM) and the reconstructed bone matrix (rBM) in the 1,25(OH) 2 D
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treated group compared to vehicle. These results confirm 1,25(OH) 2 D's role in
inhibiting proliferation and/or inducing apoptosis within breast cancer as
previously established (García-Quiroz et al., 2013; Simboli-Campbell et al., 1996).
Additionally, our results show that 1,25(OH) 2 D significantly decreases the
amount of cells that survive metastasis to the bone, suggesting that 1,25(OH) 2 D
action causes alterations within the primary site (breast) but the effect extends
into distant sites such as the bone. Furthermore, the expected mesenchymal
phenotype was not seen in the rBM of the 1,25(OH) 2 D treated cells, suggesting
the EMT may be altered.
Due to the phenotypical alterations seen in the rBM, we examined the
effect of 1,25(OH) 2 D regulation of characteristic EMT proteins' (E-cadherin, Ncadherin, vimentin, fibronectin) mRNA abundance. Forty-eight hours of
1,25(OH) 2 D treatment lead to a trend towards an increase in E-cadherin mRNA
abundance, a significant increase in vimentin and fibronectin mRNA abundance,
and no change in N-cadherin mRNA abundance compared to vehicle. While our
E-cadherin results agree with those by Lopes (Lopes et al., 2012) and Van Roy
(van Roy and Berx, 2008), the concurrent results of increased vimentin,
fibronectin and unaltered N-cadherin suggest 1,25(OH) 2 D inhibition of metastasis
may not be through regulation of EMT alone. We additionally completed
immunofluorescent staining of EMT factors, E-cadherin and vimentin, and to test
potential alterations in lipid accumulation we also stained for perilipin 2 (PLIN2)
and cytoplasmic lipid droplets of the successfully metastasized cells in the
reconstructed breast and rBM of both 1,25(OH) 2 D and vehicle treated cells.
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These results are currently being analyzed to determine significant differences
but visual analysis did not show any alterations. While this is likely due to the
heterogeneous nature of cancerous tumors, a significant reduction in cells that
survived metastasis was seen upon 1,25(OH)2 D treatment. Taken together with
the altered characteristic EMT associated proteins' mRNA abundance, it is clear
that 1,25(OH) 2 D has an inhibitory role of breast to bone cancer metastasis.

4.2. Future Directions
We expected that 1,25(OH) 2 D would either decrease lipid metabolism or
sequesters the lipids, therefore decreasing cell viability and proliferation in
tumorigenic breast cells. Our data demonstrated that 48 hours of 1,25(OH) 2 D
(10 nM) treatment in 2D culture induced mRNA abundance of enzymes
associated with lipid storage while decreased mRNA abundance in lipolytic
enzymes and decreased CPT1a mRNA abundance which may reduce entry into
the β-oxidation pathway in the metastatic MCF10CA1a cells. It is possible that
the reason we did not observe significant differences in the other tumorigenic cell
lines, MCF10A-ras and MCF10CA1h, was due to needing a longer treatment
time and/or higher dose to elicit the effect seen in the MCF10CA1a. Additionally,
the metabolism and transcriptional control may be less regulated in the
MCF10CA1a cells compared to less metastatic cells, and the 10 nM treatment for
48 hours was sufficient to alter the transcriptional regulation of some lipid
enzymes. Thus, measuring expression of the same enzymes (FAS, CPT1a,
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PLIN2, HSL, ATGL, ACAT1, SCD1, and Insig2) with either longer treatment
times and/or higher doses with 1,25(OH) 2 D would help address this question.
Since our results suggest that 1,25(OH) 2 D may shift lipid metabolism
toward storage and decrease lipid availability via decreased lipase transcription
and entry into the mitochondria for β-oxidation, it would be beneficial to measure
these endpoints. Radio-labeling exogenous lipids and following them throughout
both vehicle and 1,25(OH) 2 D treated cells may help identify where shifts in lipid
metabolism occur. In the case that exogenous lipid uptake is not altered,
quantification of oil red O staining and/or immunofluorescent
staining/quantification of cytoplasmic lipid droplets and rate-limiting lipid
metabolism enzymes should be tested, respectively, to see if other intracellular
lipid pathways are altered. Additionally, measuring break down of oleate into
carbon dioxide, using radioisotopes, could answer the question of the impact of
decreased CPT1a on β-oxidation upon 1,25(OH) 2 D treatment.
Moreover, our lipidomics results indicate that phospholipids with long
chain fatty acids were significantly increased while glucosylceramides with long
chain fatty acids were significantly decreased in 1,25(OH) 2 D treated
MCF10CA1a cells. This indicates that both cell membrane permeability and
intracellular signaling may be altered in 1,25(OH) 2 D treated cells. To test if the
cell membrane permeability is altered, fluorescein diacetate, which freely enters
the cells, and ethidium homodimer-1, which is excluded from the cell, could be
employed with flow cytometry to see if there are shifts between the vehicle and
1,25(OH) 2 D treated cells (Aeschbacher et al., 1986). Although, it may be of
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greater interest to test the specific enzymes involved in synthesis of PIs, PCs,
PEs, sphingomyelin's, and glucosylceramide's with long chain fatty acids to
determine how 1,25(OH) 2 D may regulate these pathways. More research is
necessary to determine the mechanisms by which 1,25(OH) 2 D alters lipid
metabolism in breast cancer. This information will assist in the development of
targeted strategies for cancer prevention and prevention of metastasis, which will
lead to an increased patient survival rate and reduce the incidence of breast
cancer.
When exploring the effects of 1,25(OH) 2 D regulation on metastasis, we
expected 1,25(OH) 2 D to increase E-cadherin while simultaneously decreasing Ncadherin, vimentin, and fibronectin via transcriptional regulation in metastatic
MCF10CA1a cells. However, our data demonstrated that 1,25(OH) 2 D induced a
significant trend towards an increase in E-cadherin, a significant increase in
vimentin, and fibronectin, and had no effect on N-cadherin mRNA abundance.
To our knowledge, no research is published on the effects of 1,25(OH) 2 D
regulation of vimentin and fibronectin. Our results do not agree with PendasFranco et al. as they have showed 1,25(OH) 2 D to significantly decrease Ncadherin expression (Pendás-Franco et al., 2007). It is possible that this is due
to the high concentration (100 nM) of 1,25(OH) 2 D compared to ours (10 nM),
despite their treatment duration being shorter. Our results show a trend towards
an increase in E-cadherin upon 1,25(OH) 2 D treatment which agrees with Van
Roy et al. and Lopes et al. who show similar effects in other aggressive breast
cancer cell lines (Lopes et al., 2012; van Roy and Berx, 2008). To better
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determine how 1,25(OH) 2 D regulates EMT proteins and their impact on inhibiting
metastasis, western blots with and without transcriptional or translational
inhibitors should be performed.
While exploring the effects of 1,25(OH) 2 D regulation of metastasis, we
further expected 1,25(OH) 2 D to inhibit the amount of cells able to successfully
metastasize from breast to bone. We utilized a novel 3D reconstructed
metastasis model to test our hypothesis and defined successful metastasis as a
viable cell that has transferred from the reconstructed breast matrix down to the
rBM, embedded, and has continued to survive there. Our data agrees with our
hypothesis as 1,25(OH) 2 D treatment significantly decreased the number of cells
in the reconstructed breast matrix, and the number of live cells in the BMCM and
the rBM. Quantified characterization of the MCF10CA1a cells in the
reconstructed breast portion as well as those on the underside of the membrane
(invasive phase), in the surviving cells in the BMCM, and those surviving in the
rBM, should be completed and compared between vehicle and 1,25(OH) 2 D
treated groups. It is likely that cells in the reconstructed breast matrix will have
different protein characterization between groups, with the 1,25(OH) 2 D cells
having a less aggressive phenotype. However, I hypothesize that the cell
characterization between groups becomes more similar as metastatic steps
continue; i.e. surviving cells in the rBM of both groups may have more similar
characteristics due to both of their abilities to successfully metastasize and
survive. Further, testing the metastatic ability of knock down E-cadherin and/or
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vimentin and/or fibronectin cells with and without 1,25(OH) 2 D treatment could
help identify the 1,25(OH) 2 D mechanism of action in metastasis inhibition.
This being said, we did observe significant differences in the phenotype of
cells surviving in the rBM with an absence of mesenchymal-like phenotype in the
1,25(OH) 2 D treated cells. Therefore, characterization may not be identical
between groups and thus additional studies in animals should be completed.
Using a xenograft mouse model with MCF10CA1a cells treated with vehicle or
1,25(OH) 2 D from the 3D reconstructed metastasis model we could measure
bone tumor latency, number, size, histochemical grade, and overall survival.
Those results may provide insight into 1,25(OH) 2 D's mechanism of action in
metastatic inhibition, thus potential clinical implications.
Several future studies could lead to a link between 1,25(OH) 2 D's ability to
alter lipid metabolism and its' ability to inhibit and alter metastatic ability of
MCF10CA1a cells in vitro. A lipid panel of both vehicle and 1,25(OH) 2 D treated
MCF10CA1a cells from each stage of the 3D reconstructed metastasis model
may reveal significant alterations between groups and thus a potential
mechanism. If this is true, inhibitors of the specific lipid metabolizing enzymes of
interest could be introduced into the 3D model and a comparison of metastasis in
the cells between 1,25(OH) 2 D and vehicle treated cells. Eventually, the same
study could be repeated but with xenografts of the 3D grown and treated
MCF10CA1a cells into immuno-compromised mice and lipid panels, inhibitors,
and mechanism of action could be explored in this in vivo model. To our
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knowledge, no studies have linked 1,25(OH) 2 D to altering lipid metabolism and
thus metastasis of breast cancer in any experimental model.
Breast cancer is associated with a variety of both non-modifiable and
modifiable risk factors. The modifiable risk factors can be altered via a healthy
diet and exercise regimen. Research suggests and supports vitamin D as a
potential breast cancer preventative agent. However, little or no data is available
on 1,25(OH) 2 D's mechanism of action in altering lipid metabolism and inhibition
of metastasis and/or their interaction. Our research contributes to filling this gap
in the literature and our results support that vitamin D acts on metastatic
mammary epithelial cells. Specifically, our results support that 1,25(OH) 2 D may
shift lipid metabolism toward storage and inhibit lipolysis, which may be part of
the mechanism of our other observation, which demonstrated a significant
decrease in the number of live 1,25(OH) 2 D treated cells able to successfully
metastasize to the BMCM and ultimately, rBM. Our studies open the doors for a
wide range of future studies to further evaluate the role and mechanism of
1,25(OH) 2 D regulation of lipid metabolism and breast cancer metastasis, some of
which were outlined in this chapter. Overall, our findings contribute to the
knowledge of vitamin D biology and its function in mammary cancer and
advocates that vitamin D is a potentially safe chemopreventative agent.
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